1 |
Carboplatin FDA Label
|
2 |
Doxorubicin FDA Label
|
3 |
Gemcitabine FDA Label
|
4 |
Paclitaxel FDA Label
|
5 |
Vorinostat FDA Label
|
6 |
Nintedanib FDA Label
|
7 |
Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
|
8 |
Effect of AURKA Gene Expression Knockdown on Angiogenesis and Tumorigenesis of Human Ovarian Cancer Cell Lines.Target Oncol. 2016 Dec;11(6):771-781. doi: 10.1007/s11523-016-0436-7.
|
9 |
Identification of ovarian cancer associated genes using an integrated approach in a Boolean framework.BMC Syst Biol. 2013 Feb 6;7:12. doi: 10.1186/1752-0509-7-12.
|
10 |
Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer.J Cell Mol Med. 2012 Oct;16(10):2422-8. doi: 10.1111/j.1582-4934.2012.01559.x.
|
11 |
Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.Int J Oncol. 2011 Aug;39(2):373-81. doi: 10.3892/ijo.2011.1059. Epub 2011 May 31.
|
12 |
CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.Oncotarget. 2017 Jun 13;8(24):39021-39032. doi: 10.18632/oncotarget.16547.
|
13 |
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.Clin Exp Metastasis. 2011 Oct;28(7):689-700. doi: 10.1007/s10585-011-9401-0. Epub 2011 Jul 2.
|
14 |
E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness.PLoS One. 2017 Sep 21;12(9):e0184439. doi: 10.1371/journal.pone.0184439. eCollection 2017.
|
15 |
Hypo/unmethylated promoter status of Cdk2 gene correlates with its over-expression in ovarian cancer in north Indian population.Cell Mol Biol (Noisy-le-grand). 2016 Jan 22;62(1):67-72.
|
16 |
High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer.Gynecol Oncol. 2010 Sep;118(3):244-50. doi: 10.1016/j.ygyno.2010.05.024. Epub 2010 Jun 17.
|
17 |
MicroRNA-17 promotes normal ovarian cancer cells to cancer stem cells development via suppression of the LKB1-p53-p21/WAF1 pathway.Tumour Biol. 2015 Mar;36(3):1881-93. doi: 10.1007/s13277-014-2790-3. Epub 2014 Dec 16.
|
18 |
Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.Ultrasound Obstet Gynecol. 2019 Jan;53(1):116-123. doi: 10.1002/uog.19174.
|
19 |
Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma.Diagn Pathol. 2013 Nov 19;8:190. doi: 10.1186/1746-1596-8-190.
|
20 |
Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth.Oncogene. 2013 Feb 28;32(9):1082-90. doi: 10.1038/onc.2012.134. Epub 2012 May 7.
|
21 |
AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells.Exp Cell Res. 2013 Oct 15;319(17):2627-36. doi: 10.1016/j.yexcr.2013.07.030. Epub 2013 Aug 13.
|
22 |
Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.J Pharm Sci. 2011 Oct;100(10):4205-9. doi: 10.1002/jps.22680. Epub 2011 Jun 23.
|
23 |
Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.Biochem Pharmacol. 2004 Aug 15;68(4):601-9. doi: 10.1016/j.bcp.2004.05.007.
|
24 |
The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.Clin Exp Metastasis. 2004;21(3):191-9. doi: 10.1023/b:clin.0000037703.37275.35.
|
25 |
FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.J Clin Invest. 2013 Oct;123(10):4435-48. doi: 10.1172/JCI70625. Epub 2013 Sep 9.
|
26 |
Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo. Cell Physiol Biochem. 2016;39(1):242-52.
|
27 |
hsa_circ_0061140 Knockdown Reverses FOXM1-Mediated Cell Growth and Metastasis in Ovarian Cancer through miR-370 Sponge Activity.Mol Ther Nucleic Acids. 2018 Dec 7;13:55-63. doi: 10.1016/j.omtn.2018.08.010. Epub 2018 Aug 22.
|
28 |
Mutational analysis of FOXL2 p.C134W and expression of bone morphogenetic protein 2 in Japanese patients with granulosa cell tumor of ovary.J Obstet Gynaecol Res. 2014 May;40(5):1197-204. doi: 10.1111/jog.12324. Epub 2014 Apr 2.
|
29 |
Identification of recurrent fusion genes across multiple cancer types.Sci Rep. 2019 Jan 31;9(1):1074. doi: 10.1038/s41598-019-38550-6.
|
30 |
No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk.Breast Cancer Res Treat. 2010 Jun;121(2):497-502. doi: 10.1007/s10549-009-0589-5. Epub 2009 Oct 27.
|
31 |
Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival.Future Oncol. 2017 Sep;13(22):1981-1990. doi: 10.2217/fon-2017-0084. Epub 2017 Aug 22.
|
32 |
Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-B-mediated IKK expression.Int J Cancer. 2017 Dec 1;141(11):2305-2317. doi: 10.1002/ijc.30932. Epub 2017 Aug 30.
|
33 |
Interleukin 16 expression changes in association with ovarian malignant transformation.Am J Obstet Gynecol. 2014 Mar;210(3):272.e1-10. doi: 10.1016/j.ajog.2013.12.041. Epub 2013 Dec 28.
|
34 |
Study of kallikrein-related peptidase 6 (KLK6) and its complex with 1-antitrypsin in biological fluids.Clin Chem Lab Med. 2017 Aug 28;55(9):1385-1396. doi: 10.1515/cclm-2017-0017.
|
35 |
The luteinizing hormone receptor: insights into structure-function relationships and hormone-receptor-mediated changes in gene expression in ovarian cancer cells.Mol Cell Endocrinol. 2010 Nov 25;329(1-2):47-55. doi: 10.1016/j.mce.2010.04.025. Epub 2010 May 2.
|
36 |
The relationship of haplotype in lactotransferrin and its expression levels in Chinese Han ovarian cancer.Acta Biochim Biophys Sin (Shanghai). 2011 Nov;43(11):884-90. doi: 10.1093/abbs/gmr089. Epub 2011 Sep 20.
|
37 |
Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer. 2010 Apr 27;10:163.
|
38 |
Identification, localization and characterization of the human gamma-synuclein gene.Hum Genet. 1998 Jul;103(1):106-12. doi: 10.1007/s004390050792.
|
39 |
Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.APMIS. 2013 Dec;121(12):1177-86. doi: 10.1111/apm.12071. Epub 2013 Apr 18.
|
40 |
Multiple steps of HLA-G in ovarian carcinoma metastasis: alter NK cytotoxicity and induce matrix metalloproteinase-15 (MMP-15) expression.Hum Immunol. 2013 Apr;74(4):439-46. doi: 10.1016/j.humimm.2012.11.021. Epub 2012 Dec 8.
|
41 |
Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinoma.PLoS One. 2013 Nov 13;8(11):e78783. doi: 10.1371/journal.pone.0078783. eCollection 2013.
|
42 |
Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.Clin Cancer Res. 2013 Jul 1;19(13):3577-90. doi: 10.1158/1078-0432.CCR-12-3212. Epub 2013 Apr 30.
|
43 |
Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma.Mol Med Rep. 2015 Aug;12(2):2114-20. doi: 10.3892/mmr.2015.3580. Epub 2015 Apr 1.
|
44 |
Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.PLoS One. 2011 Mar 15;6(3):e17617. doi: 10.1371/journal.pone.0017617.
|
45 |
Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion.Int J Cancer. 2010 Jul 1;127(1):21-31. doi: 10.1002/ijc.25005.
|
46 |
p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18622-7. doi: 10.1073/pnas.0907481107. Epub 2010 Oct 6.
|
47 |
Association between newly identified variant form of DNA polymerase beta ( 208-304) and ovarian cancer.Cancer Biomark. 2012;11(4):155-60. doi: 10.3233/CBM-2012-00275.
|
48 |
Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer.J Histochem Cytochem. 2013 Mar;61(3):206-17. doi: 10.1369/0022155413475452. Epub 2013 Jan 4.
|
49 |
Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies.Cell Physiol Biochem. 2018;46(4):1716-1726. doi: 10.1159/000489586. Epub 2018 Apr 28.
|
50 |
Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH17 helper cells.Int J Oncol. 2013 Oct;43(4):1011-8. doi: 10.3892/ijo.2013.2021. Epub 2013 Jul 18.
|
51 |
Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.Pathol Oncol Res. 2012 Apr;18(2):135-48. doi: 10.1007/s12253-011-9482-8. Epub 2011 Dec 9.
|
52 |
Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer.Int J Oncol. 2012 Jun;40(6):1865-80. doi: 10.3892/ijo.2012.1371. Epub 2012 Feb 14.
|
53 |
ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).Anticancer Res. 2019 Mar;39(3):1267-1273. doi: 10.21873/anticanres.13237.
|
54 |
SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer.PLoS One. 2012;7(11):e49869. doi: 10.1371/journal.pone.0049869. Epub 2012 Nov 21.
|
55 |
Annexin A2 inhibition suppresses ovarian cancer progression via regulating -catenin/EMT. Oncol Rep. 2017 Jun;37(6):3643-3650.
|
56 |
Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT.Anticancer Res. 2011 Mar;31(3):897-906.
|
57 |
Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells.Anticancer Res. 2010 Jul;30(7):2577-81.
|
58 |
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.Cancer Cell. 2011 Feb 15;19(2):273-82. doi: 10.1016/j.ccr.2010.12.019.
|
59 |
TLR4 activates NF-B in human ovarian granulosa tumor cells.Biochem Biophys Res Commun. 2011 Jun 17;409(4):675-80. doi: 10.1016/j.bbrc.2011.05.063. Epub 2011 May 17.
|
60 |
Tumor suppressive effects of bromodomain-containing protein 7 (BRD7) in epithelial ovarian carcinoma.Clin Cancer Res. 2014 Feb 1;20(3):565-75. doi: 10.1158/1078-0432.CCR-13-1271. Epub 2013 Nov 6.
|
61 |
Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.J Immunol Methods. 2011 Jan 5;363(2):221-32. doi: 10.1016/j.jim.2010.09.001. Epub 2010 Sep 15.
|
62 |
Citrate synthase expression affects tumor phenotype and drug resistance in human ovarian carcinoma.PLoS One. 2014 Dec 29;9(12):e115708. doi: 10.1371/journal.pone.0115708. eCollection 2014.
|
63 |
M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.Cancer Biol Ther. 2019;20(7):956-966. doi: 10.1080/15384047.2018.1564567. Epub 2019 May 7.
|
64 |
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.Elife. 2019 Sep 3;8:e47327. doi: 10.7554/eLife.47327.
|
65 |
FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway.Cell Death Dis. 2014 Jul 17;5(7):e1346. doi: 10.1038/cddis.2014.302.
|
66 |
Vascular marker expression during the development of various types of gynaecological malignancy.Tumour Biol. 2014 Nov;35(11):11229-35. doi: 10.1007/s13277-014-2447-2. Epub 2014 Aug 12.
|
67 |
Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer.Exp Biol Med (Maywood). 2017 Mar;242(5):497-504. doi: 10.1177/1535370216685007. Epub 2017 Jan 5.
|
68 |
Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.Clin Cancer Res. 2009 Apr 1;15(7):2417-25. doi: 10.1158/1078-0432.CCR-08-1276. Epub 2009 Mar 24.
|
69 |
Directing the use of DDR kinase inhibitors in cancer treatment.Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355. doi: 10.1080/13543784.2017.1389895. Epub 2017 Oct 14.
|
70 |
Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?.Anticancer Agents Med Chem. 2008 Feb;8(2):232-9. doi: 10.2174/187152008783497000.
|
71 |
NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.Clin Cancer Res. 2007 Mar 1;13(5):1584-90. doi: 10.1158/1078-0432.CCR-06-1416.
|
72 |
Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression.J Biol Chem. 2008 Nov 7;283(45):31012-20. doi: 10.1074/jbc.M803547200. Epub 2008 Sep 7.
|
73 |
Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth.Cancer Res. 2005 Feb 1;65(3):925-32.
|
74 |
Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.Invest New Drugs. 2017 Apr;35(2):127-133. doi: 10.1007/s10637-016-0404-1. Epub 2016 Nov 3.
|
75 |
Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.Int J Oncol. 2009 Feb;34(2):345-53.
|
76 |
HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer.Int J Cancer. 2008 Aug 1;123(3):725-9. doi: 10.1002/ijc.23563.
|
77 |
HOXB13 promotes ovarian cancer progression.Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17093-8. doi: 10.1073/pnas.0707938104. Epub 2007 Oct 17.
|
78 |
Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma.Cancer Sci. 2007 Jun;98(6):844-9. doi: 10.1111/j.1349-7006.2007.00461.x. Epub 2007 Apr 5.
|
79 |
Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.Cancer. 2006 Sep 15;107(6):1407-18. doi: 10.1002/cncr.22134.
|
80 |
Mannan-binding lectin (MBL) in women with tumours of the reproductive system.Cancer Immunol Immunother. 2007 Jul;56(7):959-71. doi: 10.1007/s00262-006-0250-7. Epub 2006 Nov 28.
|
81 |
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).J Med Genet. 2019 Sep;56(9):574-580. doi: 10.1136/jmedgenet-2018-105930. Epub 2019 Apr 12.
|
82 |
L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade.J BUON. 2019 Mar-Apr;24(2):701-708.
|
83 |
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.J Pathol. 2013 Feb;229(3):469-76. doi: 10.1002/path.4134.
|
84 |
Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2557-65. doi: 10.1158/1055-9965.EPI-07-0542.
|
85 |
Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
|
86 |
The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI.Mol Ther Oncolytics. 2018 Dec 8;12:9-15. doi: 10.1016/j.omto.2018.12.002. eCollection 2019 Mar 29.
|
87 |
Expression levels of MRP1, GST-, and GSK3 in ovarian cancer and the relationship with drug resistance and prognosis of patients.Oncol Lett. 2019 Jul;18(1):22-28. doi: 10.3892/ol.2019.10315. Epub 2019 May 6.
|
88 |
Hypoxia-inducible factor-2 directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.Mol Oncol. 2019 Feb;13(2):403-421. doi: 10.1002/1878-0261.12419. Epub 2019 Jan 14.
|
89 |
ACR Appropriateness Criteria() StagingandFollow-Up of Ovarian Cancer.J Am Coll Radiol. 2018 May;15(5S):S198-S207. doi: 10.1016/j.jacr.2018.03.015.
|
90 |
Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation.Sci Rep. 2019 Feb 21;9(1):2527. doi: 10.1038/s41598-019-38766-6.
|
91 |
ADAM17 inhibition enhances platinum efficiency in ovarian cancer.Oncotarget. 2018 Mar 23;9(22):16043-16058. doi: 10.18632/oncotarget.24682. eCollection 2018 Mar 23.
|
92 |
Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis.Br J Cancer. 2005 May 9;92(9):1729-36. doi: 10.1038/sj.bjc.6602528.
|
93 |
Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models.J Immunol Methods. 2012 Apr 30;378(1-2):20-32. doi: 10.1016/j.jim.2012.01.013. Epub 2012 Feb 15.
|
94 |
Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.J Cell Biochem. 2019 Mar;120(3):3091-3100. doi: 10.1002/jcb.27497. Epub 2018 Nov 28.
|
95 |
AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3/NF-B axis.Cell Signal. 2018 May;45:122-131. doi: 10.1016/j.cellsig.2018.01.021. Epub 2018 Jan 31.
|
96 |
Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.Clin Cancer Res. 2008 Mar 15;14(6):1726-33. doi: 10.1158/1078-0432.CCR-07-0428.
|
97 |
Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer.Cancer Biol Ther. 2017 Apr 3;18(4):245-251. doi: 10.1080/15384047.2017.1295175. Epub 2017 Mar 27.
|
98 |
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.Oncotarget. 2017 Jun 6;8(23):37061-37079. doi: 10.18632/oncotarget.15715.
|
99 |
Profiling of selected angiogenesis-related genes in serous ovarian cancer patients.Adv Med Sci. 2017 Mar;62(1):116-120. doi: 10.1016/j.advms.2016.11.005. Epub 2017 Feb 21.
|
100 |
Inhibition of Ca(2+) -activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling.Int J Cancer. 2019 May 1;144(9):2215-2226. doi: 10.1002/ijc.31887. Epub 2019 Feb 12.
|
101 |
Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.J Exp Clin Cancer Res. 2019 Jan 8;38(1):10. doi: 10.1186/s13046-018-1017-7.
|
102 |
Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.J Transl Med. 2019 Sep 2;17(1):275. doi: 10.1186/s12967-019-2023-z.
|
103 |
Intraoperative Diagnosis Support Tool for Serous Ovarian Tumors Based on Microarray Data Using Multicategory Machine Learning.Int J Gynecol Cancer. 2016 Jan;26(1):104-13. doi: 10.1097/IGC.0000000000000566.
|
104 |
Human APC2 localization and allelic imbalance.Cancer Res. 2001 Nov 1;61(21):7978-84.
|
105 |
Silencing of Apurinic/Apyrimidinic Endonuclease 1 Inhibits the Growth and Migration in Ovarian Cancer Cell via Activator-Protein-1 Signaling.Gynecol Obstet Invest. 2017;82(2):188-199. doi: 10.1159/000447261. Epub 2016 Aug 24.
|
106 |
Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis.Mol Cancer Res. 2019 Jun;17(6):1378-1390. doi: 10.1158/1541-7786.MCR-18-0989. Epub 2019 Mar 11.
|
107 |
Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother Pharmacol. 2008 Oct;62(5):857-65. doi: 10.1007/s00280-007-0674-6. Epub 2008 Jan 23.
|
108 |
miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway.Oncogenesis. 2017 May 1;6(5):e326. doi: 10.1038/oncsis.2017.25.
|
109 |
Targeting Endothelin-1 Receptor/-Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach.Front Endocrinol (Lausanne). 2019 Sep 4;10:609. doi: 10.3389/fendo.2019.00609. eCollection 2019.
|
110 |
L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer.J Cell Mol Med. 2012 Oct;16(10):2369-78. doi: 10.1111/j.1582-4934.2012.01547.x.
|
111 |
ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.Int J Oncol. 2020 Jan;56(1):219-231. doi: 10.3892/ijo.2019.4913. Epub 2019 Nov 14.
|
112 |
Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene. 2005 Mar 3;24(10):1774-87. doi: 10.1038/sj.onc.1207991.
|
113 |
Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy.J BUON. 2018 Sep-Oct;23(5):1396-1401.
|
114 |
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.J Exp Clin Cancer Res. 2015 Jan 16;34(1):2. doi: 10.1186/s13046-015-0124-y.
|
115 |
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.Cancer Res. 2016 Sep 1;76(17):5103-14. doi: 10.1158/0008-5472.CAN-15-2980. Epub 2016 Apr 20.
|
116 |
Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.Mol Cancer Ther. 2019 Feb;18(2):389-398. doi: 10.1158/1535-7163.MCT-18-0537. Epub 2018 Nov 26.
|
117 |
BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.Cancer Lett. 2019 Mar 31;445:45-56. doi: 10.1016/j.canlet.2019.01.003. Epub 2019 Jan 14.
|
118 |
Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.Genes Chromosomes Cancer. 2015 Jan;54(1):51-62. doi: 10.1002/gcc.22218. Epub 2014 Sep 18.
|
119 |
Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low-dose fraction radiation.Cancer Med. 2019 May;8(5):2442-2448. doi: 10.1002/cam4.2116. Epub 2019 Apr 2.
|
120 |
BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.Oncotarget. 2015 Oct 13;6(31):31522-43. doi: 10.18632/oncotarget.5159.
|
121 |
Inhibition of the inflammatory cytokine TNF- increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.Mol Ther. 2011 Mar;19(3):490-9. doi: 10.1038/mt.2010.247. Epub 2010 Nov 16.
|
122 |
Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3.Cell Death Dis. 2019 Feb 4;10(2):104. doi: 10.1038/s41419-018-1200-y.
|
123 |
Identification of Key Genes and Pathway for Ovarian Neoplasms Using the OVDM1 Cell Line Based on Bioinformatics Analysis.Med Sci Monit. 2019 Jun 9;25:4305-4313. doi: 10.12659/MSM.915422.
|
124 |
Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer.Mol Cancer Ther. 2018 Jan;17(1):39-49. doi: 10.1158/1535-7163.MCT-17-0574. Epub 2017 Nov 20.
|
125 |
Loss of BMP-10 is correlated with poor survival in ovarian cancer.Pathol Res Pract. 2019 Jan;215(1):121-126. doi: 10.1016/j.prp.2018.10.025. Epub 2018 Oct 28.
|
126 |
Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop.Oncotarget. 2016 Feb 9;7(6):6916-32. doi: 10.18632/oncotarget.6870.
|
127 |
Expression Of BMP7 In Ovarian Cancer And Biological Effect Of BMP7 Knockdown On Ovarian Cancer Cells.Onco Targets Ther. 2019 Sep 26;12:7897-7909. doi: 10.2147/OTT.S217975. eCollection 2019.
|
128 |
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.Cancer Cell. 2019 Mar 18;35(3):519-533.e8. doi: 10.1016/j.ccell.2019.02.004.
|
129 |
Altered uterine contractility in response to -adrenoceptor agonists in ovarian cancer.J Physiol Sci. 2017 Nov;67(6):711-722. doi: 10.1007/s12576-016-0500-1. Epub 2016 Nov 12.
|
130 |
Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.Mol Cancer Res. 2008 Nov;6(11):1775-85. doi: 10.1158/1541-7786.MCR-08-0214.
|
131 |
microRNA-27a-3p Down-regulation Inhibits Malignant Biological Behaviors of Ovarian Cancer by Targeting BTG1.Open Med (Wars). 2019 Jul 31;14:577-585. doi: 10.1515/med-2019-0065. eCollection 2019.
|
132 |
Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.Neoplasia. 2012 Nov;14(11):994-1004. doi: 10.1593/neo.121262.
|
133 |
Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.Int J Cancer. 2020 May 1;146(9):2608-2618. doi: 10.1002/ijc.32676. Epub 2019 Nov 6.
|
134 |
Akt activation by Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells. J Biol Chem. 2017 Aug 25;292(34):14188-14204. doi: 10.1074/jbc.M117.778464. Epub 2017 Jun 20.
|
135 |
Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1.Exp Ther Med. 2017 Jul;14(1):499-506. doi: 10.3892/etm.2017.4546. Epub 2017 Jun 6.
|
136 |
CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.Nat Commun. 2018 Feb 12;9(1):631. doi: 10.1038/s41467-018-03031-3.
|
137 |
Costunolide Inhibits the Growth of OAW42-A Multidrug-Resistant Human Ovarian Cancer Cells by Activating Apoptotic and Autophagic Pathways, Production of Reactive Oxygen Species (ROS), Cleaved Caspase-3 and Cleaved Caspase-9.Med Sci Monit. 2019 May 2;25:3231-3237. doi: 10.12659/MSM.914029.
|
138 |
miR-96-5p promotes the proliferation and migration of ovarian cancer cells by suppressing Caveolae1.J Ovarian Res. 2019 Jun 22;12(1):57. doi: 10.1186/s13048-019-0533-1.
|
139 |
Inhibitory effect of carbonyl reductase 1 against peritoneal progression of ovarian cancer: evaluation by ex vivo 3D-human peritoneal model.Mol Biol Rep. 2019 Oct;46(5):4685-4697. doi: 10.1007/s11033-019-04788-6. Epub 2019 Apr 25.
|
140 |
Targeting Glutathione and Cystathionine -Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation.Nutrients. 2019 Oct 19;11(10):2523. doi: 10.3390/nu11102523.
|
141 |
CCL20 Promotes Ovarian Cancer Chemotherapy Resistance by Regulating ABCB1 Expression.Cell Struct Funct. 2019;44(1):21-28. doi: 10.1247/csf.18029.
|
142 |
Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer.Immune Netw. 2018 Aug 13;18(4):e29. doi: 10.4110/in.2018.18.e29. eCollection 2018 Aug.
|
143 |
Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients.Tumour Biol. 2015 Jun;36(6):4811-7. doi: 10.1007/s13277-015-3133-8. Epub 2015 Feb 3.
|
144 |
CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.BMC Cancer. 2019 Nov 25;19(1):1140. doi: 10.1186/s12885-019-6321-x.
|
145 |
MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer.Biochem Biophys Res Commun. 2019 Apr 30;512(2):331-337. doi: 10.1016/j.bbrc.2019.03.009. Epub 2019 Mar 16.
|
146 |
Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells.Clin Transl Oncol. 2017 Dec;19(12):1489-1497. doi: 10.1007/s12094-017-1686-2. Epub 2017 Jun 6.
|
147 |
B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models.Nucl Med Biol. 2017 Apr;47:23-30. doi: 10.1016/j.nucmedbio.2017.01.003. Epub 2017 Jan 10.
|
148 |
CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1.Front Oncol. 2019 Aug 21;9:802. doi: 10.3389/fonc.2019.00802. eCollection 2019.
|
149 |
Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide.Eur J Med Chem. 2019 Jan 1;161:594-606. doi: 10.1016/j.ejmech.2018.10.042. Epub 2018 Oct 23.
|
150 |
CDC25A Facilitates Chemo-resistance in Ovarian Cancer Multicellular Spheroids by Promoting E-cadherin Expression and Arresting Cell Cycles.J Cancer. 2019 Jun 2;10(13):2874-2884. doi: 10.7150/jca.31329. eCollection 2019.
|
151 |
Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer.Front Oncol. 2019 Apr 8;9:236. doi: 10.3389/fonc.2019.00236. eCollection 2019.
|
152 |
Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis.Medicine (Baltimore). 2019 Nov;98(44):e17803. doi: 10.1097/MD.0000000000017803.
|
153 |
BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression.Cancer Res. 2001 Oct 1;61(19):6977-81.
|
154 |
Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.Mol Cancer Ther. 2016 Jul;15(7):1691-701. doi: 10.1158/1535-7163.MCT-16-0032. Epub 2016 May 20.
|
155 |
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.Elife. 2018 Nov 13;7:e39030. doi: 10.7554/eLife.39030.
|
156 |
Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients.Dis Markers. 2018 Jun 28;2018:6714287. doi: 10.1155/2018/6714287. eCollection 2018.
|
157 |
Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.Gynecol Oncol. 2008 May;109(2):234-9. doi: 10.1016/j.ygyno.2008.01.031. Epub 2008 Mar 10.
|
158 |
The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential.Gynecol Oncol. 2010 Jun;117(3):451-9. doi: 10.1016/j.ygyno.2010.02.024. Epub 2010 Mar 15.
|
159 |
Chemiluminescence noncompetitive immunoassay based on microchip electrophoresis for the determination of -subunit of human chorionic gonadotropin.J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 15;1053:42-47. doi: 10.1016/j.jchromb.2017.03.031. Epub 2017 Mar 29.
|
160 |
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.Br J Cancer. 2014 Jan 21;110(2):330-40. doi: 10.1038/bjc.2013.729. Epub 2013 Nov 26.
|
161 |
The Emerging Role of Calcium-activated Chloride Channel Regulator 1 in Cancer.Anticancer Res. 2019 Apr;39(4):1661-1666. doi: 10.21873/anticanres.13271.
|
162 |
Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel.Mol Cancer Res. 2019 Mar;17(3):741-750. doi: 10.1158/1541-7786.MCR-18-0451. Epub 2019 Jan 3.
|
163 |
Expression and prognostic value of CLIC1 in epithelial ovarian cancer.Exp Ther Med. 2018 Jun;15(6):4943-4949. doi: 10.3892/etm.2018.6000. Epub 2018 Mar 28.
|
164 |
RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells.Mol Med Rep. 2015 Nov;12(5):6635-41. doi: 10.3892/mmr.2015.4238. Epub 2015 Aug 21.
|
165 |
Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities.Cancers (Basel). 2019 Sep 18;11(9):1389. doi: 10.3390/cancers11091389.
|
166 |
Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by siSAB1 in ovarian cancer.Oncol Rep. 2018 Nov;40(5):2788-2797. doi: 10.3892/or.2018.6658. Epub 2018 Aug 17.
|
167 |
Long noncoding RNA DQ786243 interacts with miR-506 and promotes progression of ovarian cancer through targeting cAMP responsive element binding protein 1.J Cell Biochem. 2018 Dec;119(12):9764-9780. doi: 10.1002/jcb.27295. Epub 2018 Aug 13.
|
168 |
Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.Gynecol Oncol. 2012 Feb;124(2):325-34. doi: 10.1016/j.ygyno.2011.10.013. Epub 2011 Oct 15.
|
169 |
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.Genome Med. 2016 Oct 20;8(1):107. doi: 10.1186/s13073-016-0361-5.
|
170 |
The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer.Oncogenesis. 2019 Aug 12;8(8):41. doi: 10.1038/s41389-019-0150-2.
|
171 |
Procathepsin D interacts with prosaposin in cancer cells but its internalization is not mediated by LDL receptor-related protein.Exp Cell Res. 2002 Jul 15;277(2):210-9. doi: 10.1006/excr.2002.5556.
|
172 |
Overexpression of Cathepsin L is associated with chemoresistance and invasion of epithelial ovarian cancer.Oncotarget. 2016 Jul 19;7(29):45995-46001. doi: 10.18632/oncotarget.10276.
|
173 |
A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.Int J Gynecol Cancer. 2018 Jan;28(1):51-58. doi: 10.1097/IGC.0000000000001141.
|
174 |
Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.Adv Med Sci. 2019 Sep;64(2):235-240. doi: 10.1016/j.advms.2018.12.007. Epub 2019 Feb 26.
|
175 |
IL-8 promotes cell migration through regulating EMT by activating the Wnt/-catenin pathway in ovarian cancer.J Cell Mol Med. 2020 Jan;24(2):1588-1598. doi: 10.1111/jcmm.14848. Epub 2019 Dec 2.
|
176 |
CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer.Oncotarget. 2018 Jan 15;9(11):9751-9765. doi: 10.18632/oncotarget.24231. eCollection 2018 Feb 9.
|
177 |
Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor in ovarian cancer.Mol Oncol. 2018 Oct;12(10):1689-1705. doi: 10.1002/1878-0261.12362. Epub 2018 Aug 23.
|
178 |
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.Medicine (Baltimore). 2019 Mar;98(13):e15052. doi: 10.1097/MD.0000000000015052.
|
179 |
CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.Int J Mol Med. 2015 Feb;35(2):340-8. doi: 10.3892/ijmm.2014.2041. Epub 2014 Dec 16.
|
180 |
TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.Oncogene. 2018 Mar;37(13):1714-1729. doi: 10.1038/s41388-017-0043-9. Epub 2018 Jan 19.
|
181 |
High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.Int J Cancer. 2020 Apr 1;146(7):2007-2018. doi: 10.1002/ijc.32818. Epub 2019 Dec 19.
|
182 |
Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry.Int J Mol Med. 2019 Jan;43(1):47-56. doi: 10.3892/ijmm.2018.3967. Epub 2018 Oct 31.
|
183 |
Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma.Tumour Biol. 2015 Jun;36(6):4157-65. doi: 10.1007/s13277-015-3050-x. Epub 2015 Jan 12.
|
184 |
Novel DICER1 mutation as cause of multinodular goiter in children.Head Neck. 2013 Dec;35(12):E369-71. doi: 10.1002/hed.23250. Epub 2013 Jun 1.
|
185 |
Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.Clin Biochem. 2013 Oct;46(15):1462-8. doi: 10.1016/j.clinbiochem.2013.03.010. Epub 2013 Mar 23.
|
186 |
Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.Oncogene. 2019 Apr;38(17):3201-3215. doi: 10.1038/s41388-018-0658-5. Epub 2019 Jan 9.
|
187 |
Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.Cancer Res. 2015 Oct 1;75(19):4086-96. doi: 10.1158/0008-5472.CAN-14-3773. Epub 2015 Sep 16.
|
188 |
miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells.Arch Biochem Biophys. 2019 Jan;661:1-9. doi: 10.1016/j.abb.2018.10.014. Epub 2018 Oct 23.
|
189 |
Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.Am J Transl Res. 2019 Feb 15;11(2):1145-1153. eCollection 2019.
|
190 |
Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.Clin Cancer Res. 2016 Apr 1;22(7):1713-24. doi: 10.1158/1078-0432.CCR-15-1275. Epub 2015 Nov 18.
|
191 |
Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1.Genomics. 1994 Sep 1;23(1):163-7. doi: 10.1006/geno.1994.1473.
|
192 |
The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.Int J Oncol. 2012 Apr;40(4):1203-9. doi: 10.3892/ijo.2011.1293. Epub 2011 Dec 12.
|
193 |
E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer.Front Oncol. 2019 Mar 22;9:161. doi: 10.3389/fonc.2019.00161. eCollection 2019.
|
194 |
Targeting endothelin-1 receptor/-arrestin1 network for the treatment of ovarian cancer.Expert Opin Ther Targets. 2017 Oct;21(10):925-932. doi: 10.1080/14728222.2017.1361930. Epub 2017 Sep 5.
|
195 |
Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo.Acta Biomater. 2019 Jun;91:258-269. doi: 10.1016/j.actbio.2019.04.044. Epub 2019 Apr 23.
|
196 |
ERK Regulates HIF1-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer.Clin Cancer Res. 2019 Oct 1;25(19):5947-5960. doi: 10.1158/1078-0432.CCR-18-4145. Epub 2019 Jul 8.
|
197 |
Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.Biochem Biophys Res Commun. 2019 Mar 19;510(4):580-586. doi: 10.1016/j.bbrc.2019.01.117. Epub 2019 Feb 7.
|
198 |
Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer.Cancer Res. 2001 May 1;61(9):3806-9.
|
199 |
Oncogenic role of eIF-5A2 in the development of ovarian cancer.Cancer Res. 2004 Jun 15;64(12):4197-200. doi: 10.1158/0008-5472.CAN-03-3747.
|
200 |
Human epithelial ovarian cancer cells expressing CD105, CD44 and CD106 surface markers exhibit increased invasive capacity and drug resistance.Oncol Lett. 2019 Jun;17(6):5351-5360. doi: 10.3892/ol.2019.10221. Epub 2019 Apr 5.
|
201 |
Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells.Mol Cancer Res. 2008 Mar;6(3):352-63. doi: 10.1158/1541-7786.MCR-07-0143.
|
202 |
Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer.Cancer Res. 2018 Apr 1;78(7):1779-1791. doi: 10.1158/0008-5472.CAN-17-2460. Epub 2018 Jan 26.
|
203 |
Knockdown of EPHA1 Using CRISPR/CAS9 Suppresses Aggressive Properties of Ovarian Cancer Cells.Anticancer Res. 2017 Aug;37(8):4415-4424. doi: 10.21873/anticanres.11836.
|
204 |
The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer.Gynecol Oncol. 2014 Mar;132(3):730-8. doi: 10.1016/j.ygyno.2014.01.047. Epub 2014 Feb 4.
|
205 |
EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.J Ovarian Res. 2016 Nov 25;9(1):83. doi: 10.1186/s13048-016-0292-1.
|
206 |
Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6847-58. eCollection 2015.
|
207 |
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.Br J Cancer. 2007 Apr 10;96(7):1083-91. doi: 10.1038/sj.bjc.6603642. Epub 2007 Mar 13.
|
208 |
Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells.Int J Cancer. 2008 Jan 15;122(2):274-80. doi: 10.1002/ijc.23068.
|
209 |
Epiregulin as a marker for the initial steps of ovarian cancer development.Int J Oncol. 2011 Nov;39(5):1165-72. doi: 10.3892/ijo.2011.1123. Epub 2011 Jul 14.
|
210 |
IRE1-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.Nature. 2018 Oct;562(7727):423-428. doi: 10.1038/s41586-018-0597-x. Epub 2018 Oct 10.
|
211 |
Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells.Mol Ther. 2014 Apr;22(4):743-51. doi: 10.1038/mt.2014.1. Epub 2014 Jan 14.
|
212 |
High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.Gynecol Oncol. 2016 May;141(2):348-356. doi: 10.1016/j.ygyno.2016.02.030. Epub 2016 Mar 11.
|
213 |
ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.Cancer Lett. 2018 Feb 1;414:190-204. doi: 10.1016/j.canlet.2017.11.012. Epub 2017 Nov 22.
|
214 |
Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.BMC Cancer. 2016 Nov 17;16(1):897. doi: 10.1186/s12885-016-2929-2.
|
215 |
Role of PAR-4 in ovarian cancer.Oncotarget. 2015 Sep 8;6(26):22641-52. doi: 10.18632/oncotarget.4010.
|
216 |
IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment.Cancer Immunol Immunother. 2020 Jan;69(1):115-126. doi: 10.1007/s00262-019-02445-2. Epub 2019 Dec 4.
|
217 |
FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway.Acta Biochim Biophys Sin (Shanghai). 2019 May 23;51(5):509-516. doi: 10.1093/abbs/gmz028.
|
218 |
Role of Alpha-Smooth Muscle Actin and Fibroblast Activation Protein Alpha in Ovarian Neoplasms.Gynecol Obstet Invest. 2018;83(4):381-387. doi: 10.1159/000488088. Epub 2018 Apr 5.
|
219 |
The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.Int J Cancer. 2018 Aug 15;143(4):992-1002. doi: 10.1002/ijc.31392. Epub 2018 Apr 1.
|
220 |
Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling.Tumour Biol. 2017 Jul;39(7):1010428317712592. doi: 10.1177/1010428317712592.
|
221 |
Keratinocyte growth factor binding to fibroblast growth factor receptor 2-IIIb promotes epithelial ovarian cancer cell proliferation and invasion.J Cancer Res Ther. 2018 Jun;14(Supplement):S347-S353. doi: 10.4103/0973-1482.235353.
|
222 |
Role of fibroblast growth factor 8 in growth and progression of hormonal cancer.Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):257-66. doi: 10.1016/j.cytogfr.2007.04.010. Epub 2007 May 23.
|
223 |
Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.BMC Cancer. 2019 Jun 14;19(1):584. doi: 10.1186/s12885-019-5757-3.
|
224 |
VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.Neoplasia. 2014 Apr;16(4):343-53.e1-2. doi: 10.1016/j.neo.2014.04.003.
|
225 |
C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.Br J Cancer. 2008 Oct 21;99(8):1269-75. doi: 10.1038/sj.bjc.6604650.
|
226 |
lncRNA UCA1 Mediates Resistance to Cisplatin by Regulating the miR-143/FOSL2-Signaling Pathway in Ovarian Cancer.Mol Ther Nucleic Acids. 2019 Sep 6;17:92-101. doi: 10.1016/j.omtn.2019.05.007. Epub 2019 May 24.
|
227 |
MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.Exp Ther Med. 2018 Feb;15(2):1672-1679. doi: 10.3892/etm.2017.5529. Epub 2017 Nov 17.
|
228 |
Forkhead box Q1: A key player in the pathogenesis of tumors (Review).Int J Oncol. 2016 Jul;49(1):51-8. doi: 10.3892/ijo.2016.3517. Epub 2016 May 12.
|
229 |
Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.Gynecol Oncol. 2019 May;153(2):405-415. doi: 10.1016/j.ygyno.2019.01.020. Epub 2019 Feb 20.
|
230 |
The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma.Mol Oncol. 2019 Apr;13(4):757-780. doi: 10.1002/1878-0261.12425. Epub 2019 Jan 19.
|
231 |
The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.Sci Signal. 2016 Oct 4;9(448):ra97. doi: 10.1126/scisignal.aaf8175.
|
232 |
Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.Cancer Res. 1995 Oct 1;55(19):4367-74.
|
233 |
Epithelialmesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells.Mol Med Rep. 2019 Mar;19(3):1501-1508. doi: 10.3892/mmr.2019.9814. Epub 2019 Jan 3.
|
234 |
Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFRAkt pathway.Mol Med Rep. 2019 Mar;19(3):2287-2296. doi: 10.3892/mmr.2019.9876. Epub 2019 Jan 17.
|
235 |
Regulation of Survivin Isoform Expression by GLI Proteins in Ovarian Cancer.Cells. 2019 Feb 6;8(2):128. doi: 10.3390/cells8020128.
|
236 |
Targeted Microbubbles for Ultrasound Mediated Short Hairpin RNA Plasmid Transfection to Inhibit Survivin Gene Expression and Induce Apoptosis of Ovarian Cancer A2780/DDP Cells.Mol Pharm. 2015 Sep 8;12(9):3137-45. doi: 10.1021/mp500835z. Epub 2015 Aug 3.
|
237 |
Glypican-3 gene silencing for ovarian cancer using siRNA-PLGA hybrid micelles in a murine peritoneal dissemination model.J Pharmacol Sci. 2019 Mar;139(3):231-239. doi: 10.1016/j.jphs.2019.01.009. Epub 2019 Feb 10.
|
238 |
Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.J Int Med Res. 2018 Feb;46(2):723-731. doi: 10.1177/0300060517717625. Epub 2017 Sep 12.
|
239 |
GRP137 promotes cell proliferation and metastasis through regulation of the PI3K/AKT pathway in human ovarian cancer.Tumori. 2018 Oct;104(5):330-337. doi: 10.5301/tj.5000703. Epub 2018 May 9.
|
240 |
Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.Oncogene. 2016 Apr 28;35(17):2186-96. doi: 10.1038/onc.2015.279. Epub 2015 Jul 27.
|
241 |
Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.Cell Cycle. 2017 Apr 3;16(7):693-706. doi: 10.1080/15384101.2017.1295181. Epub 2017 Feb 22.
|
242 |
GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer.Oncogene. 2016 Aug 25;35(34):4471-80. doi: 10.1038/onc.2015.505. Epub 2016 Jan 25.
|
243 |
The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.Oncogene. 2020 Feb;39(7):1600-1616. doi: 10.1038/s41388-019-1087-9. Epub 2019 Nov 7.
|
244 |
Selection of suitable reference genes for gene expression studies in normal human ovarian tissues, borderline ovarian tumours and ovarian cancer.Mol Med Rep. 2016 Dec;14(6):5725-5731. doi: 10.3892/mmr.2016.5933. Epub 2016 Nov 8.
|
245 |
Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.Cancer Med. 2014 Oct;3(5):1159-69. doi: 10.1002/cam4.301. Epub 2014 Jul 24.
|
246 |
HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.Cell Physiol Biochem. 2018;48(4):1505-1518. doi: 10.1159/000492260. Epub 2018 Aug 2.
|
247 |
HDAC10 as a potential therapeutic target in ovarian cancer.Gynecol Oncol. 2017 Mar;144(3):613-620. doi: 10.1016/j.ygyno.2017.01.009. Epub 2017 Jan 7.
|
248 |
Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1-mediated regulation of apoptosis and autophagy.Theranostics. 2019 Jan 30;9(4):1096-1114. doi: 10.7150/thno.29673. eCollection 2019.
|
249 |
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer.Cancer Res. 2019 Nov 1;79(21):5482-5489. doi: 10.1158/0008-5472.CAN-19-1302. Epub 2019 Jul 16.
|
250 |
Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.Oncogene. 2017 Mar 23;36(12):1707-1720. doi: 10.1038/onc.2016.337. Epub 2016 Oct 3.
|
251 |
MicroRNA let?d?p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1.Int J Oncol. 2019 May;54(5):1771-1784. doi: 10.3892/ijo.2019.4731. Epub 2019 Feb 27.
|
252 |
Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5.Gynecol Oncol. 2018 Nov;151(2):345-355. doi: 10.1016/j.ygyno.2018.08.032. Epub 2018 Sep 7.
|
253 |
The effect of lncRNA HOTAIR on chemoresistance of ovarian cancer through regulation of HOXA7.Biol Chem. 2018 Apr 25;399(5):485-497. doi: 10.1515/hsz-2017-0274.
|
254 |
Overexpression of MEF2D contributes to oncogenic malignancy and chemotherapeutic resistance in ovarian carcinoma.Am J Cancer Res. 2019 May 1;9(5):887-905. eCollection 2019.
|
255 |
A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.BMC Cancer. 2018 Mar 5;18(1):254. doi: 10.1186/s12885-018-4153-8.
|
256 |
Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):115-28. doi: 10.1016/j.jsbmb.2007.10.004. Epub 2007 Nov 17.
|
257 |
Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma.Int J Cancer. 1993 May 8;54(2):220-5. doi: 10.1002/ijc.2910540210.
|
258 |
The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model.PLoS One. 2016 Dec 20;11(12):e0168389. doi: 10.1371/journal.pone.0168389. eCollection 2016.
|
259 |
NF-B p65 promotes ovarian cancer cell proliferation and migration via regulating mortalin.J Cell Mol Med. 2019 Jun;23(6):4338-4348. doi: 10.1111/jcmm.14325. Epub 2019 Apr 14.
|
260 |
Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer.Clin Biochem. 2008 May;41(7-8):561-9. doi: 10.1016/j.clinbiochem.2008.01.004. Epub 2008 Jan 16.
|
261 |
Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.Clin Cancer Res. 2003 Feb;9(2):779-85.
|
262 |
SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women.Fam Cancer. 2009;8(2):135-44. doi: 10.1007/s10689-008-9218-4. Epub 2008 Sep 27.
|
263 |
Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues.Int J Mol Med. 2008 Oct;22(4):421-31.
|
264 |
Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.Mol Cancer Res. 2019 Aug;17(8):1710-1720. doi: 10.1158/1541-7786.MCR-18-1233. Epub 2019 May 20.
|
265 |
LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.BMC Cancer. 2012 Jul 31;12:325. doi: 10.1186/1471-2407-12-325.
|
266 |
IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma.Histopathology. 2011 Apr;58(5):729-38. doi: 10.1111/j.1365-2559.2011.03817.x. Epub 2011 Apr 4.
|
267 |
A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.Br J Cancer. 2017 Aug 22;117(5):666-674. doi: 10.1038/bjc.2017.199. Epub 2017 Jun 29.
|
268 |
The NF-B-modulated miR-19a-3p enhances malignancy of human ovarian cancer cells through inhibition of IGFBP-3 expression.Mol Carcinog. 2019 Dec;58(12):2254-2265. doi: 10.1002/mc.23113. Epub 2019 Sep 12.
|
269 |
The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesis.Sci Rep. 2016 Dec 23;6:39334. doi: 10.1038/srep39334.
|
270 |
Interleukin-11 receptor expression in primary ovarian carcinomas.Gynecol Oncol. 2001 Feb;80(2):121-7. doi: 10.1006/gyno.2000.6064.
|
271 |
Common Polymorphisms in IL-27 Genes May Contribute to Risk of Various Human Diseases in Asian Populations: A Meta-Analysis.Med Sci Monit. 2016 Mar 7;22:766-75. doi: 10.12659/msm.895558.
|
272 |
Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice.J Ovarian Res. 2014 Jan 20;7:8. doi: 10.1186/1757-2215-7-8.
|
273 |
Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.J Ovarian Res. 2016 Jun 27;9(1):38. doi: 10.1186/s13048-016-0248-5.
|
274 |
Dual-specificity phosphatase 5 suppresses ovarian cancer progression by inhibiting IL-33 signaling.Am J Transl Res. 2019 Feb 15;11(2):844-854. eCollection 2019.
|
275 |
Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.J Transl Med. 2018 Mar 20;16(1):73. doi: 10.1186/s12967-018-1432-8.
|
276 |
Effect of integrinlinked kinase gene silencing on microRNA expression in ovarian cancer.Mol Med Rep. 2017 Nov;16(5):7267-7276. doi: 10.3892/mmr.2017.7523. Epub 2017 Sep 19.
|
277 |
Targeting INHBA in Ovarian Cancer Cells Suppresses Cancer Xenograft Growth by Attenuating Stromal Fibroblast Activation.Dis Markers. 2019 Nov 11;2019:7275289. doi: 10.1155/2019/7275289. eCollection 2019.
|
278 |
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1362-70. doi: 10.1158/1055-9965.EPI-12-0229. Epub 2012 Jun 22.
|
279 |
Crimean-Congo Hemorrhagic Fever Virus Suppresses Innate Immune Responses via a Ubiquitin and ISG15 Specific Protease.Cell Rep. 2017 Sep 5;20(10):2396-2407. doi: 10.1016/j.celrep.2017.08.040.
|
280 |
miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin 5 expression.Am J Pathol. 2013 May;182(5):1876-89. doi: 10.1016/j.ajpath.2013.01.039. Epub 2013 Mar 15.
|
281 |
Expression of integrin -6 is associated with multi drug resistance and prognosis in ovarian cancer.Oncol Lett. 2019 Apr;17(4):3974-3980. doi: 10.3892/ol.2019.10056. Epub 2019 Feb 20.
|
282 |
Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers.Life Sci. 2007 Mar 27;80(16):1458-65. doi: 10.1016/j.lfs.2007.01.015. Epub 2007 Jan 20.
|
283 |
Non-catalytic region of tyrosine kinase adaptor protein 2 (NCK2) pathways as factor promoting aggressiveness in ovarian cancer.Int J Biol Markers. 2018 Jan;33(1):124-131. doi: 10.5301/ijbm.5000264.
|
284 |
Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.Med Sci Monit. 2018 Dec 10;24:8933-8940. doi: 10.12659/MSM.911518.
|
285 |
Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression.Mol Cancer. 2017 Oct 17;16(1):163. doi: 10.1186/s12943-017-0732-6.
|
286 |
Calcium-activated potassium channels as potential early markers of human cervical cancer.Oncol Lett. 2018 May;15(5):7249-7254. doi: 10.3892/ol.2018.8187. Epub 2018 Mar 7.
|
287 |
Low expression of KCNN3 may affect drug resistance in ovarian cancer.Mol Med Rep. 2018 Aug;18(2):1377-1386. doi: 10.3892/mmr.2018.9107. Epub 2018 May 31.
|
288 |
Lysine demethylase2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelialmesenchymal transition.Oncol Rep. 2019 Feb;41(2):917-927. doi: 10.3892/or.2018.6888. Epub 2018 Nov 27.
|
289 |
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.Oncogene. 2017 Mar;36(11):1537-1545. doi: 10.1038/onc.2016.320. Epub 2016 Oct 3.
|
290 |
KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance.Mol Med Rep. 2017 Sep;16(3):3573-3580. doi: 10.3892/mmr.2017.6960. Epub 2017 Jul 12.
|
291 |
Targeting estrogen receptor beta (ER) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ER expression and functionality.Oncogenesis. 2018 Feb 9;7(2):15. doi: 10.1038/s41389-018-0027-9.
|
292 |
Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.Int J Gynecol Cancer. 2017 Mar;27(3):412-419. doi: 10.1097/IGC.0000000000000908.
|
293 |
A comprehensive study on genome-wide coexpression network of KHDRBS1/Sam68 reveals its cancer and patient-specific association.Sci Rep. 2019 Jul 31;9(1):11083. doi: 10.1038/s41598-019-47558-x.
|
294 |
Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells.Oncogene. 2004 Nov 4;23(52):8557-62. doi: 10.1038/sj.onc.1207926.
|
295 |
Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.Mol Oncol. 2011 Feb;5(1):48-60. doi: 10.1016/j.molonc.2010.08.002. Epub 2010 Aug 11.
|
296 |
Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.J Cancer Res Clin Oncol. 2018 Jun;144(6):1109-1118. doi: 10.1007/s00432-018-2623-7. Epub 2018 Mar 15.
|
297 |
Kallikrein-related peptidase 3 (KLK3/PSA) single nucleotide polymorphisms and ovarian cancer survival.Twin Res Hum Genet. 2011 Aug;14(4):323-7. doi: 10.1375/twin.14.4.323.
|
298 |
Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.PLoS One. 2019 Feb 27;14(2):e0212968. doi: 10.1371/journal.pone.0212968. eCollection 2019.
|
299 |
Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.BMC Cancer. 2019 Jul 15;19(1):696. doi: 10.1186/s12885-019-5901-0.
|
300 |
Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.J Ovarian Res. 2014 Dec 5;7:109. doi: 10.1186/s13048-014-0109-z.
|
301 |
Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation.Oncoimmunology. 2017 Aug 21;6(9):e1339854. doi: 10.1080/2162402X.2017.1339854. eCollection 2017.
|
302 |
Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.Breast Cancer Res. 2008;10(1):R17. doi: 10.1186/bcr1863. Epub 2008 Feb 14.
|
303 |
Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.Br J Cancer. 2018 Oct;119(7):1-9. doi: 10.1038/s41416-018-0260-1. Epub 2018 Oct 5.
|
304 |
L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.PLoS One. 2016 Jan 13;11(1):e0146885. doi: 10.1371/journal.pone.0146885. eCollection 2016.
|
305 |
Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.Cancer Discov. 2016 Sep;6(9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. Epub 2016 Jul 17.
|
306 |
Lentivirus-mediated RNA Interference Targeting LAPTM4B Inhibits Human Ovarian Cancer Cell Invasion In Vitro.Chem Biol Drug Des. 2016 Jan;87(1):121-30. doi: 10.1111/cbdd.12632. Epub 2015 Aug 31.
|
307 |
The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.Nucleic Acids Res. 2016 Feb 18;44(3):1227-46. doi: 10.1093/nar/gkv1515. Epub 2015 Dec 29.
|
308 |
Outcome in serous ovarian cancer is not associated with LATS expression.J Cancer Res Clin Oncol. 2019 Nov;145(11):2737-2749. doi: 10.1007/s00432-019-03037-4. Epub 2019 Oct 4.
|
309 |
Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.Cancer Immunol Immunother. 2019 Sep;68(9):1515-1526. doi: 10.1007/s00262-019-02385-x. Epub 2019 Sep 12.
|
310 |
Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway.Am J Transl Res. 2019 Jun 15;11(6):3862-3878. eCollection 2019.
|
311 |
Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.Int J Mol Sci. 2017 Jun 8;18(6):1230. doi: 10.3390/ijms18061230.
|
312 |
Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer.J Cell Biochem. 2012 Aug;113(8):2679-86. doi: 10.1002/jcb.24143.
|
313 |
LGR5 and LGR6 in stem cell biology and ovarian cancer.Oncotarget. 2017 Aug 11;9(1):1346-1355. doi: 10.18632/oncotarget.20178. eCollection 2018 Jan 2.
|
314 |
Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.Oncogene. 2019 Feb;38(9):1576-1584. doi: 10.1038/s41388-018-0523-6. Epub 2018 Oct 10.
|
315 |
Upregulation of Limk1 caused by microRNA-138 loss aggravates the metastasis of ovarian cancer by activation of Limk1/cofilin signaling.Oncol Rep. 2014 Nov;32(5):2070-6. doi: 10.3892/or.2014.3461. Epub 2014 Sep 2.
|
316 |
The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer.Oncogene. 2019 Feb;38(9):1381-1397. doi: 10.1038/s41388-018-0512-9. Epub 2018 Sep 28.
|
317 |
Clinical and biological significance of an isozyme tumor marker--PLAP.Clin Biochem. 1987 Dec;20(6):387-92. doi: 10.1016/0009-9120(87)90003-8.
|
318 |
Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.Gynecol Oncol. 2017 Jul;146(1):170-178. doi: 10.1016/j.ygyno.2017.05.001. Epub 2017 May 9.
|
319 |
LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.BMC Cancer. 2016 Nov 4;16(1):846. doi: 10.1186/s12885-016-2865-1.
|
320 |
Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.J Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.
|
321 |
Lipoxygenase pathway receptor expression in ovarian cancer.Reprod Sci. 2008 Apr;15(3):321-6. doi: 10.1177/1933719108316390.
|
322 |
Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.Biochim Biophys Acta. 2016 Feb;1863(2):236-43. doi: 10.1016/j.bbamcr.2015.11.011. Epub 2015 Nov 17.
|
323 |
Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells.Clin Exp Metastasis. 2011 Dec;28(8):887-97. doi: 10.1007/s10585-011-9420-x. Epub 2011 Sep 2.
|
324 |
Androgen receptor gene mutations do not occur in ovarian cancer.Anticancer Res. 2000 Mar-Apr;20(2A):815-9.
|
325 |
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.BMC Cancer. 2014 Nov 18;14:837. doi: 10.1186/1471-2407-14-837.
|
326 |
Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.PLoS One. 2007 Dec 5;2(12):e1279. doi: 10.1371/journal.pone.0001279.
|
327 |
Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer.Transl Oncol. 2019 Jul;12(7):917-924. doi: 10.1016/j.tranon.2019.04.009. Epub 2019 May 10.
|
328 |
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.Cancer Res. 2004 Jun 15;64(12):4209-17. doi: 10.1158/0008-5472.CAN-04-0060.
|
329 |
ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis.JCI Insight. 2017 Sep 21;2(18):e91828. doi: 10.1172/jci.insight.91828. eCollection 2017 Sep 21.
|
330 |
Expression of Syk and MAP4 proteins in ovarian cancer.J Cancer Res Clin Oncol. 2019 Apr;145(4):909-919. doi: 10.1007/s00432-019-02856-9. Epub 2019 Feb 8.
|
331 |
Combined MEK and BCL-2/X(L) Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.Mol Cancer Ther. 2019 Mar;18(3):642-655. doi: 10.1158/1535-7163.MCT-18-0413. Epub 2019 Jan 24.
|
332 |
PKP3 interactions with MAPK-JNK-ERK1/2-mTOR pathway regulates autophagy and invasion in ovarian cancer.Biochem Biophys Res Commun. 2019 Jan 8;508(2):646-653. doi: 10.1016/j.bbrc.2018.11.163. Epub 2018 Dec 4.
|
333 |
MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.Oncotarget. 2016 Jun 21;7(25):37649-37663. doi: 10.18632/oncotarget.8726.
|
334 |
Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis.Oncotarget. 2017 Aug 24;8(43):74947-74961. doi: 10.18632/oncotarget.20471. eCollection 2017 Sep 26.
|
335 |
METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells.Int J Mol Sci. 2018 Sep 29;19(10):2976. doi: 10.3390/ijms19102976.
|
336 |
MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966. doi: 10.1073/pnas.1814742116. Epub 2019 Feb 4.
|
337 |
Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.Oncogene. 2012 Oct 18;31(42):4567-76. doi: 10.1038/onc.2011.611. Epub 2012 Jan 16.
|
338 |
Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer.Onco Targets Ther. 2019 Nov 21;12:10057-10075. doi: 10.2147/OTT.S228678. eCollection 2019.
|
339 |
Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer.Reprod Sci. 2017 Apr;24(4):494-501. doi: 10.1177/1933719116648212. Epub 2016 Sep 27.
|
340 |
The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers.Transl Res. 2019 Apr;206:71-90. doi: 10.1016/j.trsl.2018.11.001. Epub 2018 Nov 20.
|
341 |
Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.Clin Transl Oncol. 2018 Mar;20(3):374-381. doi: 10.1007/s12094-017-1724-0. Epub 2017 Aug 1.
|
342 |
Primary Ovarian Tumors With Lymphogenic and Hematogenic Metastasis Express High MMP-14, Which Colocalizes With Highly Sulfated Chondroitin Sulfate in the Stroma.Int J Gynecol Pathol. 2020 Mar;39(2):184-192. doi: 10.1097/PGP.0000000000000587.
|
343 |
Aberrant Activation Of Hedgehog Signalling Promotes Cell Migration And Invasion Via Matrix Metalloproteinase-7 In Ovarian Cancer Cells.J Cancer. 2019 Jan 29;10(4):990-1003. doi: 10.7150/jca.26478. eCollection 2019.
|
344 |
miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.Tumour Biol. 2016 Apr;37(4):5437-43. doi: 10.1007/s13277-015-4377-z. Epub 2015 Nov 12.
|
345 |
Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.Int J Oncol. 2016 Nov;49(5):1945-1952. doi: 10.3892/ijo.2016.3683. Epub 2016 Sep 6.
|
346 |
PSP94, an upstream signaling mediator of prostasin found highly elevated in ovarian cancer.Cell Death Dis. 2014 Sep 4;5(9):e1407. doi: 10.1038/cddis.2014.374.
|
347 |
MicroRNA-30c inhibits metastasis of ovarian cancer by targeting metastasis-associated gene 1.J Cancer Res Ther. 2017;13(4):676-682. doi: 10.4103/jcrt.JCRT_132_17.
|
348 |
Knockout of MTF1 Inhibits the Epithelial to Mesenchymal Transition in Ovarian Cancer Cells. J Cancer. 2018 Nov 11;9(24):4578-4585.
|
349 |
A biosensor for determination of the circulating biomarker CA125/MUC16 by Surface Plasmon Resonance Imaging.Talanta. 2020 Jan 1;206:120187. doi: 10.1016/j.talanta.2019.120187. Epub 2019 Jul 29.
|
350 |
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.EBioMedicine. 2019 May;43:225-237. doi: 10.1016/j.ebiom.2019.03.027. Epub 2019 Mar 18.
|
351 |
P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.J Ovarian Res. 2018 Jan 17;11(1):8. doi: 10.1186/s13048-018-0380-5.
|
352 |
Nucleus accumbens-1/GADD45GIP1 axis mediates cisplatin resistance through cellular senescence in ovarian cancer.Oncol Lett. 2017 Jun;13(6):4713-4719. doi: 10.3892/ol.2017.6099. Epub 2017 Apr 26.
|
353 |
Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.Cancer Res. 2017 Jul 15;77(14):3857-3869. doi: 10.1158/0008-5472.CAN-16-3079. Epub 2017 May 15.
|
354 |
NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and chemo-resistance in ovarian cancer.Biochem Biophys Res Commun. 2020 Feb 5;522(2):292-299. doi: 10.1016/j.bbrc.2019.11.014. Epub 2019 Nov 21.
|
355 |
AIB1 regulates the ovarian cancer cell cycle through TUG1.Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5610-5617. doi: 10.26355/eurrev_201712_14002.
|
356 |
Activation of androgen receptor-associated protein 70 (ARA70) mRNA expression in ovarian cancer.Gynecol Oncol. 2001 Feb;80(2):132-8. doi: 10.1006/gyno.2000.6068.
|
357 |
Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.J Biol Chem. 2017 Apr 14;292(15):6339-6351. doi: 10.1074/jbc.M116.746859. Epub 2017 Feb 23.
|
358 |
NEDD9 overexpression is associated with the progression of and an unfavorable prognosis in epithelial ovarian cancer.Hum Pathol. 2014 Feb;45(2):401-8. doi: 10.1016/j.humpath.2013.10.005. Epub 2013 Oct 19.
|
359 |
PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2.Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8239-8248. doi: 10.26355/eurrev_201910_19133.
|
360 |
TRIM52 plays an oncogenic role in ovarian cancer associated with NF-kB pathway.Cell Death Dis. 2018 Sep 5;9(9):908. doi: 10.1038/s41419-018-0881-6.
|
361 |
Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway.Mol Cancer Ther. 2015 May;14(5):1202-12. doi: 10.1158/1535-7163.MCT-14-0911. Epub 2015 Feb 27.
|
362 |
THRA1 and D17S183 flank an interval of < 4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21.Am J Hum Genet. 1993 Apr;52(4):718-22.
|
363 |
Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.Mol Cancer. 2011 Mar 8;10:24. doi: 10.1186/1476-4598-10-24.
|
364 |
Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer.Onco Targets Ther. 2019 Sep 30;12:8015-8022. doi: 10.2147/OTT.S203550. eCollection 2019.
|
365 |
The role of Sox6 and Netrin-1 in ovarian cancer cell growth, invasiveness, and angiogenesis.Tumour Biol. 2017 May;39(5):1010428317705508. doi: 10.1177/1010428317705508.
|
366 |
Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer.Medicine (Baltimore). 2017 Jul;96(30):e7621. doi: 10.1097/MD.0000000000007621.
|
367 |
Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.J Pathol. 2019 Jul;248(3):352-362. doi: 10.1002/path.5264. Epub 2019 May 14.
|
368 |
Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.Am J Physiol Regul Integr Comp Physiol. 2009 Jun;296(6):R1716-25. doi: 10.1152/ajpregu.00075.2009. Epub 2009 Mar 18.
|
369 |
Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.Oncotarget. 2016 Mar 1;7(9):10594-605. doi: 10.18632/oncotarget.7236.
|
370 |
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study.Int J Gynecol Cancer. 2020 Feb;30(2):213-220. doi: 10.1136/ijgc-2019-000512. Epub 2019 Nov 27.
|
371 |
The role of peptidylarginine deiminase 4 in ovarian cancer cell tumorigenesis and invasion.Tumour Biol. 2016 Apr;37(4):5375-83. doi: 10.1007/s13277-015-4363-5. Epub 2015 Nov 12.
|
372 |
Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.Oncogene. 2016 Apr 28;35(17):2178-85. doi: 10.1038/onc.2015.278. Epub 2015 Aug 10.
|
373 |
PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.Cell Death Dis. 2019 Feb 18;10(3):166. doi: 10.1038/s41419-019-1415-6.
|
374 |
Analysis of epigenetic alterations to proprotein convertase genes in disease.Methods Mol Biol. 2011;768:231-45. doi: 10.1007/978-1-61779-204-5_12.
|
375 |
Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.FASEB J. 2019 May;33(5):6596-6608. doi: 10.1096/fj.201802067RR. Epub 2019 Feb 25.
|
376 |
Platelet-derived growth factor-D promotes ovarian cancer invasion by regulating matrix metalloproteinases 2 and 9.Asian Pac J Cancer Prev. 2011;12(12):3367-70.
|
377 |
Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.J Cell Physiol. 2019 May;234(5):6361-6370. doi: 10.1002/jcp.27369. Epub 2018 Sep 19.
|
378 |
Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer.Mol Cancer Res. 2008 Jun;6(6):917-28. doi: 10.1158/1541-7786.MCR-08-0093.
|
379 |
Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites.Hum Gene Ther. 2001 Sep 20;12(14):1713-29. doi: 10.1089/104303401750476221.
|
380 |
Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.Tohoku J Exp Med. 2018 Apr;244(4):291-296. doi: 10.1620/tjem.244.291.
|
381 |
Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice.Endocrinology. 2009 Nov;150(11):4846-54. doi: 10.1210/en.2009-0730. Epub 2009 Oct 1.
|
382 |
Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects.J Cell Physiol. 2019 Sep;234(9):15708-15716. doi: 10.1002/jcp.28224. Epub 2019 Jan 29.
|
383 |
Ginsenoside 20(S)-Rg3 Inhibits the Warburg Effect Via Modulating DNMT3A/ MiR-532-3p/HK2 Pathway in Ovarian Cancer Cells.Cell Physiol Biochem. 2018;45(6):2548-2559. doi: 10.1159/000488273. Epub 2018 Mar 16.
|
384 |
Identification of clinical trait-related lncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer.EPMA J. 2019 Jul 19;10(3):273-290. doi: 10.1007/s13167-019-00175-0. eCollection 2019 Sep.
|
385 |
Plasminogen Activator Inhibitor Type 1 in Blood at Onset of Chemotherapy Unfavorably Affects Survival in Primary Ovarian Cancer.Adv Exp Med Biol. 2019;1153:47-54. doi: 10.1007/5584_2019_353.
|
386 |
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.Oncotarget. 2012 Jan;3(1):78-83. doi: 10.18632/oncotarget.332.
|
387 |
Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.PLoS One. 2019 Jun 26;14(6):e0217521. doi: 10.1371/journal.pone.0217521. eCollection 2019.
|
388 |
The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.J Ovarian Res. 2016 Mar 31;9:20. doi: 10.1186/s13048-016-0228-9.
|
389 |
Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay.Acta Biochim Pol. 2000;47(1):157-64.
|
390 |
Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C.Cancer Res. 2009 Dec 15;69(24):9306-14. doi: 10.1158/0008-5472.CAN-09-1213.
|
391 |
Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.Int J Cancer. 2018 Jul 15;143(2):355-367. doi: 10.1002/ijc.31324. Epub 2018 Mar 8.
|
392 |
Association between LMP2/LMP7 genetic variability and the metastasis risk of ovarian cancer in Chinese women in Beijing.Hum Immunol. 2014 Mar;75(3):239-44. doi: 10.1016/j.humimm.2013.12.006. Epub 2013 Dec 27.
|
393 |
Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor.BMC Cancer. 2018 Oct 19;18(1):999. doi: 10.1186/s12885-018-4918-0.
|
394 |
EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.J Cancer Res Clin Oncol. 2019 Oct;145(10):2519-2527. doi: 10.1007/s00432-019-03017-8. Epub 2019 Sep 4.
|
395 |
Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.ACS Omega. 2019 May 31;4(5):9251-9261. doi: 10.1021/acsomega.9b01093. Epub 2019 May 24.
|
396 |
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.Gynecol Oncol. 2017 Nov;147(2):396-401. doi: 10.1016/j.ygyno.2017.08.024. Epub 2017 Sep 19.
|
397 |
PRL-3 suppresses c-Fos and integrin 2 expression in ovarian cancer cells.BMC Cancer. 2013 Feb 18;13:80. doi: 10.1186/1471-2407-13-80.
|
398 |
Differential expression of Fas family members and Bcl-2 family members in benign versus malignant epithelial ovarian cancer (EOC) in North Indian population.Mol Cell Biochem. 2012 Sep;368(1-2):119-26. doi: 10.1007/s11010-012-1350-7. Epub 2012 Jun 12.
|
399 |
Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer.Oncotarget. 2018 Jan 4;9(7):7522-7533. doi: 10.18632/oncotarget.23943. eCollection 2018 Jan 26.
|
400 |
PTN signaling: Components and mechanistic insights in human ovarian cancer.Mol Carcinog. 2015 Dec;54(12):1772-85. doi: 10.1002/mc.22249. Epub 2014 Nov 21.
|
401 |
LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer.Mol Med Rep. 2016 Sep;14(3):2465-72. doi: 10.3892/mmr.2016.5572. Epub 2016 Jul 28.
|
402 |
Adipokine RBP4 drives ovarian cancer cell migration.J Ovarian Res. 2018 Apr 11;11(1):29. doi: 10.1186/s13048-018-0397-9.
|
403 |
Expression loss and revivification of RhoB gene in ovary carcinoma carcinogenesis and development.PLoS One. 2013 Nov 1;8(11):e78417. doi: 10.1371/journal.pone.0078417. eCollection 2013.
|
404 |
RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.Gynecol Oncol. 2010 Mar;116(3):563-71. doi: 10.1016/j.ygyno.2009.11.015.
|
405 |
Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer.J Immunol Res. 2019 Mar 17;2019:9394615. doi: 10.1155/2019/9394615. eCollection 2019.
|
406 |
Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.Transl Oncol. 2017 Jun;10(3):346-356. doi: 10.1016/j.tranon.2017.01.014. Epub 2017 Mar 23.
|
407 |
Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables.J Exp Clin Cancer Res. 2012 Oct 24;31(1):89. doi: 10.1186/1756-9966-31-89.
|
408 |
Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism.Oncotarget. 2016 Jan 5;7(1):712-28. doi: 10.18632/oncotarget.6412.
|
409 |
Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines.Med Oncol. 2016 Feb;33(2):11. doi: 10.1007/s12032-015-0724-6. Epub 2016 Jan 5.
|
410 |
MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1.Biochem Biophys Res Commun. 2013 Nov 29;441(4):693-700. doi: 10.1016/j.bbrc.2013.10.053. Epub 2013 Oct 21.
|
411 |
Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.J Ovarian Res. 2019 Nov 15;12(1):110. doi: 10.1186/s13048-019-0578-1.
|
412 |
RSF1 is a positive regulator of NF-B-induced gene expression required for ovarian cancer chemoresistance.Cancer Res. 2014 Apr 15;74(8):2258-69. doi: 10.1158/0008-5472.CAN-13-2459. Epub 2014 Feb 24.
|
413 |
The role of R-spondin 1 through activating Wnt/-catenin in the growth, survival and migration of ovarian cancer cells.Gene. 2019 Mar 20;689:124-130. doi: 10.1016/j.gene.2018.11.098. Epub 2018 Dec 17.
|
414 |
Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors.Mol Med Rep. 2013 May;7(5):1705-9. doi: 10.3892/mmr.2013.1371. Epub 2013 Mar 14.
|
415 |
Mammaglobin B expression in human endometrial cancer.Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1090-6. doi: 10.1111/j.1525-1438.2007.01137.x. Epub 2007 Nov 16.
|
416 |
Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma.Int J Mol Med. 2015 May;35(5):1374-80. doi: 10.3892/ijmm.2015.2142. Epub 2015 Mar 17.
|
417 |
VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer.Cell Mol Biol Lett. 2018 Jan 3;23:2. doi: 10.1186/s11658-017-0058-9. eCollection 2018.
|
418 |
Levels of corticosteroid-binding globulin mRNA in human ovarian cancers.Tumour Biol. 1999 Sep-Oct;20(5):263-9. doi: 10.1159/000030073.
|
419 |
Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.Eur J Obstet Gynecol Reprod Biol. 2012 Nov;165(1):96-103. doi: 10.1016/j.ejogrb.2012.06.031. Epub 2012 Jul 18.
|
420 |
SERPIND1 Affects the Malignant Biological Behavior of Epithelial Ovarian Cancer via the PI3K/AKT Pathway: A Mechanistic Study.Front Oncol. 2019 Oct 4;9:954. doi: 10.3389/fonc.2019.00954. eCollection 2019.
|
421 |
The core genes involved in the promotion of depression in patients with ovarian cancer.Oncol Lett. 2019 Dec;18(6):5995-6007. doi: 10.3892/ol.2019.10934. Epub 2019 Sep 30.
|
422 |
Malignant ascites: a source of therapeutic protein against ovarian cancer?.Oncotarget. 2019 Oct 15;10(57):5894-5905. doi: 10.18632/oncotarget.27185. eCollection 2019 Oct 15.
|
423 |
Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.PLoS One. 2012;7(2):e31885. doi: 10.1371/journal.pone.0031885. Epub 2012 Feb 21.
|
424 |
Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer.Front Oncol. 2019 Jul 9;9:542. doi: 10.3389/fonc.2019.00542. eCollection 2019.
|
425 |
SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1 pathway and Drp1-mediated mitochondrial fission in ovarian cancer.Cancer Lett. 2020 Jan 28;469:89-101. doi: 10.1016/j.canlet.2019.10.029. Epub 2019 Oct 19.
|
426 |
Downregulated Salt-inducible Kinase 3 Expression Promotes Chemoresistance in Serous Ovarian Cancer via the ATP-binding Cassette Protein ABCG2.J Cancer. 2019 Oct 15;10(24):6025-6036. doi: 10.7150/jca.34886. eCollection 2019.
|
427 |
Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression.Mol Med Rep. 2017 Apr;15(4):1638-1646. doi: 10.3892/mmr.2017.6183. Epub 2017 Feb 8.
|
428 |
Human Ovarian Cancer Tissue Exhibits Increase of Mitochondrial Biogenesis and Cristae Remodeling.Cancers (Basel). 2019 Sep 12;11(9):1350. doi: 10.3390/cancers11091350.
|
429 |
Comprehensive Analysis of Expression and Prognostic Value of Sirtuins in Ovarian Cancer.Front Genet. 2019 Sep 13;10:879. doi: 10.3389/fgene.2019.00879. eCollection 2019.
|
430 |
Mechanism of Low Expression of miR-30a-5p on Epithelial-Mesenchymal Transition and Metastasis in Ovarian Cancer.DNA Cell Biol. 2019 Apr;38(4):341-351. doi: 10.1089/dna.2018.4396. Epub 2019 Mar 6.
|
431 |
The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.J Trace Elem Med Biol. 2019 Dec;56:131-138. doi: 10.1016/j.jtemb.2019.07.008. Epub 2019 Aug 19.
|
432 |
The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies.Oncotarget. 2017 Dec 27;9(9):8614-8628. doi: 10.18632/oncotarget.23808. eCollection 2018 Feb 2.
|
433 |
GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer.J Cell Physiol. 2018 Feb;233(2):1396-1401. doi: 10.1002/jcp.26023. Epub 2017 Jul 14.
|
434 |
SLC6A1-miR133a-CDX2 loop regulates SK-OV-3 ovarian cancer cell proliferation, migration and invasion.Oncol Lett. 2018 Oct;16(4):4977-4983. doi: 10.3892/ol.2018.9273. Epub 2018 Aug 7.
|
435 |
Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer. Yonsei Med J. 2017 Jan;58(1):27-34.
|
436 |
Circular RNA circ-SMAD7 promoted ovarian cancer cell proliferation and metastasis by suppressing KLF6.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5603-5610. doi: 10.26355/eurrev_201907_18294.
|
437 |
Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.Br J Cancer. 2020 Feb;122(4):564-568. doi: 10.1038/s41416-019-0687-z. Epub 2019 Dec 17.
|
438 |
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.Int J Cancer. 2020 Mar 15;146(6):1553-1567. doi: 10.1002/ijc.32673. Epub 2019 Oct 30.
|
439 |
Manganese superoxide dismutase gene polymorphism, MnSOD plasma levels and risk of epithelial ovarian cancer.J Obstet Gynaecol Res. 2008 Oct;34(5):878-84. doi: 10.1111/j.1447-0756.2008.00851.x.
|
440 |
Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC.Oncogene. 2019 May;38(22):4366-4383. doi: 10.1038/s41388-019-0728-3. Epub 2019 Feb 14.
|
441 |
Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer. 2008 Sep 15;123(6):1376-84. doi: 10.1002/ijc.23667.
|
442 |
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 Apr;17(4):870-881.
|
443 |
Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.Gynecol Oncol. 2018 Jul;150(1):143-150. doi: 10.1016/j.ygyno.2018.04.557. Epub 2018 Apr 24.
|
444 |
Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer.Sci Rep. 2019 Sep 26;9(1):13924. doi: 10.1038/s41598-019-50436-1.
|
445 |
Stanniocalcin 1 in tumor microenvironment promotes metastasis of ovarian cancer.Onco Targets Ther. 2019 Apr 11;12:2789-2798. doi: 10.2147/OTT.S196150. eCollection 2019.
|
446 |
STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.Oncol Rep. 2015 Sep;34(3):1494-502. doi: 10.3892/or.2015.4120. Epub 2015 Jul 9.
|
447 |
Expression and clinical significance of SLP-2 in ovarian tumors.Oncol Lett. 2019 May;17(5):4626-4632. doi: 10.3892/ol.2019.10116. Epub 2019 Mar 5.
|
448 |
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.Eur J Cancer. 2019 Oct;120:132-139. doi: 10.1016/j.ejca.2019.07.024. Epub 2019 Sep 12.
|
449 |
Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells.Exp Ther Med. 2017 Sep;14(3):1947-1952. doi: 10.3892/etm.2017.4788. Epub 2017 Jul 12.
|
450 |
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.
|
451 |
Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome.J Cell Mol Med. 2017 Mar;21(3):510-518. doi: 10.1111/jcmm.12995. Epub 2016 Nov 7.
|
452 |
MicroRNA-532 and microRNA-3064 inhibit cell proliferation and invasion by acting as direct regulators of human telomerase reverse transcriptase in ovarian cancer.PLoS One. 2017 Mar 14;12(3):e0173912. doi: 10.1371/journal.pone.0173912. eCollection 2017.
|
453 |
Screening the molecular targets of ovarian cancer based on bioinformatics analysis.Tumori. 2015 Jul-Aug;101(4):384-9. doi: 10.5301/tj.5000319. Epub 2015 Jul 2.
|
454 |
Transforming growth factor-beta isoform expression in human ovarian tumours.Eur J Cancer. 1997 Dec;33(14):2397-403. doi: 10.1016/s0959-8049(97)00304-3.
|
455 |
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.Oncotarget. 2016 Oct 25;7(43):69097-69110. doi: 10.18632/oncotarget.10215.
|
456 |
Extracellular tissue transglutaminase activates noncanonical NF-B signaling and promotes metastasis in ovarian cancer.Neoplasia. 2013 Jun;15(6):609-19. doi: 10.1593/neo.121878.
|
457 |
Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts.Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):67-70. doi: 10.1016/j.ejogrb.2005.10.037. Epub 2005 Dec 15.
|
458 |
Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.Sci Rep. 2018 Sep 4;8(1):13207. doi: 10.1038/s41598-018-31069-2.
|
459 |
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.Nat Genet. 2013 Apr;45(4):362-70, 370e1-2. doi: 10.1038/ng.2564.
|
460 |
Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4536-4541.
|
461 |
Prognostic values of transketolase family genes in ovarian cancer.Oncol Lett. 2019 Nov;18(5):4845-4857. doi: 10.3892/ol.2019.10818. Epub 2019 Sep 6.
|
462 |
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.Clin Cancer Res. 2017 Apr 15;23(8):1955-1966. doi: 10.1158/1078-0432.CCR-16-1453. Epub 2016 Oct 4.
|
463 |
Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers.Int J Cancer. 2012 Mar 15;130(6):1314-8. doi: 10.1002/ijc.26134. Epub 2011 May 30.
|
464 |
Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.J Exp Clin Cancer Res. 2019 Apr 25;38(1):176. doi: 10.1186/s13046-019-1171-6.
|
465 |
Knockdown of HVEM, a Lymphocyte Regulator Gene, in Ovarian Cancer Cells Increases Sensitivity to Activated T Cells.Oncol Res. 2016;24(3):189-96. doi: 10.3727/096504016X14641336229602.
|
466 |
Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer.PLoS One. 2017 Oct 18;12(10):e0186965. doi: 10.1371/journal.pone.0186965. eCollection 2017.
|
467 |
Pro-survival effects by NF-B, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.Biomed Pharmacother. 2016 Dec;84:1078-1087. doi: 10.1016/j.biopha.2016.10.028. Epub 2016 Oct 22.
|
468 |
Interferon- produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells.Angiogenesis. 2014 Jul;17(3):529-40. doi: 10.1007/s10456-013-9397-y. Epub 2013 Oct 20.
|
469 |
Tankyrase Promotes Aerobic Glycolysis and Proliferation of Ovarian Cancer through Activation of Wnt/-Catenin Signaling.Biomed Res Int. 2019 Feb 20;2019:2686340. doi: 10.1155/2019/2686340. eCollection 2019.
|
470 |
TPX2 gene silencing inhibits cell proliferation and promotes apoptosis through negative regulation of AKT signaling pathway in ovarian cancer.J Cell Biochem. 2018 Sep;119(9):7540-7555. doi: 10.1002/jcb.27065. Epub 2018 Jun 15.
|
471 |
Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27.Biomed Pharmacother. 2019 Jan;109:595-601. doi: 10.1016/j.biopha.2018.10.148. Epub 2018 Nov 3.
|
472 |
High levels of KAP1 expression are associated with aggressive clinical features in ovarian cancer.Int J Mol Sci. 2014 Dec 26;16(1):363-77. doi: 10.3390/ijms16010363.
|
473 |
TRIM59 Is a Novel Marker of Poor Prognosis and Promotes Malignant Progression of Ovarian Cancer by Inducing Annexin A2 Expression.Int J Biol Sci. 2018 Nov 3;14(14):2073-2082. doi: 10.7150/ijbs.28757. eCollection 2018.
|
474 |
Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.Int J Oncol. 2016 Jan;48(1):243-52. doi: 10.3892/ijo.2015.3254. Epub 2015 Nov 19.
|
475 |
FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3.Endocr Relat Cancer. 2013 May 30;20(3):415-29. doi: 10.1530/ERC-12-0005. Print 2013 Jun.
|
476 |
TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling.J Exp Clin Cancer Res. 2019 Feb 28;38(1):106. doi: 10.1186/s13046-019-1061-y.
|
477 |
Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model.J Cancer. 2018 Aug 6;9(17):3196-3207. doi: 10.7150/jca.20639. eCollection 2018.
|
478 |
Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses.Mol Cell Proteomics. 2007 Feb;6(2):294-304. doi: 10.1074/mcp.M600305-MCP200. Epub 2006 Nov 16.
|
479 |
MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2.Biol Res. 2019 Apr 3;52(1):18. doi: 10.1186/s40659-019-0219-6.
|
480 |
Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase.Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):E542-9. doi: 10.1073/pnas.1104829108. Epub 2011 Jul 27.
|
481 |
Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.J Clin Invest. 2017 Dec 1;127(12):4554-4568. doi: 10.1172/JCI92914. Epub 2017 Nov 13.
|
482 |
UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-B pathway.Oncogene. 2020 Jan;39(2):322-333. doi: 10.1038/s41388-019-0987-z. Epub 2019 Sep 2.
|
483 |
The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948.
|
484 |
Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.Genet Mol Res. 2015 Jun 29;14(2):7241-7. doi: 10.4238/2015.June.29.17.
|
485 |
Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.PLoS One. 2019 May 15;14(5):e0216553. doi: 10.1371/journal.pone.0216553. eCollection 2019.
|
486 |
USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability.Sci Adv. 2019 May 8;5(5):eaav3235. doi: 10.1126/sciadv.aav3235. eCollection 2019 May.
|
487 |
Amplification of USP13 drives ovarian cancer metabolism.Nat Commun. 2016 Nov 28;7:13525. doi: 10.1038/ncomms13525.
|
488 |
Inhibition of ubiquitinspecific protease14 promotes connexin32 internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells.Oncol Rep. 2019 Sep;42(3):1237-1247. doi: 10.3892/or.2019.7232. Epub 2019 Jul 15.
|
489 |
Ubiquitin-specific peptidase 5 and ovarian tumor deubiquitinase6A are differentially expressed in p53+/+ and p53-/- HCT116 cells.Int J Oncol. 2018 May;52(5):1705-1714. doi: 10.3892/ijo.2018.4302. Epub 2018 Mar 5.
|
490 |
SPARC suppresses lymph node metastasis by regulating the expression of VEGFs in ovarian carcinoma.Int J Oncol. 2017 Dec;51(6):1920-1928. doi: 10.3892/ijo.2017.4168. Epub 2017 Oct 19.
|
491 |
VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.Cancer Immunol Immunother. 2020 Jan;69(1):33-42. doi: 10.1007/s00262-019-02434-5. Epub 2019 Nov 28.
|
492 |
Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer.Oncoimmunology. 2019 Sep 30;8(12):e1665460. doi: 10.1080/2162402X.2019.1665460. eCollection 2019.
|
493 |
Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.Cancer Treat Rev. 2018 Dec;71:1-7. doi: 10.1016/j.ctrv.2018.09.003. Epub 2018 Sep 11.
|
494 |
An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.Oncogene. 2017 Jun 15;36(24):3384-3396. doi: 10.1038/onc.2016.487. Epub 2017 Jan 23.
|
495 |
Molecular changes in endometriosis-associated ovarian clear cell carcinoma.Eur J Cancer. 2015 Sep;51(13):1831-42. doi: 10.1016/j.ejca.2015.05.011. Epub 2015 Jun 6.
|
496 |
Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.Clin Cancer Res. 2017 Mar 15;23(6):1552-1563. doi: 10.1158/1078-0432.CCR-16-1333. Epub 2016 Sep 20.
|
497 |
Expression of Yes-associated protein1 and its clinical significance in ovarian serous cystadenocarcinoma.Oncol Rep. 2017 May;37(5):2620-2632. doi: 10.3892/or.2017.5517. Epub 2017 Mar 21.
|
498 |
Placental Growth Factor Promotes Ovarian Cancer Cell Invasion via ZEB2.Cell Physiol Biochem. 2016;38(1):351-8. doi: 10.1159/000438635. Epub 2016 Jan 29.
|
499 |
ZNF217 is associated with poor prognosis and enhances proliferation and metastasis in ovarian cancer.Int J Clin Exp Pathol. 2014 May 15;7(6):3038-47. eCollection 2014.
|
500 |
A mobile loop near the active site acts as a switch between the dual activities of a viral protease/deubiquitinase.PLoS Pathog. 2017 Nov 8;13(11):e1006714. doi: 10.1371/journal.ppat.1006714. eCollection 2017 Nov.
|
501 |
[Value of P-glycoprotein and glutathione S-transferase-pi as chemo-resistant indicators in ovarian cancers].Zhonghua Zhong Liu Za Zhi. 2001 Jul;23(4):313-6.
|
502 |
Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.Gynecol Oncol. 1998 Apr;69(1):23-31. doi: 10.1006/gyno.1998.4958.
|
503 |
Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer.Cancer Sci. 2012 Feb;103(2):239-444. doi: 10.1111/j.1349-7006.2011.02156.x. Epub 2011 Dec 23.
|
504 |
Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer.J Mol Recognit. 2018 Feb;31(2). doi: 10.1002/jmr.2679. Epub 2017 Oct 6.
|
505 |
Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours.Br J Cancer. 2001 Sep 14;85(6):891-7. doi: 10.1054/bjoc.2001.2020.
|
506 |
Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.Int J Mol Sci. 2019 Feb 3;20(3):660. doi: 10.3390/ijms20030660.
|
507 |
Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer.Tumour Biol. 2015 Nov;36(11):9023-30. doi: 10.1007/s13277-015-3652-3. Epub 2015 Jun 18.
|
508 |
Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation.Br J Cancer. 2007 Sep 3;97(5):637-45. doi: 10.1038/sj.bjc.6603918. Epub 2007 Jul 31.
|
509 |
A rare population of tumor antigen-specific CD4(+)CD8(+) double-positive T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells.J Immunother Cancer. 2019 Jan 9;7(1):7. doi: 10.1186/s40425-018-0467-y.
|
510 |
MiR-34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy.J Cell Biochem. 2019 Mar;120(3):2940-2953. doi: 10.1002/jcb.26865. Epub 2018 Dec 9.
|
511 |
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.Cell Death Dis. 2014 Nov 6;5(11):e1510. doi: 10.1038/cddis.2014.468.
|
512 |
Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case-control studies.Gene. 2013 Jul 25;524(2):168-74. doi: 10.1016/j.gene.2013.04.038. Epub 2013 Apr 26.
|
513 |
Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis.Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5331-6. doi: 10.1073/pnas.1317242111. Epub 2014 Mar 24.
|
514 |
miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.Oncogene. 2019 Jan;38(4):564-580. doi: 10.1038/s41388-018-0459-x. Epub 2018 Aug 30.
|
515 |
Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.Gynecol Oncol. 2017 Apr;145(1):167-175. doi: 10.1016/j.ygyno.2017.01.022. Epub 2017 Jan 29.
|
516 |
A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer.BMC Cancer. 2005 Apr 29;5:43. doi: 10.1186/1471-2407-5-43.
|
517 |
Genetic and molecular analyses reveal G6PC as a key element connecting glucose metabolism and cell cycle control in ovarian cancer.Tumour Biol. 2015 Sep;36(10):7649-58. doi: 10.1007/s13277-015-3463-6. Epub 2015 Apr 30.
|
518 |
Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion.Mol Ther. 2013 Jan;21(1):78-90. doi: 10.1038/mt.2012.187. Epub 2012 Nov 20.
|
519 |
Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer.Steroids. 2006 Nov;71(11-12):1019-23. doi: 10.1016/j.steroids.2006.09.001. Epub 2006 Oct 9.
|
520 |
Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system?.Oncotarget. 2017 Nov 11;8(63):107176-107187. doi: 10.18632/oncotarget.22412. eCollection 2017 Dec 5.
|
521 |
Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.Cytokine. 2008 Apr;42(1):77-84. doi: 10.1016/j.cyto.2008.01.011. Epub 2008 Mar 7.
|
522 |
[Significantly increased interleukin-1A and interleukin-1 soluble type II receptor levels in women with ovarian cancer].Ginekol Pol. 2003 Sep;74(9):761-6.
|
523 |
PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.Cancer Immunol Res. 2015 Aug;3(8):926-35. doi: 10.1158/2326-6066.CIR-14-0239. Epub 2015 May 8.
|
524 |
Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis.Thromb Haemost. 2009 Mar;101(3):541-6.
|
525 |
Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.J Biol Chem. 2004 Feb 27;279(9):7576-83. doi: 10.1074/jbc.M311659200. Epub 2003 Dec 8.
|
526 |
Matrix metalloproteinase-8 promoter gene polymorphisms in Mexican women with ovarian cancer.Med Oncol. 2014 Aug;31(8):132. doi: 10.1007/s12032-014-0132-3. Epub 2014 Jul 18.
|
527 |
Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas.Am J Surg Pathol. 2019 May;43(5):591-600. doi: 10.1097/PAS.0000000000001220.
|
528 |
The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.Exp Cell Res. 2003 Aug 15;288(2):382-9. doi: 10.1016/s0014-4827(03)00250-7.
|
529 |
Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case-Control Study in Northern Sweden.Transl Oncol. 2020 Jan;13(1):86-91. doi: 10.1016/j.tranon.2019.09.007. Epub 2019 Dec 2.
|
530 |
Notch3 Targeting: A Novel Weapon against Ovarian Cancer Stem Cells.Stem Cells Int. 2019 Jan 6;2019:6264931. doi: 10.1155/2019/6264931. eCollection 2019.
|
531 |
Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers.BMC Cancer. 2018 Mar 7;18(1):267. doi: 10.1186/s12885-018-4073-7.
|
532 |
Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer.Oncol Rep. 2015 Sep;34(3):1193-202. doi: 10.3892/or.2015.4113. Epub 2015 Jul 7.
|
533 |
Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA(1-/2-) carriers.Acta Obstet Gynecol Scand. 2019 Feb;98(2):250-261. doi: 10.1111/aogs.13485. Epub 2018 Nov 15.
|
534 |
Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.Am J Cancer Res. 2019 Jan 1;9(1):145-159. eCollection 2019.
|
535 |
Aberrant expression of pim-3 promotes proliferation and migration of ovarian cancer cells.Asian Pac J Cancer Prev. 2015;16(8):3325-31. doi: 10.7314/apjcp.2015.16.8.3325.
|
536 |
Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells.J Biol Chem. 2006 Sep 29;281(39):29357-68. doi: 10.1074/jbc.M513105200. Epub 2006 Aug 1.
|
537 |
In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells.Gene Ther. 2000 Oct;7(20):1738-43. doi: 10.1038/sj.gt.3301286.
|
538 |
Autoantibody to thioredoxin reductase in an ovarian cancer patient.Biochem Biophys Res Commun. 1998 Jan 14;242(2):267-71. doi: 10.1006/bbrc.1997.7914.
|
539 |
Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells.J Biol Chem. 2005 Jul 15;280(28):26233-40. doi: 10.1074/jbc.M502003200. Epub 2005 May 19.
|
540 |
Activation of the PKC pathway stimulates ovarian cancer cell proliferation, migration, and expression of MMP7 and MMP10.Biol Reprod. 2013 Sep 27;89(3):73. doi: 10.1095/biolreprod.112.102327. Print 2013 Sep.
|
541 |
PKC regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.Oncogene. 2017 Jan 26;36(4):534-545. doi: 10.1038/onc.2016.224. Epub 2016 Jun 20.
|
542 |
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary.Cancer Biol Ther. 2006 Sep;5(9):1136-41. doi: 10.4161/cbt.5.9.2953. Epub 2006 Sep 28.
|
543 |
K-ras activation in neoplasms of the human female reproductive tract.Cancer Res. 1990 Oct 1;50(19):6139-45.
|
544 |
The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma.BMC Cancer. 2015 Jun 16;15:471. doi: 10.1186/s12885-015-1435-2.
|
545 |
The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel.Fam Cancer. 2006;5(4):389-95. doi: 10.1007/s10689-006-0010-z. Epub 2006 Aug 31.
|
546 |
Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates.Int J Gynecol Pathol. 2006 Apr;25(2):131-9. doi: 10.1097/01.pgp.0000183050.30212.2f.
|
547 |
MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells.Oncol Rep. 2015 Jul;34(1):111-20. doi: 10.3892/or.2015.3952. Epub 2015 May 5.
|
548 |
Effects of shRNA-mediated knockdown of SPOCK1 on ovarian cancer growth and metastasis.Cell Mol Biol (Noisy-le-grand). 2015 Nov 30;61(7):102-9.
|
549 |
Decreasing the ratio of matriptase/HAI? by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer.Mol Med Rep. 2016 Aug;14(2):1465-74. doi: 10.3892/mmr.2016.5435. Epub 2016 Jun 23.
|
550 |
4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression.J Ovarian Res. 2014 Oct 11;7:94. doi: 10.1186/s13048-014-0094-2.
|
551 |
MicroRNA-365 inhibits ovarian cancer progression by targeting Wnt5a.Am J Cancer Res. 2017 May 1;7(5):1096-1106. eCollection 2017.
|
552 |
Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer.PLoS Genet. 2014 Oct 30;10(10):e1004751. doi: 10.1371/journal.pgen.1004751. eCollection 2014 Oct.
|
553 |
The impact of microRNA expression on cellular proliferation.Hum Genet. 2014 Jul;133(7):931-8. doi: 10.1007/s00439-014-1434-4. Epub 2014 Mar 8.
|
554 |
GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer.Oncology. 2004;66(5):404-10. doi: 10.1159/000079489.
|
555 |
Theaflavin-3,3'-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells.Int J Mol Sci. 2018 Jan 2;19(1):117. doi: 10.3390/ijms19010117.
|
556 |
Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence.Front Genet. 2016 Mar 22;7:37. doi: 10.3389/fgene.2016.00037. eCollection 2016.
|
557 |
Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614. doi: 10.1593/neo.09286.
|
558 |
ATP-binding cassette transporter A7 accelerates epithelial-to-mesenchymal transition in ovarian cancer cells by upregulating the transforming growth factor- signaling pathway.Oncol Lett. 2018 Nov;16(5):5868-5874. doi: 10.3892/ol.2018.9366. Epub 2018 Aug 24.
|
559 |
ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer.Medicine (Baltimore). 2019 May;98(19):e15698. doi: 10.1097/MD.0000000000015698.
|
560 |
Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.Invest New Drugs. 2018 Apr;36(2):187-194. doi: 10.1007/s10637-017-0523-3. Epub 2017 Oct 30.
|
561 |
miR-139 Controls Viability Of Ovarian Cancer Cells Through Apoptosis Induction And Exosome Shedding Inhibition By Targeting ATP7A.Onco Targets Ther. 2019 Dec 6;12:10727-10737. doi: 10.2147/OTT.S221236. eCollection 2019.
|
562 |
A water-soluble polysaccharide from the roots of Polygala tenuifolia suppresses ovarian tumor growth and angiogenesis in vivo.Int J Biol Macromol. 2018 Feb;107(Pt A):713-718. doi: 10.1016/j.ijbiomac.2017.09.043. Epub 2017 Sep 15.
|
563 |
A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia.Sci Rep. 2016 Mar 10;6:22811. doi: 10.1038/srep22811.
|
564 |
SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer.Neoplasma. 2018 Nov 15;65(6):915-924. doi: 10.4149/neo_2018_180122N48. Epub 2018 Sep 4.
|
565 |
GLUT5 increases fructose utilization in ovarian cancer.Onco Targets Ther. 2019 Jul 8;12:5425-5436. doi: 10.2147/OTT.S205522. eCollection 2019.
|
566 |
MiRNA-8073 targets ZnT1 to inhibit malignant progression of ovarian cancer.Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6062-6069. doi: 10.26355/eurrev_201907_18419.
|
567 |
Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.J Genet Couns. 2017 Dec;26(6):1280-1291. doi: 10.1007/s10897-017-0108-5. Epub 2017 May 24.
|
568 |
The novel ZIP4 regulation and its role in ovarian cancer.Oncotarget. 2017 Sep 30;8(52):90090-90107. doi: 10.18632/oncotarget.21435. eCollection 2017 Oct 27.
|
569 |
High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer. PLoS One. 2017 Nov 1;12(11):e0187385.
|
570 |
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Nat Genet. 2017 May;49(5):680-691. doi: 10.1038/ng.3826. Epub 2017 Mar 27.
|
571 |
Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.Gynecol Oncol. 2005 Apr;97(1):110-7. doi: 10.1016/j.ygyno.2004.12.031.
|
572 |
Decreased expression of CYP27B1 correlates with the increased aggressiveness of ovarian carcinomas.Oncol Rep. 2015 Feb;33(2):599-606. doi: 10.3892/or.2014.3666. Epub 2014 Dec 11.
|
573 |
The ABO Blood Group is an Independent Prognostic Factor in Patients with Ovarian Cancer.J Cancer. 2019 Oct 22;10(26):6754-6760. doi: 10.7150/jca.36236. eCollection 2019.
|
574 |
ALDH1A2 Is a Candidate Tumor Suppressor Gene in Ovarian Cancer.Cancers (Basel). 2019 Oct 14;11(10):1553. doi: 10.3390/cancers11101553.
|
575 |
Asparagine Synthetase and Filamin A Have Different Roles in Ovarian Cancer.Front Oncol. 2019 Oct 18;9:1072. doi: 10.3389/fonc.2019.01072. eCollection 2019.
|
576 |
Association between EPHX1 polymorphism rs1051740 and the risk of ovarian cancer: a meta-analysis.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2338-2342. doi: 10.1080/21691401.2019.1622551.
|
577 |
Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) promotes the EMT of serous ovarian cancer by activating the hexosamine biosynthetic pathway to increase the nuclear location of -catenin.Pathol Res Pract. 2019 Dec;215(12):152681. doi: 10.1016/j.prp.2019.152681. Epub 2019 Oct 3.
|
578 |
-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.Gynecol Oncol. 2018 Apr;149(1):163-172. doi: 10.1016/j.ygyno.2018.01.023. Epub 2018 Feb 9.
|
579 |
FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes.Cancer Res. 2018 Mar 1;78(5):1184-1199. doi: 10.1158/0008-5472.CAN-17-2506. Epub 2017 Dec 19.
|
580 |
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.Oncology. 2018;94(4):233-242. doi: 10.1159/000485624. Epub 2018 Jan 12.
|
581 |
Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.J Steroid Biochem Mol Biol. 2009 Sep;116(3-5):134-53. doi: 10.1016/j.jsbmb.2009.05.005. Epub 2009 May 19.
|
582 |
MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK.Oncol Lett. 2017 Jun;13(6):4039-4046. doi: 10.3892/ol.2017.5961. Epub 2017 Mar 31.
|
583 |
Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.Medicine (Baltimore). 2018 Apr;97(17):e0098. doi: 10.1097/MD.0000000000010098.
|
584 |
Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer.Cell Death Dis. 2018 Mar 12;9(3):392. doi: 10.1038/s41419-018-0395-2.
|
585 |
Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3/-catenin signaling pathway.J Transl Med. 2019 Jun 6;17(1):190. doi: 10.1186/s12967-019-1932-1.
|
586 |
Expression and biological role of the prostaglandin D synthase/SOX9 pathway in human ovarian cancer cells.Cancer Lett. 2007 Oct 8;255(2):182-93. doi: 10.1016/j.canlet.2007.04.007. Epub 2007 May 29.
|
587 |
Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia.Adv Exp Med Biol. 2008;617:359-66. doi: 10.1007/978-0-387-69080-3_34.
|
588 |
A novel p70 S6 kinase-microRNA biogenesis axis mediates multicellular spheroid formation in ovarian cancer progression.Oncotarget. 2016 Jun 21;7(25):38064-38077. doi: 10.18632/oncotarget.9345.
|
589 |
ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.J Pathol. 2020 Feb;250(2):159-169. doi: 10.1002/path.5356. Epub 2019 Dec 3.
|
590 |
Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer.Br J Cancer. 2001 Sep 28;85(7):1032-6. doi: 10.1054/bjoc.2001.2034.
|
591 |
Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):199-204. doi: 10.1111/j.1742-7843.2011.00802.x. Epub 2011 Oct 25.
|
592 |
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3534-45.
|
593 |
Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin.Carcinogenesis. 2005 Oct;26(10):1677-86. doi: 10.1093/carcin/bgi129. Epub 2005 May 19.
|
594 |
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.PLoS One. 2016 May 12;11(5):e0155660. doi: 10.1371/journal.pone.0155660. eCollection 2016.
|
595 |
Frequent translocations of 11q13.2 and 19p13.2 in ovarian cancer.Genes Chromosomes Cancer. 2014 Jun;53(6):447-53. doi: 10.1002/gcc.22152. Epub 2014 Feb 24.
|
596 |
Common variants at 19p13 are associated with susceptibility to ovarian cancer.Nat Genet. 2010 Oct;42(10):880-4. doi: 10.1038/ng.666. Epub 2010 Sep 19.
|
597 |
Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients.J Cell Mol Med. 2012 Feb;16(2):337-48. doi: 10.1111/j.1582-4934.2011.01316.x.
|
598 |
LncRNA CACS15 accelerates the malignant progression of ovarian cancer through stimulating EZH2-induced inhibition of APC.Am J Transl Res. 2019 Oct 15;11(10):6561-6568. eCollection 2019.
|
599 |
Down-regulated aquaporin 5 inhibits proliferation and migration of human epithelial ovarian cancer 3AO cells.J Ovarian Res. 2014 Aug 15;7:78. doi: 10.1186/s13048-014-0078-2.
|
600 |
ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival.Br J Cancer. 2011 May 10;104(10):1602-10. doi: 10.1038/bjc.2011.117. Epub 2011 Apr 19.
|
601 |
ATP11B mediates platinum resistance in ovarian cancer.J Clin Invest. 2013 May;123(5):2119-30. doi: 10.1172/JCI65425. Epub 2013 Apr 15.
|
602 |
An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population.Mol Diagn Ther. 2014 Feb;18(1):85-91. doi: 10.1007/s40291-013-0059-y.
|
603 |
BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment.Gynecol Oncol. 2010 May;117(2):189-97. doi: 10.1016/j.ygyno.2009.12.034. Epub 2010 Feb 26.
|
604 |
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.J Natl Cancer Inst. 2011 Nov 2;103(21):1596-612. doi: 10.1093/jnci/djr372. Epub 2011 Sep 28.
|
605 |
Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues.Int J Oncol. 2013 Dec;43(6):1925-34. doi: 10.3892/ijo.2013.2124. Epub 2013 Oct 3.
|
606 |
BMPR1B up-regulation via a miRNA binding site variation defines endometriosis susceptibility and CA125 levels.PLoS One. 2013 Dec 5;8(12):e80630. doi: 10.1371/journal.pone.0080630. eCollection 2013.
|
607 |
CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.Oncotarget. 2010 Sep;1(5):329-38. doi: 10.18632/oncotarget.165.
|
608 |
CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1/CXCR4 axis.Mol Cancer. 2013 Oct 5;12(1):115. doi: 10.1186/1476-4598-12-115.
|
609 |
Human chorionic gonadotropin beta subunit genes CGB1 and CGB2 are transcriptionally active in ovarian cancer.Int J Mol Sci. 2013 Jun 17;14(6):12650-60. doi: 10.3390/ijms140612650.
|
610 |
Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients.Br J Cancer. 2012 Jan 3;106(1):189-98. doi: 10.1038/bjc.2011.510. Epub 2011 Nov 22.
|
611 |
CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.Tumour Biol. 2012 Dec;33(6):2299-306. doi: 10.1007/s13277-012-0492-2. Epub 2012 Aug 25.
|
612 |
MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1.FEBS Lett. 2013 May 2;587(9):1434-9. doi: 10.1016/j.febslet.2013.03.023. Epub 2013 Mar 20.
|
613 |
CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells.Eur J Pharmacol. 2011 Nov 16;670(1):96-104. doi: 10.1016/j.ejphar.2011.08.006. Epub 2011 Sep 3.
|
614 |
EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo.Cancer Sci. 2011 Mar;102(3):530-9. doi: 10.1111/j.1349-7006.2010.01836.x. Epub 2011 Jan 18.
|
615 |
Flaxseed enriched diet-mediated reduction in ovarian cancer severity is correlated to the reduction of prostaglandin E(2) in laying hen ovaries.Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):179-87. doi: 10.1016/j.plefa.2013.08.001. Epub 2013 Aug 14.
|
616 |
Expression and biological role of -catenin in human ovarian cancer.J Cancer Res Clin Oncol. 2012 Oct;138(10):1769-76. doi: 10.1007/s00432-012-1257-4. Epub 2012 Jun 15.
|
617 |
Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.Cancer Res. 2010 Nov 15;70(22):9197-206. doi: 10.1158/0008-5472.CAN-10-1568. Epub 2010 Nov 2.
|
618 |
Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis.Lab Invest. 2001 Jun;81(6):863-73. doi: 10.1038/labinvest.3780295.
|
619 |
Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.Gynecol Oncol. 2013 Aug;130(2):369-76. doi: 10.1016/j.ygyno.2013.05.002. Epub 2013 May 14.
|
620 |
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.Clin Cancer Res. 2011 Jun 15;17(12):4052-62. doi: 10.1158/1078-0432.CCR-10-3021. Epub 2011 Apr 1.
|
621 |
Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.Neoplasia. 2010 Jul;12(7):579-89. doi: 10.1593/neo.10340.
|
622 |
Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis.Cancer Res. 2010 Dec 1;70(23):9979-90. doi: 10.1158/0008-5472.CAN-10-2394. Epub 2010 Nov 30.
|
623 |
Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization.Oncogene. 2011 Jun 23;30(25):2874-87. doi: 10.1038/onc.2011.11. Epub 2011 Feb 21.
|
624 |
Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours.Cancer Immunol Immunother. 2013 Aug;62(8):1411-9. doi: 10.1007/s00262-013-1445-3. Epub 2013 Jun 7.
|
625 |
C4orf7 contributes to ovarian cancer metastasis by promoting cancer cell migration and invasion.Oncol Rep. 2010 Oct;24(4):933-9.
|
626 |
The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.PLoS One. 2015 Sep 30;10(9):e0138692. doi: 10.1371/journal.pone.0138692. eCollection 2015.
|
627 |
Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA.Folia Biol (Praha). 2012;58(6):246-50.
|
628 |
Suppression of GNAI2 message in ovarian cancer.J Ovarian Res. 2014 Jan 14;7:6. doi: 10.1186/1757-2215-7-6.
|
629 |
Relations between GPR4 expression, microvascular density (MVD) and clinical pathological characteristics of patients with epithelial ovarian carcinoma (EOC).Curr Pharm Des. 2014;20(11):1904-16. doi: 10.2174/13816128113199990530.
|
630 |
Low penetrance alleles as risk modifiers in familial and sporadic breast cancer.Fam Cancer. 2012 Dec;11(4):629-36. doi: 10.1007/s10689-012-9563-1.
|
631 |
Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.PLoS One. 2011;6(12):e28141. doi: 10.1371/journal.pone.0028141. Epub 2011 Dec 7.
|
632 |
Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.Int J Cancer. 2012 Apr 15;130(8):1787-97. doi: 10.1002/ijc.26190. Epub 2011 Aug 16.
|
633 |
Comparison of Inhibin Alpha Subunit and Antimllerian Hormone Immunoreactivity in Granulosa Cell and Mucinous Ovarian Tumors.Appl Immunohistochem Mol Morphol. 2017 Jan;25(1):71-77. doi: 10.1097/PAI.0000000000000251.
|
634 |
Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer.J Cell Mol Med. 2019 Jun;23(6):4005-4018. doi: 10.1111/jcmm.14286. Epub 2019 Apr 16.
|
635 |
Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.FASEB J. 2013 Oct;27(10):4244-53. doi: 10.1096/fj.13-230441. Epub 2013 Jul 3.
|
636 |
KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study.J Ovarian Res. 2018 Apr 24;11(1):32. doi: 10.1186/s13048-018-0407-y.
|
637 |
Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.Arch Gynecol Obstet. 2014 Jul;290(1):149-54. doi: 10.1007/s00404-014-3177-9. Epub 2014 Feb 21.
|
638 |
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):745-50. doi: 10.1073/pnas.1016538108. Epub 2010 Dec 27.
|
639 |
Identification of LMX1B as a novel oncogene in human ovarian cancer.Oncogene. 2014 Aug 14;33(33):4226-35. doi: 10.1038/onc.2013.375. Epub 2013 Sep 23.
|
640 |
Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.Mol Cancer Ther. 2013 Jun;12(6):937-49. doi: 10.1158/1535-7163.MCT-12-1082. Epub 2013 Mar 27.
|
641 |
Knockdown of mediator complex subunit 19 inhibits the growth of ovarian cancer.Mol Med Rep. 2012 Nov;6(5):1050-6. doi: 10.3892/mmr.2012.1065. Epub 2012 Sep 5.
|
642 |
Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.Fam Cancer. 2017 Jul;16(3):351-355. doi: 10.1007/s10689-017-9973-1.
|
643 |
Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.Mod Pathol. 2012 Dec;25(12):1644-53. doi: 10.1038/modpathol.2012.118. Epub 2012 Jul 13.
|
644 |
Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.Acta Pharmacol Sin. 2013 Apr;34(4):541-8. doi: 10.1038/aps.2012.197. Epub 2013 Mar 11.
|
645 |
NFATC1 promotes cell growth and tumorigenesis in ovarian cancer up-regulating c-Myc through ERK1/2/p38 MAPK signal pathway.Tumour Biol. 2016 Apr;37(4):4493-500. doi: 10.1007/s13277-015-4245-x. Epub 2015 Oct 26.
|
646 |
Common variation in Nemo-like kinase is associated with risk of ovarian cancer.Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):523-8. doi: 10.1158/1055-9965.EPI-11-0797. Epub 2012 Jan 17.
|
647 |
MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1.Oncotarget. 2017 Sep 30;8(60):101649-101658. doi: 10.18632/oncotarget.21417. eCollection 2017 Nov 24.
|
648 |
Expression and functional pathway analysis of nuclear receptor NR2F2 in ovarian cancer.J Clin Endocrinol Metab. 2013 Jul;98(7):E1152-62. doi: 10.1210/jc.2013-1081. Epub 2013 May 20.
|
649 |
Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment.Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16348-53. doi: 10.1073/pnas.1205226109. Epub 2012 Sep 17.
|
650 |
PES1 differentially regulates the expression of ER and ER in ovarian cancer.IUBMB Life. 2013 Dec;65(12):1017-25. doi: 10.1002/iub.1228. Epub 2013 Nov 24.
|
651 |
Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.BMC Cancer. 2010 Nov 8;10:611. doi: 10.1186/1471-2407-10-611.
|
652 |
PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer.Mol Genet Genomic Med. 2019 Jun;7(6):e721. doi: 10.1002/mgg3.721. Epub 2019 May 5.
|
653 |
Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer.BMC Cancer. 2011 Jun 25;11:270. doi: 10.1186/1471-2407-11-270.
|
654 |
iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.Clin Cancer Res. 2011 Nov 1;17(21):6924-33. doi: 10.1158/1078-0432.CCR-11-0588. Epub 2011 Sep 16.
|
655 |
Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.J Biol Chem. 2013 Nov 15;288(46):33387-97. doi: 10.1074/jbc.M113.485581. Epub 2013 Oct 4.
|
656 |
Rab5a overexpression promoting ovarian cancer cell proliferation may be associated with APPL1-related epidermal growth factor signaling pathway.Cancer Sci. 2010 Jun;101(6):1454-62. doi: 10.1111/j.1349-7006.2010.01558.x. Epub 2010 Mar 10.
|
657 |
RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation.Mol Cancer Res. 2012 Sep;10(9):1169-77. doi: 10.1158/1541-7786.MCR-12-0331. Epub 2012 Jul 13.
|
658 |
Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways.PLoS One. 2013 Nov 11;8(11):e79117. doi: 10.1371/journal.pone.0079117. eCollection 2013.
|
659 |
Mutation analysis of the SHFM1 gene in breast/ovarian cancer families.J Cancer Res Clin Oncol. 2013 Mar;139(3):529-32. doi: 10.1007/s00432-013-1385-5. Epub 2013 Feb 1.
|
660 |
Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer.Mol Cancer. 2018 Jun 21;17(1):96. doi: 10.1186/s12943-018-0844-7.
|
661 |
Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.Biochem Biophys Res Commun. 2013 Sep 20;439(2):187-90. doi: 10.1016/j.bbrc.2013.08.065. Epub 2013 Aug 29.
|
662 |
NSSR1 is regulated by testosterone in the mouse uterus and extensively expressed in endometrial carcinoma.Tumour Biol. 2011 Apr;32(2):359-66. doi: 10.1007/s13277-010-0128-3. Epub 2010 Nov 12.
|
663 |
Frequent hypermethylation and loss of heterozygosity of the testis derived transcript gene in ovarian cancer.Cancer Sci. 2010 May;101(5):1255-60. doi: 10.1111/j.1349-7006.2010.01497.x. Epub 2010 Jan 18.
|
664 |
Transcriptional regulation of hTREX84 in human cancer cells.PLoS One. 2012;7(8):e43610. doi: 10.1371/journal.pone.0043610. Epub 2012 Aug 27.
|
665 |
Inhibitory effect of soluble EP2 receptor on ovarian tumor growth in nude mice and utility of TMPRSS4 as a combinatorial molecular target.Int J Oncol. 2013 Aug;43(2):416-24. doi: 10.3892/ijo.2013.1957. Epub 2013 May 24.
|
666 |
DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.BMC Cancer. 2012 May 14;12:176. doi: 10.1186/1471-2407-12-176.
|
667 |
STAMP alters the growth of transformed and ovarian cancer cells.BMC Cancer. 2010 Apr 7;10:128. doi: 10.1186/1471-2407-10-128.
|
668 |
Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells.Differentiation. 2009 Feb;77(2):162-71. doi: 10.1016/j.diff.2008.09.018. Epub 2008 Oct 25.
|
669 |
Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility.Tumour Biol. 2014 Apr;35(4):3385-9. doi: 10.1007/s13277-013-1446-z. Epub 2013 Nov 28.
|
670 |
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.Mol Cancer. 2014 Aug 12;13:189. doi: 10.1186/1476-4598-13-189.
|
671 |
Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer.Biomed Res Int. 2014;2014:159459. doi: 10.1155/2014/159459. Epub 2014 Jul 9.
|
672 |
Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer.BMC Cancer. 2014 Aug 27;14:620. doi: 10.1186/1471-2407-14-620.
|
673 |
Cathepsin B and its interacting proteins, bikunin and TSRC1, correlate with TNF-induced apoptosis of ovarian cancer cells OV-90.FEBS Lett. 2006 Jan 9;580(1):245-50. doi: 10.1016/j.febslet.2005.12.005. Epub 2005 Dec 12.
|
674 |
Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.Clin Cancer Res. 2007 Dec 15;13(24):7370-9. doi: 10.1158/1078-0432.CCR-07-0747.
|
675 |
Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.Cancer Res. 2008 Jul 1;68(13):5067-75. doi: 10.1158/0008-5472.CAN-08-0062.
|
676 |
Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.Int J Cancer. 2009 Sep 15;125(6):1454-63. doi: 10.1002/ijc.24546.
|
677 |
Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.Cancer Res. 2007 Jul 1;67(13):6100-5. doi: 10.1158/0008-5472.CAN-07-0369.
|
678 |
Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.Cancer. 2005 Dec 1;104(11):2417-29. doi: 10.1002/cncr.21538.
|
679 |
Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer.Oncogene. 2005 Jul 28;24(32):5089-100. doi: 10.1038/sj.onc.1208700.
|
680 |
Mechanisms of Cables 1 gene inactivation in human ovarian cancer development.Cancer Biol Ther. 2008 Feb;7(2):180-88. doi: 10.4161/cbt.7.2.5253. Epub 2007 Nov 15.
|
681 |
Distribution of microsatellite instability in Danish ovarian tumor patients and the prognostic value in ovarian cancer patients.Oncol Res. 2008;17(1):43-9. doi: 10.3727/096504008784046090.
|
682 |
Tumor-associated alterations in caspase-14 expression in epithelial malignancies.Clin Cancer Res. 2005 Aug 1;11(15):5462-71. doi: 10.1158/1078-0432.CCR-04-2527.
|
683 |
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.Cancer Cell. 2007 Jun;11(6):498-512. doi: 10.1016/j.ccr.2007.04.011.
|
684 |
Overexpression of CHP2 enhances tumor cell growth, invasion and metastasis in ovarian cancer.In Vivo. 2007 Jul-Aug;21(4):593-8.
|
685 |
Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer.Int J Gynecol Cancer. 2009 May;19(4):513-25. doi: 10.1111/IGC.0b013e3181a3cd38.
|
686 |
Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers.Cancer Biol Ther. 2005 Dec;4(12):1409-14. doi: 10.4161/cbt.4.12.2378. Epub 2005 Dec 5.
|
687 |
Characterization of a putative ovarian oncogene, elongation factor 1alpha, isolated by panning a synthetic phage display single-chain variable fragment library with cultured human ovarian cancer cells.Clin Cancer Res. 2007 Oct 1;13(19):5889-96. doi: 10.1158/1078-0432.CCR-07-0703.
|
688 |
Molecular pathogenesis of Fanconi anemia: recent progress.Blood. 2006 Jun 1;107(11):4223-33. doi: 10.1182/blood-2005-10-4240. Epub 2006 Feb 21.
|
689 |
Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer.Br J Cancer. 2009 Oct 20;101(8):1433-43. doi: 10.1038/sj.bjc.6605316. Epub 2009 Sep 15.
|
690 |
Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours.Br J Cancer. 2006 Mar 13;94(5):686-91. doi: 10.1038/sj.bjc.6602988.
|
691 |
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.Oncotarget. 2014 Jan 30;5(2):544-60. doi: 10.18632/oncotarget.1652.
|
692 |
Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes.Mol Carcinog. 2008 Jan;47(1):56-65. doi: 10.1002/mc.20361.
|
693 |
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.Cancer. 2009 Feb 15;115(4):800-11. doi: 10.1002/cncr.24048.
|
694 |
Epigenetic and genetic alterations of p33ING1b in ovarian cancer.Carcinogenesis. 2005 Apr;26(4):855-63. doi: 10.1093/carcin/bgi011. Epub 2005 Jan 27.
|
695 |
Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro.J Exp Clin Cancer Res. 2008 Nov 27;27(1):77. doi: 10.1186/1756-9966-27-77.
|
696 |
Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.Int J Cancer. 2009 May 15;124(10):2353-60. doi: 10.1002/ijc.24214.
|
697 |
Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study.Pathology. 2009;41(3):229-33. doi: 10.1080/00313020902756279.
|
698 |
ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.Hum Gene Ther. 2014 Oct;25(10):897-904. doi: 10.1089/hum.2013.229. Epub 2014 Sep 17.
|
699 |
Mutation and expression analysis of LZTS1 in ovarian cancer.Cancer Lett. 2006 Feb 20;233(1):151-7. doi: 10.1016/j.canlet.2005.03.008.
|
700 |
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.Cancer Cell. 2009 Dec 8;16(6):521-32. doi: 10.1016/j.ccr.2009.10.018.
|
701 |
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.Hum Mol Genet. 2009 Jun 15;18(12):2297-304. doi: 10.1093/hmg/ddp138. Epub 2009 Mar 20.
|
702 |
The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO.Cancer Biol Ther. 2008 Sep;7(9):1460-7. doi: 10.4161/cbt.7.9.6427. Epub 2008 Sep 11.
|
703 |
Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.BMC Cancer. 2009 Jun 6;9:170. doi: 10.1186/1471-2407-9-170.
|
704 |
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer.Br J Cancer. 2009 Mar 24;100(6):993-1001. doi: 10.1038/sj.bjc.6604947. Epub 2009 Feb 24.
|
705 |
SPOC1, a novel PHD-finger protein: association with residual disease and survival in ovarian cancer.Int J Cancer. 2005 Sep 10;116(4):547-54. doi: 10.1002/ijc.20912.
|
706 |
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.Br J Cancer. 2009 Oct 20;101(8):1461-8. doi: 10.1038/sj.bjc.6605284. Epub 2009 Sep 8.
|
707 |
pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin Cancer Res. 2004 Dec 1;10(23):8085-93. doi: 10.1158/1078-0432.CCR-04-0996.
|
708 |
Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.Clin Cancer Res. 2004 Jul 15;10(14):4652-60. doi: 10.1158/1078-0432.CCR-03-0439.
|
709 |
RAD52 Y415X truncation polymorphism and epithelial ovarian cancer risk in Australian women.Cancer Lett. 2005 Feb 10;218(2):191-7. doi: 10.1016/j.canlet.2004.09.023.
|
710 |
Sohlh2 inhibits human ovarian cancer cell invasion and metastasis by transcriptional inactivation of MMP9.Mol Carcinog. 2016 Jul;55(7):1127-37. doi: 10.1002/mc.22355. Epub 2015 Jul 8.
|
711 |
Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer.Eur J Cancer. 2006 Oct;42(15):2647-52. doi: 10.1016/j.ejca.2006.05.030. Epub 2006 Aug 23.
|
712 |
Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.Int J Cancer. 2005 Dec 20;117(6):1049-54. doi: 10.1002/ijc.21250.
|
713 |
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16472-7. doi: 10.1073/pnas.0605752103. Epub 2006 Oct 23.
|
714 |
Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer.Oncotarget. 2016 Jul 26;7(30):47620-47636. doi: 10.18632/oncotarget.9951.
|
715 |
Inhibitory short peptides targeting EPS8/ABI1/SOS1 tri-complex suppress invasion and metastasis of ovarian cancer cells.BMC Cancer. 2019 Sep 5;19(1):878. doi: 10.1186/s12885-019-6087-1.
|
716 |
Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility.Breast Cancer Res Treat. 2009 Jan;113(2):371-6. doi: 10.1007/s10549-008-9933-4. Epub 2008 Feb 13.
|
717 |
Breast and ovarian cancer referrals to the ACT Genetic Service: are we meeting guidelines?.Intern Med J. 2017 Mar;47(3):311-317. doi: 10.1111/imj.13357.
|
718 |
ACTL6A regulates follicle-stimulating hormone-driven glycolysis in ovarian cancer cells via PGK1.Cell Death Dis. 2019 Oct 24;10(11):811. doi: 10.1038/s41419-019-2050-y.
|
719 |
Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance.Mod Pathol. 2009 Apr;22(4):499-507. doi: 10.1038/modpathol.2008.234. Epub 2009 Jan 16.
|
720 |
MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci. 2011 Feb 1;124(Pt 3):359-68. doi: 10.1242/jcs.072223. Epub 2011 Jan 11.
|
721 |
Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.Lab Invest. 2010 Mar;90(3):414-25. doi: 10.1038/labinvest.2009.138. Epub 2010 Jan 11.
|
722 |
Genome-wide association study (GWAS) of ovarian cancer in Japanese predicted regulatory variants in 22q13.1.PLoS One. 2018 Dec 17;13(12):e0209096. doi: 10.1371/journal.pone.0209096. eCollection 2018.
|
723 |
Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.Gynecol Oncol. 2019 May;153(2):343-355. doi: 10.1016/j.ygyno.2019.02.023. Epub 2019 Mar 19.
|
724 |
MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.Neoplasia. 2019 Feb;21(2):206-215. doi: 10.1016/j.neo.2018.12.005. Epub 2019 Jan 9.
|
725 |
Expression of adiponectin and its receptors is altered in epithelial ovarian tumors and ascites-derived ovarian cancer cell lines.Int J Gynecol Cancer. 2015 Mar;25(3):399-406. doi: 10.1097/IGC.0000000000000369.
|
726 |
Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.EBioMedicine. 2019 Dec;50:191-202. doi: 10.1016/j.ebiom.2019.11.009. Epub 2019 Nov 22.
|
727 |
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.J Ovarian Res. 2017 Aug 7;10(1):53. doi: 10.1186/s13048-017-0347-y.
|
728 |
High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma.Oncol Lett. 2019 Nov;18(5):4900-4906. doi: 10.3892/ol.2019.10829. Epub 2019 Sep 9.
|
729 |
Autophagic degradation of SQSTM1 inhibits ovarian cancer motility by decreasing DICER1 and AGO2 to induce MIRLET7A-3P.Autophagy. 2018;14(12):2065-2082. doi: 10.1080/15548627.2018.1501135. Epub 2018 Aug 17.
|
730 |
Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.J Proteome Res. 2015 Apr 3;14(4):1900-10. doi: 10.1021/pr5012894. Epub 2015 Mar 19.
|
731 |
Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma.Oncol Rep. 2012 Nov;28(5):1792-8. doi: 10.3892/or.2012.2002. Epub 2012 Aug 30.
|
732 |
Ovarian cancer detection by DNA methylation in cervical scrapings.Clin Epigenetics. 2019 Nov 27;11(1):166. doi: 10.1186/s13148-019-0773-3.
|
733 |
Molecular cloning of differentially expressed genes in human epithelial ovarian cancer.Gynecol Oncol. 1994 Feb;52(2):247-52. doi: 10.1006/gyno.1994.1040.
|
734 |
Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes.Int J Cancer. 2020 Apr 15;146(8):2147-2155. doi: 10.1002/ijc.32545. Epub 2019 Jul 16.
|
735 |
The role of annexin A4 in cancer.Front Biosci (Landmark Ed). 2016 Jun 1;21(5):949-57. doi: 10.2741/4432.
|
736 |
Luteolin promotes the sensitivity of cisplatin in ovarian cancer by decreasing PRPA1-medicated autophagy.Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):17-22.
|
737 |
APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.Gynecol Oncol. 2017 Dec;147(3):663-671. doi: 10.1016/j.ygyno.2017.10.016. Epub 2017 Oct 24.
|
738 |
APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.Histol Histopathol. 2019 Apr;34(4):405-417. doi: 10.14670/HH-18-050. Epub 2018 Oct 5.
|
739 |
CXCL12 promotes human ovarian cancer cell invasion through suppressing ARHGAP10 expression.Biochem Biophys Res Commun. 2019 Oct 20;518(3):416-422. doi: 10.1016/j.bbrc.2019.07.098. Epub 2019 Aug 22.
|
740 |
Rgnef promotes ovarian tumor progression and confers protection from oxidative stress.Oncogene. 2019 Sep;38(36):6323-6337. doi: 10.1038/s41388-019-0881-8. Epub 2019 Jul 15.
|
741 |
ARID3B Directly Regulates Ovarian Cancer Promoting Genes.PLoS One. 2015 Jun 29;10(6):e0131961. doi: 10.1371/journal.pone.0131961. eCollection 2015.
|
742 |
Association of the ARLTS1 variants with familial ovarian cancer risk in China.Int J Gynecol Cancer. 2009 May;19(4):585-90. doi: 10.1111/IGC.0b013e3181a39d03.
|
743 |
Uterine and ovarian aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) mRNA expression in benign and malignant gynaecological conditions.Mol Hum Reprod. 2002 Jan;8(1):75-80. doi: 10.1093/molehr/8.1.75.
|
744 |
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8.
|
745 |
Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.Oncogene. 2007 Jan 11;26(2):198-214. doi: 10.1038/sj.onc.1209773. Epub 2006 Jul 10.
|
746 |
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011 Oct 1;17(19):6356-66. doi: 10.1158/1078-0432.CCR-11-0735. Epub 2011 Aug 17.
|
747 |
Silencing of BAG3 promotes the sensitivity of ovarian cancer cells to cisplatin via inhibition of autophagy.Oncol Rep. 2017 Jul;38(1):309-316. doi: 10.3892/or.2017.5706. Epub 2017 Jun 6.
|
748 |
The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.J Biol Chem. 2018 Oct 5;293(40):15483-15496. doi: 10.1074/jbc.RA118.004084. Epub 2018 Aug 22.
|
749 |
Low BCL7A expression predicts poor prognosis in ovarian cancer.J Ovarian Res. 2019 May 10;12(1):41. doi: 10.1186/s13048-019-0518-0.
|
750 |
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.Oncotarget. 2016 Nov 8;7(45):72654-72661. doi: 10.18632/oncotarget.12056.
|
751 |
Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer.Genet Epidemiol. 2014 Jul;38(5):457-66. doi: 10.1002/gepi.21815. Epub 2014 May 22.
|
752 |
Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.Br J Cancer. 2003 Jan 27;88(2):270-6. doi: 10.1038/sj.bjc.6600674.
|
753 |
Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer.J Ovarian Res. 2019 Apr 30;12(1):38. doi: 10.1186/s13048-019-0514-4.
|
754 |
Oncogene miR-934 promotes ovarian cancer cell proliferation and inhibits cell apoptosis through targeting BRMS1L.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5595-5602. doi: 10.26355/eurrev_201907_18293.
|
755 |
BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer.J Cell Biochem. 2020 Mar;121(3):2643-2654. doi: 10.1002/jcb.29485. Epub 2019 Nov 6.
|
756 |
Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer.Cancer Res. 1999 Oct 15;59(20):5370-5.
|
757 |
The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.Oncogene. 2012 Apr 26;31(17):2175-86. doi: 10.1038/onc.2011.399. Epub 2011 Sep 19.
|
758 |
URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell. 2011 Mar 8;19(3):317-32. doi: 10.1016/j.ccr.2011.01.019.
|
759 |
C1GALT1 Seems to Promote In Vitro Disease Progression in Ovarian Cancer.Int J Gynecol Cancer. 2017 Jun;27(5):863-871. doi: 10.1097/IGC.0000000000000965.
|
760 |
Knockdown of long non-coding RNA LINC00176 suppresses ovarian cancer progression by BCL3-mediated down-regulation of ceruloplasmin.J Cell Mol Med. 2020 Jan;24(1):202-213. doi: 10.1111/jcmm.14701. Epub 2019 Oct 30.
|
761 |
It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.Br J Cancer. 2015 Jan 6;112(1):9-13. doi: 10.1038/bjc.2014.594. Epub 2014 Dec 9.
|
762 |
CALB1 enhances the interaction between p53 and MDM2, and inhibits the senescence of ovarian cancer cells.Mol Med Rep. 2019 Jun;19(6):5097-5104. doi: 10.3892/mmr.2019.10212. Epub 2019 Apr 30.
|
763 |
Capn4 overexpression indicates poor prognosis of ovarian cancer patients.J Cancer. 2018 Jan 1;9(2):304-309. doi: 10.7150/jca.22004. eCollection 2018.
|
764 |
Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.Oncogene. 2008 Feb 21;27(9):1273-80. doi: 10.1038/sj.onc.1210746. Epub 2007 Aug 27.
|
765 |
Small molecule inhibition of the CBF/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.Gynecol Oncol. 2018 May;149(2):350-360. doi: 10.1016/j.ygyno.2018.03.005. Epub 2018 Mar 16.
|
766 |
CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer.Oncogenesis. 2018 Nov 26;7(11):92. doi: 10.1038/s41389-018-0103-1.
|
767 |
Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer.Front Oncol. 2019 Oct 1;9:986. doi: 10.3389/fonc.2019.00986. eCollection 2019.
|
768 |
Development of a M cell-targeted microparticulate platform, BSK02? for oral immunization against the ovarian cancer antigen, sperm protein 17.J Biomed Mater Res B Appl Biomater. 2019 Jan;107(1):29-36. doi: 10.1002/jbm.b.34092. Epub 2018 Mar 4.
|
769 |
Evaluation of serum CCL18 as a potential biomarker for ovarian cancer.Cancer Biomark. 2017 Dec 12;21(1):97-104. doi: 10.3233/CBM-170305.
|
770 |
Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.Eur J Cancer. 2016 Nov;67:152-163. doi: 10.1016/j.ejca.2016.08.007. Epub 2016 Sep 24.
|
771 |
LncRNA HOTAIR Regulates CCND1 and CCND2 Expression by Sponging miR-206 in Ovarian Cancer.Cell Physiol Biochem. 2018;49(4):1289-1303. doi: 10.1159/000493408. Epub 2018 Sep 11.
|
772 |
CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.Cancer Med. 2019 Jan;8(1):351-362. doi: 10.1002/cam4.1812. Epub 2018 Dec 18.
|
773 |
Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7.Mol Biol Cell. 2008 Nov;19(11):4968-79. doi: 10.1091/mbc.e08-03-0259. Epub 2008 Sep 10.
|
774 |
APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study.Cancer Cell Int. 2018 May 29;18:78. doi: 10.1186/s12935-018-0572-5. eCollection 2018.
|
775 |
Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.Cell Rep. 2017 Mar 7;18(10):2343-2358. doi: 10.1016/j.celrep.2017.02.028.
|
776 |
Expression and significance of the protein and mRNA of metastasis suppressor gene ME491/CD63 and integrin alpha5 in ovarian cancer tissues.Eur J Gynaecol Oncol. 2007;28(3):179-83.
|
777 |
Alternative splicing of KAI1 abrogates its tumor-suppressive effects on integrin v3-mediated ovarian cancer biology.Cell Signal. 2015 Mar;27(3):652-62. doi: 10.1016/j.cellsig.2014.11.028. Epub 2014 Nov 27.
|
778 |
lncRNA UCA1-Mediated Cdc42 Signaling Promotes Oncolytic Vaccinia Virus Cell-to-Cell Spread in Ovarian Cancer.Mol Ther Oncolytics. 2019 Mar 26;13:35-48. doi: 10.1016/j.omto.2019.03.003. eCollection 2019 Jun 28.
|
779 |
Prediction of key genes in ovarian cancer treated with decitabine based on network strategy.Oncol Rep. 2016 Jun;35(6):3548-58. doi: 10.3892/or.2016.4697. Epub 2016 Mar 23.
|
780 |
MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.Oncogene. 2019 Aug;38(32):6035-6050. doi: 10.1038/s41388-019-0860-0. Epub 2019 Jul 5.
|
781 |
Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach.Pathol Oncol Res. 2019 Oct;25(4):1457-1465. doi: 10.1007/s12253-018-0500-y. Epub 2018 Oct 27.
|
782 |
MiR-542-3p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer.Biomed Pharmacother. 2019 Feb;110:850-856. doi: 10.1016/j.biopha.2018.11.104. Epub 2018 Dec 14.
|
783 |
Hypermethylation of P15, P16, and E-cadherin genes in ovarian cancer.Toxicol Ind Health. 2015 Oct;31(10):924-30. doi: 10.1177/0748233713484657. Epub 2013 Apr 9.
|
784 |
Overexpression of WDFY2 inhibits prostate cancer cell growth and migration via inactivation of Akt pathway.Tumour Biol. 2017 Jun;39(6):1010428317704821. doi: 10.1177/1010428317704821.
|
785 |
CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer.Int J Clin Exp Pathol. 2015 May 1;8(5):4535-44. eCollection 2015.
|
786 |
Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer.Cancer Biomark. 2017 Dec 6;20(4):369-387. doi: 10.3233/CBM-170652.
|
787 |
CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signaling pathway.Biomed Pharmacother. 2019 Jun;114:108787. doi: 10.1016/j.biopha.2019.108787. Epub 2019 Mar 27.
|
788 |
CircRNA UBAP2 promotes the progression of ovarian cancer by sponging microRNA-144.Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7283-7294. doi: 10.26355/eurrev_201909_18833.
|
789 |
CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.Gynecol Obstet Invest. 2011;72(3):203-7. doi: 10.1159/000323883. Epub 2011 Aug 23.
|
790 |
The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.Cell Death Dis. 2018 Jan 24;9(2):93. doi: 10.1038/s41419-017-0137-x.
|
791 |
The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.Clin Cancer Res. 2014 Dec 15;20(24):6504-16. doi: 10.1158/1078-0432.CCR-14-1553. Epub 2014 Oct 14.
|
792 |
A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants.Nat Genet. 2019 May;51(5):815-823. doi: 10.1038/s41588-019-0395-x. Epub 2019 May 1.
|
793 |
The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.Cancer Gene Ther. 2012 Aug;19(8):588-91. doi: 10.1038/cgt.2012.33. Epub 2012 Jun 8.
|
794 |
Chordin is underexpressed in ovarian tumors and reduces tumor cell motility.FASEB J. 2006 Feb;20(2):240-50. doi: 10.1096/fj.05-4126com.
|
795 |
CIB2 Negatively Regulates Oncogenic Signaling in Ovarian Cancer via Sphingosine Kinase 1.Cancer Res. 2017 Sep 15;77(18):4823-4834. doi: 10.1158/0008-5472.CAN-17-0025. Epub 2017 Jul 20.
|
796 |
MiR-1307 influences the chemotherapeutic sensitivity in ovarian cancer cells through the regulation of the CIC transcriptional repressor.Pathol Res Pract. 2019 Oct;215(10):152606. doi: 10.1016/j.prp.2019.152606. Epub 2019 Aug 19.
|
797 |
Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.Oncol Rep. 2017 May;37(5):3084-3092. doi: 10.3892/or.2017.5534. Epub 2017 Mar 27.
|
798 |
Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis.Int J Biochem Cell Biol. 2013 May;45(5):979-86. doi: 10.1016/j.biocel.2013.02.003. Epub 2013 Feb 14.
|
799 |
Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element.Cancer Res. 2001 Feb 15;61(4):1291-5.
|
800 |
Folate-linked lipoplexes for short hairpin RNA targeting claudin-3 delivery in ovarian cancer xenografts.J Control Release. 2013 Dec 28;172(3):679-89. doi: 10.1016/j.jconrel.2013.10.015. Epub 2013 Oct 18.
|
801 |
Claudin-7 expression in human epithelial ovarian cancer.Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1262-71. doi: 10.1111/j.1525-1438.2008.01194.x. Epub 2008 Feb 19.
|
802 |
An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.J Immunother Cancer. 2018 Apr 17;6(1):28. doi: 10.1186/s40425-018-0339-5.
|
803 |
Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer.Biol Reprod. 2000 Jun;62(6):1600-9. doi: 10.1095/biolreprod62.6.1600.
|
804 |
Blockage of transdifferentiation from fibroblast to myofibroblast in experimental ovarian cancer models.Mol Cancer. 2009 Sep 27;8:78. doi: 10.1186/1476-4598-8-78.
|
805 |
CNDP2 Acts as an Activator for Human Ovarian Cancer Growth and Metastasis via the PI3K/AKT Pathway.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819874773. doi: 10.1177/1533033819874773.
|
806 |
Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.Oncogene. 2018 Aug;37(35):4809-4820. doi: 10.1038/s41388-018-0297-x. Epub 2018 May 17.
|
807 |
Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.Oncol Rep. 2019 Jul;42(1):151-175. doi: 10.3892/or.2019.7147. Epub 2019 May 3.
|
808 |
Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.PLoS One. 2016 Oct 27;11(10):e0165385. doi: 10.1371/journal.pone.0165385. eCollection 2016.
|
809 |
Investigating key genes associated with ovarian cancer by integrating affinity propagation clustering and mutual information network analysis.Eur Rev Med Pharmacol Sci. 2016 Jun;20(12):2532-40.
|
810 |
Copine-III interacts with ErbB2 and promotes tumor cell migration.Oncogene. 2010 Mar 18;29(11):1598-610. doi: 10.1038/onc.2009.456. Epub 2009 Dec 14.
|
811 |
High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids.Oncoimmunology. 2019 Jun 4;8(9):e1614856. doi: 10.1080/2162402X.2019.1614856. eCollection 2019.
|
812 |
The role of CT10 regulation of kinase-like in cancer.Future Oncol. 2014 Dec;10(16):2687-97. doi: 10.2217/fon.14.199.
|
813 |
circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge.Biomed Pharmacother. 2019 Jun;114:108832. doi: 10.1016/j.biopha.2019.108832. Epub 2019 Apr 11.
|
814 |
Transforming growth factor?miR?43?p/cystatin B axis is a therapeutic target in human ovarian cancer.Int J Oncol. 2019 Jul;55(1):267-276. doi: 10.3892/ijo.2019.4815. Epub 2019 May 28.
|
815 |
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.Cell. 2018 Sep 20;175(1):159-170.e16. doi: 10.1016/j.cell.2018.08.065.
|
816 |
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.Cancer Res. 2003 Sep 15;63(18):6076-83.
|
817 |
Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.Mol Pharmacol. 2019 Jul;96(1):99-108. doi: 10.1124/mol.118.114363. Epub 2019 Apr 29.
|
818 |
BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.Neoplasia. 2013 Jun;15(6):600-8. doi: 10.1593/neo.121674.
|
819 |
CTCF promotes epithelial ovarian cancer metastasis by broadly controlling the expression of metastasis-associated genes.Oncotarget. 2017 Jul 10;8(37):62217-62230. doi: 10.18632/oncotarget.19216. eCollection 2017 Sep 22.
|
820 |
Correlation of Collagen Triple Helix Repeat Containing 1 Overexpression With Lymph Node and Peritoneal Metastasis in Epithelial Ovarian Cancer.Int J Gynecol Cancer. 2017 Jan;27(1):22-27. doi: 10.1097/IGC.0000000000000850.
|
821 |
Amazon Fruits Inhibit Growth and Promote Pro-apoptotic Effects on Human Ovarian Carcinoma Cell Lines.Biomolecules. 2019 Nov 6;9(11):707. doi: 10.3390/biom9110707.
|
822 |
Mllerian inhibiting substance inhibits an ovarian cancer cell line via -catenin interacting protein deregulation of the Wnt signal pathway.Int J Oncol. 2017 Mar;50(3):1022-1028. doi: 10.3892/ijo.2017.3874. Epub 2017 Feb 13.
|
823 |
Spliceosome-associated factor CTNNBL1 promotes proliferation and invasion in ovarian cancer.Exp Cell Res. 2017 Aug 1;357(1):124-134. doi: 10.1016/j.yexcr.2017.05.008. Epub 2017 May 10.
|
824 |
MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research.BMC Cancer. 2019 Feb 22;19(1):171. doi: 10.1186/s12885-019-5371-4.
|
825 |
miR?77 targets CUL4A and regulates metastatic capability in ovarian cancer.Int J Mol Med. 2018 Jun;41(6):3147-3156. doi: 10.3892/ijmm.2018.3540. Epub 2018 Mar 7.
|
826 |
Expression and biological role of cytoglobin in human ovarian cancer.Tumour Biol. 2014 Jul;35(7):6933-9. doi: 10.1007/s13277-014-1941-x. Epub 2014 Apr 17.
|
827 |
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.Eur J Hum Genet. 2017 Apr;25(4):432-438. doi: 10.1038/ejhg.2016.203. Epub 2017 Feb 1.
|
828 |
DAAM1-mediated migration and invasion of ovarian cancer cells are suppressed by miR-208a-5p.Pathol Res Pract. 2019 Jul;215(7):152452. doi: 10.1016/j.prp.2019.152452. Epub 2019 May 14.
|
829 |
DACT1 Overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy.Sci Rep. 2017 Aug 24;7(1):9285. doi: 10.1038/s41598-017-08249-7.
|
830 |
DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway.J Ovarian Res. 2018 Oct 18;11(1):90. doi: 10.1186/s13048-018-0462-4.
|
831 |
Cell Cycle Regulator p27 Mediates Body Mass Index Effects in Ovarian Cancer in FIGO-stages I-II.Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):443-450. doi: 10.21873/cgp.20148.
|
832 |
DDA1 is induced by NR2F6 in ovarian cancer and predicts poor survival outcome.Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1206-1213.
|
833 |
DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1.Cell Death Dis. 2018 May 1;9(5):561. doi: 10.1038/s41419-018-0585-y.
|
834 |
The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression.Cell Rep. 2014 Sep 11;8(5):1447-60. doi: 10.1016/j.celrep.2014.07.058. Epub 2014 Aug 28.
|
835 |
Epigenetic down-regulated DDX10 promotes cell proliferation through Akt/NF-B pathway in ovarian cancer.Biochem Biophys Res Commun. 2016 Jan 22;469(4):1000-5. doi: 10.1016/j.bbrc.2015.12.069. Epub 2015 Dec 20.
|
836 |
Vitamin D and DDX4 regulate the proliferation and invasion of ovarian cancer cells.Oncol Lett. 2018 Jul;16(1):905-909. doi: 10.3892/ol.2018.8718. Epub 2018 May 16.
|
837 |
RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.Sci Rep. 2017 Aug 15;7(1):8126. doi: 10.1038/s41598-017-05326-9.
|
838 |
Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer.Oncol Rep. 2011 Sep;26(3):703-10. doi: 10.3892/or.2011.1337. Epub 2011 Jun 6.
|
839 |
Long noncoding RNA SNHG14 enhances migration and invasion of ovarian cancer by upregulating DGCR8.Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10226-10233. doi: 10.26355/eurrev_201912_19659.
|
840 |
Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.Epigenetics. 2020 Jan-Feb;15(1-2):122-133. doi: 10.1080/15592294.2019.1656155. Epub 2019 Sep 3.
|
841 |
The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts.Cancer. 2019 Apr 15;125(8):1267-1280. doi: 10.1002/cncr.31935. Epub 2019 Jan 8.
|
842 |
MicroRNA-23a depletion promotes apoptosis of ovarian cancer stem cell and inhibits cell migration by targeting DLG2.Cancer Biol Ther. 2019;20(6):897-911. doi: 10.1080/15384047.2019.1579960. Epub 2019 Mar 12.
|
843 |
DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-/SMAD4 signaling.Oncogene. 2017 Mar;36(10):1404-1416. doi: 10.1038/onc.2016.307. Epub 2016 Sep 5.
|
844 |
Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers.Clin Cancer Res. 2004 Dec 15;10(24):8501-11. doi: 10.1158/1078-0432.CCR-04-1072.
|
845 |
Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.Mol Oncol. 2016 Jun;10(6):789-805. doi: 10.1016/j.molonc.2016.01.003. Epub 2016 Jan 29.
|
846 |
Erratum: Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer [Corrigendum].Onco Targets Ther. 2019 Nov 15;12:9793. doi: 10.2147/OTT.S236659. eCollection 2019.
|
847 |
Elmo1 helps dock180 to regulate Rac1 activity and cell migration of ovarian cancer.Int J Gynecol Cancer. 2014 Jun;24(5):844-50. doi: 10.1097/IGC.0000000000000137.
|
848 |
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.
|
849 |
OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia.Oncol Lett. 2017 May;13(5):2929-2936. doi: 10.3892/ol.2017.5848. Epub 2017 Mar 13.
|
850 |
Dicer, Drosha, and outcomes in patients with ovarian cancer.N Engl J Med. 2008 Dec 18;359(25):2641-50. doi: 10.1056/NEJMoa0803785.
|
851 |
Desmocollin 3 mediates follicle stimulating hormone-induced ovarian epithelial cancer cell proliferation by activating the EGFR/Akt signaling pathway.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6716-23. eCollection 2015.
|
852 |
Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.Carcinogenesis. 2008 Sep;29(9):1742-50. doi: 10.1093/carcin/bgn167. Epub 2008 Jul 16.
|
853 |
Effects of dynein light chain Tctex-type 3 on the biological behavior of ovarian cancer.Cancer Manag Res. 2019 Jul 1;11:5925-5938. doi: 10.2147/CMAR.S205158. eCollection 2019.
|
854 |
E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness.Cancer Sci. 2019 Mar;110(3):1085-1095. doi: 10.1111/cas.13920. Epub 2019 Jan 25.
|
855 |
Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.Clin Cancer Res. 2007 Jan 1;13(1):144-51. doi: 10.1158/1078-0432.CCR-06-0780.
|
856 |
The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women.Fam Cancer. 2009;8(4):399-402. doi: 10.1007/s10689-009-9255-7. Epub 2009 Jun 11.
|
857 |
Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.BMC Cancer. 2015 Mar 4;15:91. doi: 10.1186/s12885-015-1100-9.
|
858 |
Knockdown of EHF inhibited the proliferation, invasion and tumorigenesis of ovarian cancer cells.Mol Carcinog. 2016 Jun;55(6):1048-59. doi: 10.1002/mc.22349. Epub 2015 Aug 10.
|
859 |
eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.Oncotarget. 2015 Sep 22;6(28):25441-51. doi: 10.18632/oncotarget.4555.
|
860 |
Identifying Gene Network Rewiring by Integrating Gene Expression and Gene Network Data.IEEE/ACM Trans Comput Biol Bioinform. 2018 Nov-Dec;15(6):2079-2085. doi: 10.1109/TCBB.2018.2809603. Epub 2018 Feb 26.
|
861 |
ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.Oncotarget. 2017 Mar 7;8(10):16951-16963. doi: 10.18632/oncotarget.15208.
|
862 |
NF-B1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.Oncotarget. 2017 Apr 11;8(15):24853-24868. doi: 10.18632/oncotarget.15267.
|
863 |
TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer.Oncol Rep. 2016 Jan;35(1):359-65. doi: 10.3892/or.2015.4388. Epub 2015 Nov 3.
|
864 |
Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.BMC Cancer. 2018 Oct 3;18(1):943. doi: 10.1186/s12885-018-4816-5.
|
865 |
circEPSTI1 regulates ovarian cancer progression via decoying miR-942.J Cell Mol Med. 2019 May;23(5):3597-3602. doi: 10.1111/jcmm.14260. Epub 2019 Mar 19.
|
866 |
Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial.Int J Gynecol Cancer. 2017 Jun;27(5):1046-1050. doi: 10.1097/IGC.0000000000000982.
|
867 |
Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells.Mol Cancer. 2010 Sep 24;9:259. doi: 10.1186/1476-4598-9-259.
|
868 |
Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.Int J Cancer. 2007 Jan 1;120(1):81-90. doi: 10.1002/ijc.22256.
|
869 |
ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells.Oncogenesis. 2017 Oct 9;6(10):e389. doi: 10.1038/oncsis.2017.87.
|
870 |
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.Nat Rev Clin Oncol. 2017 May;14(5):284-296. doi: 10.1038/nrclinonc.2016.191. Epub 2016 Dec 13.
|
871 |
PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.Mol Cancer Res. 2007 May;5(5):413-21. doi: 10.1158/1541-7786.MCR-07-0019. Epub 2007 May 2.
|
872 |
Analysis of gene expression regulated by the ETV5 transcription factor in OV90 ovarian cancer cells identifies FOXM1 overexpression in ovarian cancer.Mol Cancer Res. 2012 Jul;10(7):914-24. doi: 10.1158/1541-7786.MCR-11-0449. Epub 2012 May 15.
|
873 |
LFG-500, a newly synthesized flavonoid, induces apoptosis in human ovarian carcinoma SKOV3 cells with involvement of the reactive oxygen species-mitochondria pathway.Exp Ther Med. 2017 Jun;13(6):2819-2827. doi: 10.3892/etm.2017.4343. Epub 2017 Apr 18.
|
874 |
TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells.Oncol Lett. 2017 Mar;13(3):1398-1405. doi: 10.3892/ol.2016.5534. Epub 2016 Dec 27.
|
875 |
Loss of the novel mitochondrial protein FAM210B promotes metastasis via PDK4-dependent metabolic reprogramming.Cell Death Dis. 2017 Jun 8;8(6):e2870. doi: 10.1038/cddis.2017.273.
|
876 |
Upregulation of circular RNA circFAM53B predicts adverse prognosis and accelerates the progression of ovarian cancer via the miR?46/VAMP2 and miR?47/MDM2 signaling pathways.Oncol Rep. 2019 Dec;42(6):2728-2737. doi: 10.3892/or.2019.7366. Epub 2019 Oct 10.
|
877 |
The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.Int J Cancer. 2019 Jun 1;144(11):2683-2694. doi: 10.1002/ijc.31992. Epub 2019 Jan 11.
|
878 |
FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.BMC Med Genet. 2018 Jan 19;19(1):12. doi: 10.1186/s12881-018-0524-x.
|
879 |
Fibulin-5 is a tumour suppressor inhibiting cell migration and invasion in ovarian cancer.J Clin Pathol. 2016 Feb;69(2):109-16. doi: 10.1136/jclinpath-2015-203129. Epub 2015 Aug 6.
|
880 |
Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells.Oncol Rep. 2019 Apr;41(4):2321-2328. doi: 10.3892/or.2019.6986. Epub 2019 Jan 28.
|
881 |
Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma.Mod Pathol. 2008 Apr;21(4):445-54. doi: 10.1038/modpathol.3801022. Epub 2008 Jan 18.
|
882 |
Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction.Cancer. 1995 Apr 15;75(8):2139-46. doi: 10.1002/1097-0142(19950415)75:8<2139::aid-cncr2820750817>3.0.co;2-6.
|
883 |
FGF9-induced ovarian cancer cell invasion involves VEGF-A/VEGFR2 augmentation by virtue of ETS1 upregulation and metabolic reprogramming.J Cell Biochem. 2018 Nov;119(10):8174-8189. doi: 10.1002/jcb.26820. Epub 2018 Jun 15.
|
884 |
miR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer.Cell Death Dis. 2019 May 8;10(5):372. doi: 10.1038/s41419-019-1604-3.
|
885 |
Enhanced antitumor effect of biodegradable cationic heparin-polyethyleneimine nanogels delivering FILIP1LC103 gene combined with low-dose cisplatin on ovarian cancer.Oncotarget. 2017 Jul 22;8(44):76432-76442. doi: 10.18632/oncotarget.19464. eCollection 2017 Sep 29.
|
886 |
Flotillin 1 is differentially expressed in human epithelial ovarian tumors.Neoplasma. 2018;65(4):561-571. doi: 10.4149/neo_2018_170714N483.
|
887 |
Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age.Maturitas. 2013 Jun;75(2):148-51. doi: 10.1016/j.maturitas.2013.03.002. Epub 2013 Mar 23.
|
888 |
MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma.Cell Cycle. 2018;17(21-22):2474-2483. doi: 10.1080/15384101.2018.1542898. Epub 2018 Nov 18.
|
889 |
miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2-Versican Pathway.Cancer Res. 2018 Aug 1;78(15):4175-4190. doi: 10.1158/0008-5472.CAN-17-3014. Epub 2018 May 10.
|
890 |
FOXK1 facilitates cell proliferation through regulating the expression of p21, and promotes metastasis in ovarian cancer.Oncotarget. 2017 Jul 31;8(41):70441-70451. doi: 10.18632/oncotarget.19713. eCollection 2017 Sep 19.
|
891 |
The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.Mol Cancer Res. 2015 Mar;13(3):502-9. doi: 10.1158/1541-7786.MCR-14-0407. Epub 2014 Nov 3.
|
892 |
MicroRNA-1 inhibits ovarian cancer cell proliferation and migration through c-Met pathway.Clin Chim Acta. 2017 Oct;473:237-244. doi: 10.1016/j.cca.2017.07.008. Epub 2017 Jul 8.
|
893 |
c-Fos mediates 1, 2-fucosyltransferase 1 and Lewisy expression in response to TGF-1 in ovarian cancer.Oncol Rep. 2017 Dec;38(6):3355-3366. doi: 10.3892/or.2017.6052. Epub 2017 Oct 23.
|
894 |
A FXYD5/TGF?SMAD positive feedback loop drives epithelialtomesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.Int J Oncol. 2020 Jan;56(1):301-314. doi: 10.3892/ijo.2019.4911. Epub 2019 Nov 13.
|
895 |
Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.Oncol Rep. 2009 Feb;21(2):313-20.
|
896 |
Elevated expression of Gab1 promotes breast cancer metastasis by dissociating the PAR complex.J Exp Clin Cancer Res. 2019 Jan 21;38(1):27. doi: 10.1186/s13046-019-1025-2.
|
897 |
MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression.Biomed Pharmacother. 2016 May;80:381-387. doi: 10.1016/j.biopha.2015.12.027. Epub 2016 Apr 8.
|
898 |
GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.Oncotarget. 2017 Jun 27;8(26):42588-42601. doi: 10.18632/oncotarget.16585.
|
899 |
The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.Sci Rep. 2018 May 31;8(1):8485. doi: 10.1038/s41598-018-26468-4.
|
900 |
MicroRNA-16 inhibits migration and invasion via regulation of the Wnt/-catenin signaling pathway in ovarian cancer.Oncol Lett. 2019 Mar;17(3):2631-2638. doi: 10.3892/ol.2019.9923. Epub 2019 Jan 14.
|
901 |
GEN-1 immunotherapy for the treatment of ovarian cancer.Future Oncol. 2019 Feb;15(4):421-438. doi: 10.2217/fon-2018-0423. Epub 2018 Oct 16.
|
902 |
ZFP403, a novel tumor suppressor, inhibits the proliferation and metastasis in ovarian cancer.Gynecol Oncol. 2017 Nov;147(2):418-425. doi: 10.1016/j.ygyno.2017.08.025. Epub 2017 Aug 31.
|
903 |
Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.Horm Metab Res. 2011 Oct;43(11):816-20. doi: 10.1055/s-0031-1287766. Epub 2011 Oct 18.
|
904 |
Therapeutic implications of GIPC1 silencing in cancer.PLoS One. 2010 Dec 30;5(12):e15581. doi: 10.1371/journal.pone.0015581.
|
905 |
The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4039-4044.
|
906 |
The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-B signaling pathway.J Exp Clin Cancer Res. 2017 Oct 4;36(1):137. doi: 10.1186/s13046-017-0607-0.
|
907 |
Grb7 gene amplification and protein expression by FISH and IHC in ovarian cancer.Int J Clin Exp Pathol. 2015 Sep 1;8(9):11296-304. eCollection 2015.
|
908 |
GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer.Oncogene. 2018 Nov;37(44):5873-5886. doi: 10.1038/s41388-018-0377-y. Epub 2018 Jul 4.
|
909 |
Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1.Cancer Lett. 2018 Oct 1;433:242-251. doi: 10.1016/j.canlet.2018.06.030. Epub 2018 Jun 28.
|
910 |
A natural entkaurane diterpenoid induces antiproliferation in ovarian cancer cells via ERK1/2 regulation and inhibition of cellular migration and invasion.Mol Med Rep. 2018 Oct;18(4):3898-3906. doi: 10.3892/mmr.2018.9377. Epub 2018 Aug 9.
|
911 |
HPIP Silencing Prevents Epithelial-Mesenchymal Transition Induced by TGF-1 in Human Ovarian Cancer Cells.Oncol Res. 2016;24(1):33-9. doi: 10.3727/096504016X14575597858654.
|
912 |
Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.Cancer Lett. 2017 Dec 28;411:65-73. doi: 10.1016/j.canlet.2017.09.048. Epub 2017 Oct 6.
|
913 |
Screening of HELQ in breast and ovarian cancer families.Fam Cancer. 2016 Jan;15(1):19-23. doi: 10.1007/s10689-015-9838-4.
|
914 |
LINC01342 promotes the progression of ovarian cancer by absorbing microRNA-30c-2-3p to upregulate HIF3A.J Cell Physiol. 2020 Apr;235(4):3939-3949. doi: 10.1002/jcp.29289. Epub 2019 Oct 9.
|
915 |
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.Clin Cancer Res. 2008 Dec 1;14(23):7667-73. doi: 10.1158/1078-0432.CCR-08-0479.
|
916 |
T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.Clin Cancer Res. 2018 Nov 15;24(22):5562-5573. doi: 10.1158/1078-0432.CCR-18-0573. Epub 2018 May 31.
|
917 |
Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer.Cancer Sci. 2015 May;106(5):522-8. doi: 10.1111/cas.12641. Epub 2015 Apr 13.
|
918 |
Early expression of the Helicase-Like Transcription Factor (HLTF/SMARCA3) in an experimental model of estrogen-induced renal carcinogenesis.Mol Cancer. 2006 Jun 8;5:23. doi: 10.1186/1476-4598-5-23.
|
919 |
Humoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer.J Immunol Res. 2014;2014:326593. doi: 10.1155/2014/326593. Epub 2014 Apr 27.
|
920 |
Low expression level of HMBOX1 in high-grade serous ovarian cancer accelerates cell proliferation by inhibiting cell apoptosis.Biochem Biophys Res Commun. 2018 Jun 22;501(2):380-386. doi: 10.1016/j.bbrc.2018.04.203. Epub 2018 May 10.
|
921 |
SRPX and HMCN1 regulate cancerassociated fibroblasts to promote the invasiveness of ovarian carcinoma.Oncol Rep. 2019 Dec;42(6):2706-2715. doi: 10.3892/or.2019.7379. Epub 2019 Oct 17.
|
922 |
Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin.Cancer Res. 2019 Jul 1;79(13):3185-3191. doi: 10.1158/0008-5472.CAN-19-0542. Epub 2019 May 6.
|
923 |
Increased RHAMM expression relates to ovarian cancer progression.J Ovarian Res. 2017 Sep 27;10(1):66. doi: 10.1186/s13048-017-0360-1.
|
924 |
MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT/mTOR signaling pathway and EMT in ovarian cancer.Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4663-4672. doi: 10.26355/eurrev_201906_18046.
|
925 |
HOXA9 promotes homotypic and heterotypic cell interactions that facilitate ovarian cancer dissemination via its induction of P-cadherin.Mol Cancer. 2014 Jul 14;13:170. doi: 10.1186/1476-4598-13-170.
|
926 |
Endocrine disrupting chemical, bisphenol-A, induces breast cancer associated gene HOXB9 expression in vitro and in vivo. Gene. 2016 Sep 30;590(2):234-43. doi: 10.1016/j.gene.2016.05.009. Epub 2016 May 13.
|
927 |
Ovarian cancer variant rs2072590 is associated with HOXD1 and HOXD3 gene expression.Oncotarget. 2017 Oct 13;8(61):103410-103414. doi: 10.18632/oncotarget.21902. eCollection 2017 Nov 28.
|
928 |
Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.Anticancer Drugs. 2019 Feb;30(2):117-127. doi: 10.1097/CAD.0000000000000696.
|
929 |
Role of Hydroxysteroid Dehydrogenase-Like 2 (HSDL2) in Human Ovarian Cancer.Med Sci Monit. 2018 Jun 12;24:3997-4008. doi: 10.12659/MSM.909418.
|
930 |
HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer.Sci Rep. 2019 Sep 2;9(1):12628. doi: 10.1038/s41598-019-48992-7.
|
931 |
Secretion of cytokines and heat shock protein (HspA1A) by ovarian cancer cells depending on the tumor type and stage of disease.Cytokine. 2017 Jan;89:136-142. doi: 10.1016/j.cyto.2016.01.017. Epub 2016 Feb 8.
|
932 |
Heat shock protein 70-2 (HSP70-2) a novel cancer testis antigen that promotes growth of ovarian cancer.Am J Cancer Res. 2017 Jun 1;7(6):1252-1269. eCollection 2017.
|
933 |
High-temperature requirement factor A3 (Htra3): a novel serine protease and its potential role in ovarian function and ovarian cancers.Mol Cell Endocrinol. 2010 Oct 7;327(1-2):13-8. doi: 10.1016/j.mce.2010.06.001. Epub 2010 Jun 9.
|
934 |
Huwe1 Sustains Normal Ovarian Epithelial Cell Transformation and Tumor Growth through the Histone H1.3-H19 Cascade.Cancer Res. 2017 Sep 15;77(18):4773-4784. doi: 10.1158/0008-5472.CAN-16-2597. Epub 2017 Jul 7.
|
935 |
Isoprenylcysteine carboxylmethyltransferase regulates ovarian cancer cell response to chemotherapy and Ras activation.Biochem Biophys Res Commun. 2018 Jun 22;501(2):556-562. doi: 10.1016/j.bbrc.2018.05.038. Epub 2018 May 11.
|
936 |
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4.Sci Transl Med. 2012 Aug 15;4(147):147ra112. doi: 10.1126/scitranslmed.3003778.
|
937 |
MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.J Ovarian Res. 2017 Jan 11;10(1):1. doi: 10.1186/s13048-016-0301-4.
|
938 |
Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.Oncotarget. 2015 Apr 30;6(12):10548-62. doi: 10.18632/oncotarget.3307.
|
939 |
Elevated plasma levels of the novel hormone INSL3 in a woman with metastatic ovarian cancer.Int J Biol Markers. 2007 Apr-Jun;22(2):159-60. doi: 10.1177/172460080702200210.
|
940 |
Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/-catenin signaling.Int J Oncol. 2016 Jan;48(1):153-60. doi: 10.3892/ijo.2015.3228. Epub 2015 Nov 4.
|
941 |
Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer.Cancer Biomark. 2020;27(1):51-61. doi: 10.3233/CBM-190460.
|
942 |
Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer.Oncol Rep. 2008 May;19(5):1245-51.
|
943 |
Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.Gynecol Oncol. 2016 Mar;140(3):545-53. doi: 10.1016/j.ygyno.2015.12.006. Epub 2015 Dec 12.
|
944 |
Knockdown of JARID2 inhibits the proliferation and invasion of ovarian cancer through the PI3K/Akt signaling pathway.Mol Med Rep. 2017 Sep;16(3):3600-3605. doi: 10.3892/mmr.2017.7024. Epub 2017 Jul 17.
|
945 |
Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer.Signal Transduct Target Ther. 2019 Jul 26;4:24. doi: 10.1038/s41392-019-0055-8. eCollection 2019.
|
946 |
JRK is a positive regulator of -catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer.Oncogene. 2016 Jun 2;35(22):2834-41. doi: 10.1038/onc.2015.347. Epub 2015 Oct 12.
|
947 |
GCN-5/PGC-1 signaling is activated and associated with metabolism in cyclin E1-driven ovarian cancer.Aging (Albany NY). 2019 Jul 17;11(14):4890-4899. doi: 10.18632/aging.102082.
|
948 |
HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells.Nanomedicine. 2019 Apr;17:254-265. doi: 10.1016/j.nano.2019.01.017. Epub 2019 Feb 10.
|
949 |
Expression of hMOF in different ovarian tissues and its effects on ovarian cancer prognosis.Oncol Rep. 2015 Feb;33(2):685-92. doi: 10.3892/or.2014.3649. Epub 2014 Dec 5.
|
950 |
Clinical relevance of cytoskeleton associated proteins for ovarian cancer.J Cancer Res Clin Oncol. 2018 Nov;144(11):2195-2205. doi: 10.1007/s00432-018-2710-9. Epub 2018 Aug 9.
|
951 |
The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.Oncogene. 2019 Feb;38(7):1080-1092. doi: 10.1038/s41388-018-0490-y. Epub 2018 Sep 11.
|
952 |
miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.Cell Death Dis. 2018 Nov 8;9(11):1123. doi: 10.1038/s41419-018-1093-9.
|
953 |
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.Oncogene. 2017 May 4;36(18):2565-2576. doi: 10.1038/onc.2016.412. Epub 2016 Nov 21.
|
954 |
Inhibition of KIF20A by BKS0349 reduces endometriotic lesions in a xenograft mouse model.Mol Hum Reprod. 2019 Sep 1;25(9):562-571. doi: 10.1093/molehr/gaz044.
|
955 |
Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23.Cell Cycle. 2019 Jul;18(14):1601-1618. doi: 10.1080/15384101.2019.1624112. Epub 2019 Jun 9.
|
956 |
Overexpression of KIF2A is Suppressed by miR-206 and Associated with Poor Prognosis in Ovarian Cancer.Cell Physiol Biochem. 2018;50(3):810-822. doi: 10.1159/000494467. Epub 2018 Oct 23.
|
957 |
KIFCI, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitries.J Ovarian Res. 2014 May 12;7:53. doi: 10.1186/1757-2215-7-53. eCollection 2014.
|
958 |
LINC00702 accelerates the progression of ovarian cancer through interacting with EZH2 to inhibit the transcription of KLF2.Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):201-208. doi: 10.26355/eurrev_201908_18648.
|
959 |
Long non-coding RNA OR3A4 promotes metastasis of ovarian cancer via inhibiting KLF6.Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2360-2365. doi: 10.26355/eurrev_201903_17380.
|
960 |
Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells.J Biol Chem. 2008 May 16;283(20):13934-42. doi: 10.1074/jbc.M709300200. Epub 2008 Mar 19.
|
961 |
Lentivirus-mediated knockdown of Krppel-like factor 9 inhibits the growth of ovarian cancer.Arch Gynecol Obstet. 2015 Feb;291(2):377-82. doi: 10.1007/s00404-014-3405-3. Epub 2014 Sep 13.
|
962 |
ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.Cancer Lett. 2018 Jul 28;427:9-17. doi: 10.1016/j.canlet.2018.04.013. Epub 2018 Apr 13.
|
963 |
Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer.Clin Cancer Res. 2004 Apr 15;10(8):2766-70. doi: 10.1158/1078-0432.ccr-03-0269.
|
964 |
A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.BMC Cancer. 2011 Apr 1;11:119. doi: 10.1186/1471-2407-11-119.
|
965 |
Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.PLoS One. 2017 Nov 2;12(11):e0186847. doi: 10.1371/journal.pone.0186847. eCollection 2017.
|
966 |
Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.Oncotarget. 2017 Mar 14;8(11):17819-17832. doi: 10.18632/oncotarget.14867.
|
967 |
Epidermolytic palmoplantar keratoderma cosegregates with a keratin 9 mutation in a pedigree with breast and ovarian cancer.Nat Genet. 1994 Jan;6(1):106-10. doi: 10.1038/ng0194-106.
|
968 |
Correlation of LAMA3 with onset and prognosis of ovarian cancer.Oncol Lett. 2019 Sep;18(3):2813-2818. doi: 10.3892/ol.2019.10600. Epub 2019 Jul 10.
|
969 |
LAMP3 expression correlated with poor clinical outcome in human ovarian cancer.Tumour Biol. 2017 Mar;39(3):1010428317695014. doi: 10.1177/1010428317695014.
|
970 |
La-Related Protein 4 as a Suppressor for Motility of Ovarian Cancer Cells.Tohoku J Exp Med. 2019 Jan;247(1):59-67. doi: 10.1620/tjem.247.59.
|
971 |
Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.Arch Pharm Res. 2004 Jun;27(6):633-9. doi: 10.1007/BF02980163.
|
972 |
Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/-Catenin Signaling in Ovarian Cancer.Mol Ther Oncolytics. 2019 Apr 19;14:94-106. doi: 10.1016/j.omto.2019.04.002. eCollection 2019 Sep 27.
|
973 |
Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling.Oncotarget. 2016 Jan 12;7(2):1408-20. doi: 10.18632/oncotarget.6368.
|
974 |
Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer.Br J Cancer. 2015 Jul 28;113(3):414-24. doi: 10.1038/bjc.2015.254. Epub 2015 Jul 9.
|
975 |
Long noncoding RNA CASC9 promotes LIN7A expression via miR-758-3p to facilitate the malignancy of ovarian cancer.J Cell Physiol. 2019 Jul;234(7):10800-10808. doi: 10.1002/jcp.27903. Epub 2018 Dec 7.
|
976 |
LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial-mesenchymal transition and stem-like properties of epithelial ovarian cancer.Gynecol Oncol. 2013 Mar;128(3):475-82. doi: 10.1016/j.ygyno.2012.12.018. Epub 2012 Dec 24.
|
977 |
Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.J Clin Invest. 2018 Feb 1;128(2):589-606. doi: 10.1172/JCI95200. Epub 2017 Dec 18.
|
978 |
Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome.Arch Pathol Lab Med. 1988 Feb;112(2):151-4.
|
979 |
A multiple mixed TiO(2) mesocrystal junction based PEC-colorimetric immunoassay for specific recognition of lipolysis stimulated lipoprotein receptor.Biosens Bioelectron. 2020 Jan 15;148:111809. doi: 10.1016/j.bios.2019.111809. Epub 2019 Oct 26.
|
980 |
Identification of key genes associated with the effect of estrogen on ovarian cancer using microarray analysis.Arch Gynecol Obstet. 2016 Feb;293(2):421-7. doi: 10.1007/s00404-015-3833-8. Epub 2015 Aug 12.
|
981 |
The significance of lumican expression in ovarian cancer drug-resistant cell lines.Oncotarget. 2017 Aug 10;8(43):74466-74478. doi: 10.18632/oncotarget.20169. eCollection 2017 Sep 26.
|
982 |
Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys.Int J Cancer. 1996 Jan 26;65(3):284-94. doi: 10.1002/(SICI)1097-0215(19960126)65:3<284::AID-IJC2>3.0.CO;2-W.
|
983 |
Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells.J Exp Clin Cancer Res. 2011 Sep 16;30(1):83. doi: 10.1186/1756-9966-30-83.
|
984 |
The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings.J Gynecol Oncol. 2018 Jan;29(1):e17. doi: 10.3802/jgo.2018.29.e17.
|
985 |
Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.Br J Cancer. 2019 Nov;121(11):944-953. doi: 10.1038/s41416-019-0607-2. Epub 2019 Oct 29.
|
986 |
Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer.Sci Rep. 2017 Feb 7;7:41977. doi: 10.1038/srep41977.
|
987 |
MKK4 acts as a potential tumor suppressor in ovarian cancer.Tumour Biol. 2011 Aug;32(4):661-70. doi: 10.1007/s13277-011-0166-5. Epub 2011 Apr 14.
|
988 |
MAP2K6-FP Enhances the Sensitiveness of Paclitaxel for Ovarian Cancer via Inducing Autophagy.Int J Gynecol Cancer. 2017 Jul;27(6):1082-1087. doi: 10.1097/IGC.0000000000001003.
|
989 |
MARCH5 RNA promotes autophagy, migration, and invasion of ovarian cancer cells.Autophagy. 2017 Feb;13(2):333-344. doi: 10.1080/15548627.2016.1256520. Epub 2016 Nov 22.
|
990 |
Interaction of E3 Ubiquitin Ligase MARCH7 with Long Noncoding RNA MALAT1 and Autophagy-Related Protein ATG7 Promotes Autophagy and Invasion in Ovarian Cancer.Cell Physiol Biochem. 2018;47(2):654-666. doi: 10.1159/000490020. Epub 2018 May 22.
|
991 |
MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition.Tumour Biol. 2015 Jun;36(6):4261-9. doi: 10.1007/s13277-015-3063-5. Epub 2015 Jan 16.
|
992 |
SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide.Biochim Biophys Acta. 2013 Oct;1833(10):2357-68. doi: 10.1016/j.bbamcr.2013.06.003. Epub 2013 Jun 13.
|
993 |
Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.Reproduction. 2017 Mar;153(3):277-284. doi: 10.1530/REP-16-0265. Epub 2016 Dec 13.
|
994 |
METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.Gynecol Oncol. 2018 Nov;151(2):356-365. doi: 10.1016/j.ygyno.2018.09.015. Epub 2018 Sep 21.
|
995 |
The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer.J Biol Chem. 2017 Sep 29;292(39):16351-16359. doi: 10.1074/jbc.M117.783936. Epub 2017 Aug 23.
|
996 |
Silencing of MICAL-L2 suppresses malignancy of ovarian cancer by inducing mesenchymal-epithelial transition.Cancer Lett. 2015 Jul 10;363(1):71-82. doi: 10.1016/j.canlet.2015.04.002. Epub 2015 Apr 9.
|
997 |
MICU1 drives glycolysis and chemoresistance in ovarian cancer.Nat Commun. 2017 May 22;8:14634. doi: 10.1038/ncomms14634.
|
998 |
Involvement of AF1q/MLLT11 in the progression of ovarian cancer.Oncotarget. 2017 Apr 4;8(14):23246-23264. doi: 10.18632/oncotarget.15574.
|
999 |
Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome.Sci Rep. 2019 Aug 12;9(1):11677. doi: 10.1038/s41598-019-47871-5.
|
1000 |
Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.Oncogene. 2017 Mar 23;36(12):1698-1706. doi: 10.1038/onc.2016.336. Epub 2016 Oct 10.
|
1001 |
MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer.Oncol Rep. 2019 Aug;42(2):679-687. doi: 10.3892/or.2019.7199. Epub 2019 Jun 12.
|
1002 |
Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.Clin Cancer Res. 2016 Jun 15;22(12):3097-3104. doi: 10.1158/1078-0432.CCR-15-1669. Epub 2016 Jan 13.
|
1003 |
Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.Tumour Biol. 2017 Jun;39(6):1010428317713389. doi: 10.1177/1010428317713389.
|
1004 |
Overexpression of mucin 13 due to promoter methylation promotes aggressive behavior in ovarian cancer cells.Yonsei Med J. 2014 Sep;55(5):1206-13. doi: 10.3349/ymj.2014.55.5.1206.
|
1005 |
MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer.Biochem Biophys Res Commun. 2016 Aug 5;476(4):493-500. doi: 10.1016/j.bbrc.2016.05.152. Epub 2016 May 30.
|
1006 |
Diverse functions of myosin VI elucidated by an isoform-specific -helix domain.Nat Struct Mol Biol. 2016 Apr;23(4):300-308. doi: 10.1038/nsmb.3187. Epub 2016 Mar 7.
|
1007 |
Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.Br J Cancer. 2017 May 9;116(10):1287-1293. doi: 10.1038/bjc.2017.83. Epub 2017 Mar 28.
|
1008 |
Cloning and expression of functional cDNA genes of a mouse/human chimeric antibody rcM4.Tumori. 1994 Dec 31;80(6):473-9. doi: 10.1177/030089169408000613.
|
1009 |
[Corrigendum] miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1.Int J Oncol. 2017 Jun;50(6):2236. doi: 10.3892/ijo.2017.3977. Epub 2017 Apr 27.
|
1010 |
New insight into NANOG: A novel therapeutic target for ovarian cancer (OC).Eur J Pharmacol. 2019 Jun 5;852:51-57. doi: 10.1016/j.ejphar.2019.03.003. Epub 2019 Mar 2.
|
1011 |
The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.Gynecol Oncol. 2015 Apr;137(1):143-51. doi: 10.1016/j.ygyno.2014.12.042. Epub 2015 Jan 8.
|
1012 |
Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family.Hum Mutat. 2003 Jun;21(6):654. doi: 10.1002/humu.9148.
|
1013 |
High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.J Transl Med. 2019 May 20;17(1):166. doi: 10.1186/s12967-019-1904-5.
|
1014 |
NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.Oncotarget. 2016 Jan 19;7(3):3018-32. doi: 10.18632/oncotarget.6576.
|
1015 |
Nectin-2 in ovarian cancer: How is it expressed and what might be its functional role?.Cancer Sci. 2019 Jun;110(6):1872-1882. doi: 10.1111/cas.13992. Epub 2019 May 2.
|
1016 |
Nectin-3 is a new biomarker that mediates the upregulation of MMP2 and MMP9 in ovarian cancer cells.Biomed Pharmacother. 2019 Feb;110:139-144. doi: 10.1016/j.biopha.2018.11.020. Epub 2018 Nov 20.
|
1017 |
Deregulation of sialidases in human normal and tumor tissues.Cancer Biomark. 2018 Feb 14;21(3):591-601. doi: 10.3233/CBM-170548.
|
1018 |
Nrf2 induces cisplatin resistance via suppressing the iron export related gene SLC40A1 in ovarian cancer cells.Oncotarget. 2017 Jul 25;8(55):93502-93515. doi: 10.18632/oncotarget.19548. eCollection 2017 Nov 7.
|
1019 |
Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway.Oncogene. 2001 Jul 27;20(33):4457-65. doi: 10.1038/sj.onc.1204608.
|
1020 |
NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells.Oncotarget. 2017 May 16;8(20):33110-33121. doi: 10.18632/oncotarget.16145.
|
1021 |
Evaluation of Serum Nidogen-2 as a Screening and Diagnostic Tool for Ovarian Cancer.Gynecol Obstet Invest. 2018;83(5):461-465. doi: 10.1159/000481798. Epub 2017 Nov 7.
|
1022 |
Nucleoside Diphosphate Kinase-3 (NME3) Enhances TLR5-Induced NFB Activation.Mol Cancer Res. 2018 Jun;16(6):986-999. doi: 10.1158/1541-7786.MCR-17-0603. Epub 2018 Mar 9.
|
1023 |
Trabid, a new positive regulator of Wnt-induced transcription with preference for binding and cleaving K63-linked ubiquitin chains.Genes Dev. 2008 Feb 15;22(4):528-42. doi: 10.1101/gad.463208.
|
1024 |
Clinicopathological significance of steroidogenic factor-1 expression in ovarian cancer versus ovarian sex cord stromal tumor.Tumour Biol. 2015 Mar;36(3):1429-35. doi: 10.1007/s13277-014-2187-3. Epub 2015 Jan 22.
|
1025 |
Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.Biomed Pharmacother. 2017 Jan;85:248-255. doi: 10.1016/j.biopha.2016.11.012. Epub 2016 Nov 28.
|
1026 |
E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival.Eur Rev Med Pharmacol Sci. 2017 May;21(9):2150-2156.
|
1027 |
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.PLoS Genet. 2013;9(3):e1003212. doi: 10.1371/journal.pgen.1003212. Epub 2013 Mar 27.
|
1028 |
NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.Tumour Biol. 2017 Sep;39(9):1010428317714631. doi: 10.1177/1010428317714631.
|
1029 |
Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.Int J Cancer. 2018 Aug 1;143(3):515-526. doi: 10.1002/ijc.31335. Epub 2018 Mar 8.
|
1030 |
Single nucleotide variant in Nucleoporin 107 may be predictive of sensitivity to chemotherapy in patients with ovarian cancer.Pharmacogenet Genomics. 2017 Jul;27(7):264-269. doi: 10.1097/FPC.0000000000000288.
|
1031 |
Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.Gynecol Oncol. 2017 Nov;147(2):465-480. doi: 10.1016/j.ygyno.2017.07.138. Epub 2017 Aug 8.
|
1032 |
Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion.Gynecol Oncol. 2008 May;109(2):226-33. doi: 10.1016/j.ygyno.2007.12.024. Epub 2008 Mar 6.
|
1033 |
Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.Clin Chem Lab Med. 2014 May;52(5):735-42. doi: 10.1515/cclm-2013-0736.
|
1034 |
The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res. 2001 Apr;7(4):806-11.
|
1035 |
The non-coding RNA OTUB1-isoform2 promotes ovarian tumour progression and predicts poor prognosis.J Cell Mol Med. 2018 Oct;22(10):4794-4806. doi: 10.1111/jcmm.13733. Epub 2018 Jul 25.
|
1036 |
Ovarian tumor domain-containing protein 1 deubiquitinates and stabilizes p53.Cell Signal. 2017 May;33:22-29. doi: 10.1016/j.cellsig.2017.02.011. Epub 2017 Feb 13.
|
1037 |
Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.Drug Deliv. 2018 Nov;25(1):995-1003. doi: 10.1080/10717544.2018.1461956.
|
1038 |
hPaf1/PD2 interacts with OCT3/4 to promote self-renewal of ovarian cancer stem cells.Oncotarget. 2017 Feb 28;8(9):14806-14820. doi: 10.18632/oncotarget.14775.
|
1039 |
miR-193b-3p possesses anti-tumor activity in ovarian carcinoma cells by targeting p21-activated kinase 3.Biomed Pharmacother. 2017 Dec;96:1275-1282. doi: 10.1016/j.biopha.2017.11.086. Epub 2017 Nov 21.
|
1040 |
PAK5 Induces EMT and Promotes Cell Migration and Invasion by Activating the PI3K/AKT Pathway in Ovarian Cancer.Anal Cell Pathol (Amst). 2018 Sep 2;2018:8073124. doi: 10.1155/2018/8073124. eCollection 2018.
|
1041 |
AKAP2 is upregulated in ovarian cancer, and promotes growth and migration of cancer cells.Mol Med Rep. 2017 Oct;16(4):5151-5156. doi: 10.3892/mmr.2017.7286. Epub 2017 Aug 18.
|
1042 |
Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.PLoS One. 2019 Nov 21;14(11):e0224564. doi: 10.1371/journal.pone.0224564. eCollection 2019.
|
1043 |
An epigenetic marker panel for screening and prognostic prediction of ovarian cancer.Int J Cancer. 2009 Jan 15;124(2):387-93. doi: 10.1002/ijc.23957.
|
1044 |
UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer.Cancers (Basel). 2018 Aug 8;10(8):262. doi: 10.3390/cancers10080262.
|
1045 |
PBOV1 correlates with progression of ovarian cancer and inhibits proliferation of ovarian cancer cells.Oncol Rep. 2016 Jan;35(1):488-96. doi: 10.3892/or.2015.4396. Epub 2015 Nov 4.
|
1046 |
Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1.Cancer Res. 2016 Nov 1;76(21):6351-6361. doi: 10.1158/0008-5472.CAN-16-0980. Epub 2016 Sep 2.
|
1047 |
HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.Cell Oncol (Dordr). 2017 Apr;40(2):133-144. doi: 10.1007/s13402-016-0308-2. Epub 2016 Dec 30.
|
1048 |
Low Expression of Protocadherin-8 Promotes the Progression of Ovarian Cancer.Int J Gynecol Cancer. 2018 Feb;28(2):346-354. doi: 10.1097/IGC.0000000000001169.
|
1049 |
MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9.Onco Targets Ther. 2019 Oct 8;12:8329-8338. doi: 10.2147/OTT.S220339. eCollection 2019.
|
1050 |
PCNA-associated factor P15(PAF) , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.Int J Cancer. 2018 Dec 1;143(11):2973-2984. doi: 10.1002/ijc.31800. Epub 2018 Oct 4.
|
1051 |
Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.Oncogene. 2015 Apr 16;34(16):2125-37. doi: 10.1038/onc.2014.117. Epub 2014 Jun 9.
|
1052 |
Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis.Nanoscale. 2017 Sep 14;9(35):13142-13152. doi: 10.1039/c7nr04473a.
|
1053 |
Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.Acta Biochim Biophys Sin (Shanghai). 2013 Sep;45(9):756-62. doi: 10.1093/abbs/gmt075. Epub 2013 Jul 3.
|
1054 |
ERp57small interfering RNA silencing can enhance the sensitivity of drugresistant human ovarian cancer cells to paclitaxel.Int J Oncol. 2019 Jan;54(1):249-260. doi: 10.3892/ijo.2018.4628. Epub 2018 Nov 7.
|
1055 |
Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.J Cell Biochem. 2019 Apr;120(4):6057-6070. doi: 10.1002/jcb.27892. Epub 2018 Oct 18.
|
1056 |
Overexpression of PDK4 is associated with cell proliferation, drug resistance and poor prognosis in ovarian cancer.Cancer Manag Res. 2018 Dec 24;11:251-262. doi: 10.2147/CMAR.S185015. eCollection 2019.
|
1057 |
PDZ and LIM domain protein 4 suppresses the growth and invasion of ovarian cancer cells via inactivation of STAT3 signaling.Life Sci. 2019 Sep 15;233:116715. doi: 10.1016/j.lfs.2019.116715. Epub 2019 Jul 31.
|
1058 |
PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival.Cancer Res. 2008 Nov 15;68(22):9302-10. doi: 10.1158/0008-5472.CAN-08-2592.
|
1059 |
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.Cancer. 2008 Apr 1;112(7):1489-502. doi: 10.1002/cncr.23323.
|
1060 |
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.Clin Cancer Res. 2011 Apr 15;17(8):2250-9. doi: 10.1158/1078-0432.CCR-10-2718. Epub 2011 Mar 18.
|
1061 |
BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study.Cell Cycle. 2015;14(12):1884-92. doi: 10.1080/15384101.2015.1036203.
|
1062 |
miR-211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma.FASEB J. 2018 Jun 6:fj201800495RR. doi: 10.1096/fj.201800495RR. Online ahead of print.
|
1063 |
PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage.Cell Signal. 2013 Jan;25(1):74-84. doi: 10.1016/j.cellsig.2012.09.009. Epub 2012 Sep 11.
|
1064 |
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.Neoplasia. 2010 Feb;12(2):161-72. doi: 10.1593/neo.91542.
|
1065 |
HOTAIR Promotes Proliferation, Migration, and Invasion of Ovarian Cancer SKOV3 Cells Through Regulating PIK3R3.Med Sci Monit. 2016 Jan 31;22:325-31. doi: 10.12659/msm.894913.
|
1066 |
Invasion of ovarian cancer cells is induced byPITX2-mediated activation of TGF- and Activin-A.Mol Cancer. 2015 Aug 23;14:162. doi: 10.1186/s12943-015-0433-y.
|
1067 |
Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.Gynecol Oncol. 2004 Dec;95(3):449-55. doi: 10.1016/j.ygyno.2004.08.051.
|
1068 |
Broad, ectopic expression of the sperm protein PLCZ1 induces parthenogenesis and ovarian tumours in mice.Development. 2007 Nov;134(21):3941-52. doi: 10.1242/dev.007930.
|
1069 |
MiR-126-3p inhibits ovarian cancer proliferation and invasion via targeting PLXNB2.Reprod Biol. 2018 Sep;18(3):218-224. doi: 10.1016/j.repbio.2018.07.005. Epub 2018 Jul 24.
|
1070 |
EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer.Mol Carcinog. 2003 Dec;38(4):188-200. doi: 10.1002/mc.10162.
|
1071 |
The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.Gynecol Endocrinol. 2009 Feb;25(2):104-9. doi: 10.1080/09513590802549841.
|
1072 |
Identification of potential prognostic TF-associated lncRNAs for predicting survival in ovarian cancer.J Cell Mol Med. 2019 Mar;23(3):1840-1851. doi: 10.1111/jcmm.14084. Epub 2018 Dec 13.
|
1073 |
Epigenetic activation of POTE genes in ovarian cancer.Epigenetics. 2019 Feb;14(2):185-197. doi: 10.1080/15592294.2019.1581590. Epub 2019 Mar 4.
|
1074 |
Expression of Inorganic Pyrophosphatase (PPA1) Correlates with Poor Prognosis of Epithelial Ovarian Cancer.Tohoku J Exp Med. 2017 Feb;241(2):165-173. doi: 10.1620/tjem.241.165.
|
1075 |
The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity.Cell Tissue Res. 2018 Dec;374(3):577-585. doi: 10.1007/s00441-018-2906-y. Epub 2018 Sep 4.
|
1076 |
Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.Mol Med Rep. 2013 Jun;7(6):1826-30. doi: 10.3892/mmr.2013.1416. Epub 2013 Apr 9.
|
1077 |
Upregulation of miR-614 promotes proliferation and inhibits apoptosis in ovarian cancer by suppressing PPP2R2A expression.Mol Med Rep. 2018 May;17(5):6285-6292. doi: 10.3892/mmr.2018.8714. Epub 2018 Mar 9.
|
1078 |
MiR-572 prompted cell proliferation of human ovarian cancer cells by suppressing PPP2R2C expression. Biomed Pharmacother. 2016 Feb;77:92-7.
|
1079 |
Age is associated with prognosis in serous ovarian carcinoma.J Ovarian Res. 2017 Jun 12;10(1):36. doi: 10.1186/s13048-017-0331-6.
|
1080 |
Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer.Ann Agric Environ Med. 2019 Sep 19;26(3):415-419. doi: 10.26444/aaem/105899. Epub 2019 Apr 1.
|
1081 |
Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance.Biochem Biophys Res Commun. 2019 Feb 5;509(2):373-378. doi: 10.1016/j.bbrc.2018.12.127. Epub 2018 Dec 25.
|
1082 |
PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.Mol Cancer Ther. 2019 Jan;18(1):162-172. doi: 10.1158/1535-7163.MCT-17-1050. Epub 2018 Oct 10.
|
1083 |
Long non-coding RNA RP11-552M11.4 favors tumorigenesis and development of cervical cancer via modulating miR-3941/ATF1 signaling.Int J Biol Macromol. 2019 Jun 1;130:24-33. doi: 10.1016/j.ijbiomac.2019.02.083. Epub 2019 Feb 18.
|
1084 |
PRR11 Overexpression Facilitates Ovarian Carcinoma Cell Proliferation, Migration, and Invasion Through Activation of the PI3K/AKT/-Catenin Pathway.Cell Physiol Biochem. 2018;49(2):696-705. doi: 10.1159/000493034. Epub 2018 Aug 30.
|
1085 |
PRSS21/testisin inhibits ovarian tumor metastasis and antagonizes proangiogenic angiopoietins ANG2 and ANGPTL4.J Mol Med (Berl). 2019 May;97(5):691-709. doi: 10.1007/s00109-019-01763-3. Epub 2019 Mar 25.
|
1086 |
PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer.Gynecol Oncol. 2015 Jun;137(3):546-52. doi: 10.1016/j.ygyno.2015.02.022. Epub 2015 Feb 28.
|
1087 |
Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker.J Proteome Res. 2007 Nov;6(11):4127-34. doi: 10.1021/pr0702722. Epub 2007 Oct 16.
|
1088 |
PTTG1: a Unique Regulator of Stem/Cancer Stem Cells in the Ovary and Ovarian Cancer.Stem Cell Rev Rep. 2019 Dec;15(6):866-879. doi: 10.1007/s12015-019-09911-5.
|
1089 |
circPUM1 Promotes Tumorigenesis and Progression of Ovarian Cancer by Sponging miR-615-5p and miR-6753-5p.Mol Ther Nucleic Acids. 2019 Dec 6;18:882-892. doi: 10.1016/j.omtn.2019.09.032. Epub 2019 Oct 23.
|
1090 |
High expression of PXDN is associated with poor prognosis and promotes proliferation, invasion as well as migration in ovarian cancer.Ann Diagn Pathol. 2018 Jun;34:161-165. doi: 10.1016/j.anndiagpath.2018.03.002. Epub 2018 Mar 14.
|
1091 |
Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer.Cancer Res. 2008 Jul 15;68(14):5839-48. doi: 10.1158/0008-5472.CAN-07-5771.
|
1092 |
Epigenetic inactivation of TMS1/ASC in ovarian cancer.Clin Cancer Res. 2004 Mar 15;10(6):2000-6. doi: 10.1158/1078-0432.ccr-0932-03.
|
1093 |
Tumor microenvironment-associated modifications of alternative splicing.RNA. 2014 Feb;20(2):189-201. doi: 10.1261/rna.042168.113. Epub 2013 Dec 11.
|
1094 |
Histone modifications silence the GATA transcription factor genes in ovarian cancer.Oncogene. 2006 Aug 31;25(39):5446-61. doi: 10.1038/sj.onc.1209533. Epub 2006 Apr 10.
|
1095 |
Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway.Oncol Lett. 2018 Apr;15(4):5155-5160. doi: 10.3892/ol.2018.7949. Epub 2018 Feb 5.
|
1096 |
Upregulation of Circular RNA VPS13C-has-circ-001567 Promotes Ovarian Cancer Cell Proliferation and Invasion.Cancer Biother Radiopharm. 2019 Mar;34(2):110-118. doi: 10.1089/cbr.2018.2641. Epub 2018 Oct 30.
|
1097 |
Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B.Nat Commun. 2015 Jan 8;6:5917. doi: 10.1038/ncomms6917.
|
1098 |
Polymorphisms of the Ras-Association Domain Family 1 Isoform A (RASSF1A) Gene are Associated with Ovarian Cancer, and with the Prognostic Factors of Grade and Stage, in Women in Southern China.Med Sci Monit. 2018 Apr 19;24:2360-2367. doi: 10.12659/msm.910058.
|
1099 |
The HRAS1 minisatellite locus and risk of ovarian cancer.Cancer Res. 2000 Jan 15;60(2):259-61.
|
1100 |
Suppression of FIP200 and autophagy by tumor-derived lactate promotes nave T cell apoptosis and affects tumor immunity.Sci Immunol. 2017 Nov 17;2(17):eaan4631. doi: 10.1126/sciimmunol.aan4631.
|
1101 |
The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing.Mol Carcinog. 2019 Feb;58(2):196-205. doi: 10.1002/mc.22919. Epub 2018 Oct 28.
|
1102 |
Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid. Oncogene. 2006 Aug 28;25(38):5315-25. doi: 10.1038/sj.onc.1209679.
|
1103 |
High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer.Med Sci Monit. 2017 Dec 21;23:6033-6041. doi: 10.12659/msm.905314.
|
1104 |
CRBP-1 over-expression is associated with poor prognosis in tongue squamous cell carcinoma.BMC Cancer. 2018 May 2;18(1):514. doi: 10.1186/s12885-018-4249-1.
|
1105 |
RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.FASEB J. 2019 Apr;33(4):5350-5365. doi: 10.1096/fj.201801529RR. Epub 2019 Feb 15.
|
1106 |
Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells.Oncotarget. 2017 Aug 7;8(41):70798-70810. doi: 10.18632/oncotarget.19990. eCollection 2017 Sep 19.
|
1107 |
Knockdown of NRSF inhibits cell proliferation of ovarian cancer via activating Hippo pathway.Life Sci. 2018 Dec 15;215:73-79. doi: 10.1016/j.lfs.2018.10.070. Epub 2018 Nov 2.
|
1108 |
Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.PLoS One. 2014 Jan 27;9(1):e87455. doi: 10.1371/journal.pone.0087455. eCollection 2014.
|
1109 |
RGS5 decreases the proliferation of human ovarian carcinomaderived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia.Oncol Rep. 2019 Jan;41(1):165-177. doi: 10.3892/or.2018.6811. Epub 2018 Oct 22.
|
1110 |
RIF1 promotes human epithelial ovarian cancer growth and progression via activating human telomerase reverse transcriptase expression.J Exp Clin Cancer Res. 2018 Aug 3;37(1):182. doi: 10.1186/s13046-018-0854-8.
|
1111 |
Risk of Ovarian Malignancy Algorithm versus Risk Malignancy Index-I for Preoperative Assessment of Adnexal Masses: A Systematic Review and Meta-Analysis.Gynecol Obstet Invest. 2019;84(6):591-598. doi: 10.1159/000501681. Epub 2019 Jul 16.
|
1112 |
Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.Int J Cancer. 2006 Mar 15;118(6):1565-71. doi: 10.1002/ijc.21520.
|
1113 |
Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer.Oncol Rep. 2014 Jul;32(1):362-72. doi: 10.3892/or.2014.3175. Epub 2014 May 13.
|
1114 |
Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.Am J Physiol Cell Physiol. 2018 Aug 1;315(2):C225-C235. doi: 10.1152/ajpcell.00283.2017. Epub 2018 May 2.
|
1115 |
Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.Cancer Res. 2019 Feb 15;79(4):760-772. doi: 10.1158/0008-5472.CAN-18-2297. Epub 2018 Dec 18.
|
1116 |
Cloning of a human ortholog (RPH3AL) of (RNO)Rph3al from a candidate 17p13.3 medulloblastoma tumor suppressor locus.Genomics. 1999 Jul 1;59(1):97-101. doi: 10.1006/geno.1999.5864.
|
1117 |
Ribosomal L22-like1 (RPL22L1) Promotes Ovarian Cancer Metastasis by Inducing Epithelial-to-Mesenchymal Transition.PLoS One. 2015 Nov 30;10(11):e0143659. doi: 10.1371/journal.pone.0143659. eCollection 2015.
|
1118 |
A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells.Virus Res. 2019 Apr 2;263:145-150. doi: 10.1016/j.virusres.2019.01.014. Epub 2019 Jan 23.
|
1119 |
Long non-coding RNA EPB41L4A-AS2 suppresses progression of ovarian cancer by sequestering microRNA-103a to upregulate transcription factor RUNX1T1.Exp Physiol. 2020 Jan;105(1):75-87. doi: 10.1113/EP087847. Epub 2019 Dec 9.
|
1120 |
Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.Int J Cancer. 2011 May 1;128(9):2063-74. doi: 10.1002/ijc.25554.
|
1121 |
H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer.Mol Med. 1996 Mar;2(2):189-203.
|
1122 |
Prognostic values of S100 family mRNA expression in ovarian cancer.Cancer Biomark. 2019;25(1):67-78. doi: 10.3233/CBM-182276.
|
1123 |
S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin.J Ovarian Res. 2019 Nov 18;12(1):113. doi: 10.1186/s13048-019-0592-3.
|
1124 |
Expression of S100A11 is a Prognostic Factor for Disease-free Survival and Overall Survival in Patients With High-grade Serous Ovarian Cancer.Appl Immunohistochem Mol Morphol. 2017 Feb;25(2):110-116. doi: 10.1097/PAI.0000000000000275.
|
1125 |
S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.DNA Cell Biol. 2018 May;37(5):491-500. doi: 10.1089/dna.2017.3953. Epub 2018 Feb 27.
|
1126 |
Unfavourable prognostic significance of S100P expression in ovarian cancers.Histopathology. 2007 Jul;51(1):125-8. doi: 10.1111/j.1365-2559.2007.02714.x. Epub 2007 May 31.
|
1127 |
SALL2 represses cyclins D1 and E1 expression and restrains G1/S cell cycle transition and cancer-related phenotypes.Mol Oncol. 2018 Jun;12(7):1026-1046. doi: 10.1002/1878-0261.12308. Epub 2018 May 21.
|
1128 |
Functional and clinical significance of SALL4 in breast cancer.Tumour Biol. 2016 Sep;37(9):11701-11709. doi: 10.1007/s13277-016-5150-7. Epub 2016 Jul 21.
|
1129 |
Discovery and expression analysis of novel transcripts of the human SR-related CTD-associated factor 1 (SCAF1) gene in human cancer cells using Next-Generation Sequencing.Gene. 2018 Sep 5;670:155-165. doi: 10.1016/j.gene.2018.05.044. Epub 2018 May 19.
|
1130 |
Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression.Mol Ther Nucleic Acids. 2019 Dec 6;18:24-33. doi: 10.1016/j.omtn.2019.07.012. Epub 2019 Jul 29.
|
1131 |
Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality.J Biomed Inform. 2019 Dec;100:103313. doi: 10.1016/j.jbi.2019.103313. Epub 2019 Oct 23.
|
1132 |
Genomic characterization of human SEC14L1 splice variants within a 17q25 candidate tumor suppressor gene region and identification of an unrelated embedded expressed sequence tag.Mamm Genome. 2001 Dec;12(12):925-9. doi: 10.1007/s00335-001-2073-3.
|
1133 |
Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer.Gynecol Oncol. 2008 Apr;109(1):115-21. doi: 10.1016/j.ygyno.2007.12.030. Epub 2008 Feb 13.
|
1134 |
Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis.Int J Cancer. 2006 Mar 1;118(5):1325-9. doi: 10.1002/ijc.21486.
|
1135 |
Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.Gynecol Obstet Invest. 2018;83(5):508-514. doi: 10.1159/000479027. Epub 2017 Jul 22.
|
1136 |
Treading the beaten path with old and new obstacles: a report from the Indian HIPEC registry.Int J Hyperthermia. 2018;35(1):361-369. doi: 10.1080/02656736.2018.1503345. Epub 2018 Oct 9.
|
1137 |
SEI1 induces genomic instability by inhibiting DNA damage response in ovarian cancer.Cancer Lett. 2017 Jan 28;385:271-279. doi: 10.1016/j.canlet.2016.09.032. Epub 2016 Oct 3.
|
1138 |
Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer.Onco Targets Ther. 2019 Sep 11;12:7451-7457. doi: 10.2147/OTT.S220700. eCollection 2019.
|
1139 |
Genetic and epigenetic alterations of steroidogenic factor? in ovarian tumors.Int J Oncol. 2013 Feb;42(2):627-34. doi: 10.3892/ijo.2012.1758. Epub 2012 Dec 28.
|
1140 |
Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer.Biochem Biophys Res Commun. 2004 Apr 16;316(4):1156-62. doi: 10.1016/j.bbrc.2004.02.171.
|
1141 |
MiR-1180 from bone marrow-derived mesenchymal stem cells induces glycolysis and chemoresistance in ovarian cancer cells by upregulating the Wnt signaling pathway.J Zhejiang Univ Sci B. 2019 Mar.;20(3):219-237. doi: 10.1631/jzus.B1800190.
|
1142 |
SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway.Gynecol Oncol. 2009 Mar;112(3):646-53. doi: 10.1016/j.ygyno.2008.10.026. Epub 2008 Dec 18.
|
1143 |
Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway.Int J Cancer. 2010 Aug 1;127(3):555-67. doi: 10.1002/ijc.25083.
|
1144 |
Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.Prostate. 2017 May;77(7):718-728. doi: 10.1002/pros.23302. Epub 2017 Feb 23.
|
1145 |
Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis.PLoS Med. 2019 Aug 7;16(8):e1002893. doi: 10.1371/journal.pmed.1002893. eCollection 2019 Aug.
|
1146 |
SHMT1 inhibits the metastasis of HCC by repressing NOX1-mediated ROS production.J Exp Clin Cancer Res. 2019 Feb 12;38(1):70. doi: 10.1186/s13046-019-1067-5.
|
1147 |
EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.Cancer Lett. 2013 Aug 9;336(1):53-60. doi: 10.1016/j.canlet.2013.04.012. Epub 2013 Apr 18.
|
1148 |
Bioinformatics analysis to screen the key prognostic genes in ovarian cancer.J Ovarian Res. 2017 Apr 13;10(1):27. doi: 10.1186/s13048-017-0323-6.
|
1149 |
Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells.Gynecol Oncol. 2011 Sep;122(3):656-62. doi: 10.1016/j.ygyno.2011.04.052. Epub 2011 Jun 14.
|
1150 |
Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer.Int J Biochem Cell Biol. 2014 Aug;53:389-98. doi: 10.1016/j.biocel.2014.05.031. Epub 2014 May 29.
|
1151 |
Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop.J Cell Biochem. 2019 Jun;120(6):10643-10651. doi: 10.1002/jcb.28354. Epub 2019 Jan 22.
|
1152 |
SNAP23 promotes the malignant process of ovarian cancer.J Ovarian Res. 2016 Nov 17;9(1):80. doi: 10.1186/s13048-016-0289-9.
|
1153 |
Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer.Theranostics. 2018 Oct 6;8(19):5200-5212. doi: 10.7150/thno.27806. eCollection 2018.
|
1154 |
The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts.Genome Biol. 2018 Mar 16;19(1):35. doi: 10.1186/s13059-018-1412-6.
|
1155 |
MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression.Int J Mol Sci. 2017 Jun 6;18(6):1208. doi: 10.3390/ijms18061208.
|
1156 |
SOX18 Affects Cell Viability, Migration, Invasiveness, and Apoptosis in Hepatocellular Carcinoma (HCC) Cells by Participating in Epithelial-to-Mesenchymal Transition (EMT) Progression and Adenosine Monophosphate Activated Protein Kinase (AMPK)/Mammalian Target of Rapamycin (mTOR).Med Sci Monit. 2019 Aug 20;25:6244-6254. doi: 10.12659/MSM.915729.
|
1157 |
Sex-determining region Y-box3 (SOX3) functions as an oncogene in promoting epithelial ovarian cancer by targeting Src kinase.Tumour Biol. 2016 Sep;37(9):12263-12271. doi: 10.1007/s13277-016-5095-x. Epub 2016 Jun 1.
|
1158 |
SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.Gynecol Oncol. 2019 Jun;153(3):651-660. doi: 10.1016/j.ygyno.2019.03.099. Epub 2019 Mar 21.
|
1159 |
Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.Tumour Biol. 2018 May;40(5):1010428318773652. doi: 10.1177/1010428318773652.
|
1160 |
Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer.Cancer Sci. 2019 Mar;110(3):1117-1126. doi: 10.1111/cas.13955. Epub 2019 Feb 16.
|
1161 |
Spy1 participates in the proliferation and apoptosis of epithelial ovarian cancer.J Mol Histol. 2016 Feb;47(1):47-57. doi: 10.1007/s10735-015-9646-z. Epub 2015 Dec 7.
|
1162 |
Emerging Roles of SPINK1 in Cancer.Clin Chem. 2016 Mar;62(3):449-57. doi: 10.1373/clinchem.2015.241513. Epub 2015 Dec 11.
|
1163 |
Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells.Cell Physiol Biochem. 2018;45(3):1061-1071. doi: 10.1159/000487348. Epub 2018 Feb 7.
|
1164 |
Dysregulation of pseudogene/lncRNA-hsa-miR-363-3p-SPOCK2 pathway fuels stage progression of ovarian cancer.Aging (Albany NY). 2019 Dec 3;11(23):11416-11439. doi: 10.18632/aging.102538. Epub 2019 Dec 3.
|
1165 |
SPOP Regulates The Biological Mechanism Of Ovarian Cancer Cells Through The Hh Signaling Pathway.Onco Targets Ther. 2019 Nov 6;12:9239-9248. doi: 10.2147/OTT.S215940. eCollection 2019.
|
1166 |
Knockdown of SPRY4 and SPRY4-IT1 inhibits cell growth and phosphorylation of Akt in human testicular germ cell tumours.Sci Rep. 2018 Feb 6;8(1):2462. doi: 10.1038/s41598-018-20846-8.
|
1167 |
SPSB1 enhances ovarian cancer cell survival by destabilizing p21.Biochem Biophys Res Commun. 2019 Mar 12;510(3):364-369. doi: 10.1016/j.bbrc.2019.01.088. Epub 2019 Jan 31.
|
1168 |
Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer.Biochem Biophys Res Commun. 2006 Jun 2;344(2):667-74. doi: 10.1016/j.bbrc.2006.03.184. Epub 2006 Apr 7.
|
1169 |
Serine/arginine-rich splicing factor 3 (SRSF3) regulates homologous recombination-mediated DNA repair.Mol Cancer. 2015 Aug 19;14:158. doi: 10.1186/s12943-015-0422-1.
|
1170 |
Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.Gynecol Oncol. 2016 Sep;142(3):539-47. doi: 10.1016/j.ygyno.2016.06.017. Epub 2016 Jun 30.
|
1171 |
Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-1-induced EMT and confers paclitaxel resistance in ovarian cancer.Cell Death Dis. 2018 Oct 30;9(11):1102. doi: 10.1038/s41419-018-1101-0.
|
1172 |
Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer.Glycobiology. 2018 Nov 1;28(11):898-903. doi: 10.1093/glycob/cwy065.
|
1173 |
Stimulative role of ST6GALNAC1 in proliferation, migration and invasion of ovarian cancer stem cells via the Akt signaling pathway.Cancer Cell Int. 2019 Apr 5;19:86. doi: 10.1186/s12935-019-0780-7. eCollection 2019.
|
1174 |
Sequencing of a 'mouse azoospermia' gene panel in azoospermic men: identification of RNF212 and STAG3 mutations as novel genetic causes of meiotic arrest.Hum Reprod. 2019 Jun 4;34(6):978-988. doi: 10.1093/humrep/dez042.
|
1175 |
Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.Oncotarget. 2017 Apr 18;8(16):27380-27392. doi: 10.18632/oncotarget.16068.
|
1176 |
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
|
1177 |
Identification of cell membrane protein stress-induced phosphoprotein 1 as a potential ovarian cancer biomarker using aptamers selected by cell systematic evolution of ligands by exponential enrichment.Anal Chem. 2014 May 6;86(9):4521-7. doi: 10.1021/ac500466x. Epub 2014 Apr 9.
|
1178 |
Synergistic effects of eukaryotic co-expression plasmid-based STAT3-specific siRNA and LKB1 on ovarian cancer in vitro and in vivo.Oncol Rep. 2015 Feb;33(2):774-82. doi: 10.3892/or.2014.3623. Epub 2014 Nov 25.
|
1179 |
Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.PLoS One. 2019 Dec 11;14(12):e0225860. doi: 10.1371/journal.pone.0225860. eCollection 2019.
|
1180 |
Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells.Platelets. 2018 Dec;29(8):834-837. doi: 10.1080/09537104.2018.1530345. Epub 2018 Oct 18.
|
1181 |
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.Int J Mol Med. 2018 Dec;42(6):3542-3550. doi: 10.3892/ijmm.2018.3870. Epub 2018 Sep 11.
|
1182 |
Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF-B pathway.Cell Prolif. 2016 Dec;49(6):657-668. doi: 10.1111/cpr.12293. Epub 2016 Sep 21.
|
1183 |
TBC1D8 Amplification Drives Tumorigenesis through Metabolism Reprogramming in Ovarian Cancer.Theranostics. 2019 Jan 24;9(3):676-690. doi: 10.7150/thno.30224. eCollection 2019.
|
1184 |
Role of APC-mediated MDR-1/CLCX-1 signaling pathway in ovarian tumors.J Biol Regul Homeost Agents. 2018 May-Jun;32(3):529-536.
|
1185 |
Downregulation of TCEAL7 expression induces CCND1 expression in non-small cell lung cancer.Mol Biol Rep. 2019 Oct;46(5):5251-5256. doi: 10.1007/s11033-019-04982-6. Epub 2019 Jul 18.
|
1186 |
TCF12 overexpression as a poor prognostic factor in ovarian cancer.Pathol Res Pract. 2019 Sep;215(9):152527. doi: 10.1016/j.prp.2019.152527. Epub 2019 Jul 7.
|
1187 |
Functional balance between Tcf21-Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines.Carcinogenesis. 2020 Jun 17;41(4):515-526. doi: 10.1093/carcin/bgz119.
|
1188 |
Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.Int J Oncol. 2009 Nov;35(5):1069-79.
|
1189 |
Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.PLoS One. 2017 May 4;12(5):e0177244. doi: 10.1371/journal.pone.0177244. eCollection 2017.
|
1190 |
TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer.Cell Biol Int. 2017 Apr;41(4):405-414. doi: 10.1002/cbin.10734. Epub 2017 Feb 16.
|
1191 |
TET3 inhibits TGF-1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells.J Exp Clin Cancer Res. 2016 May 4;35:72. doi: 10.1186/s13046-016-0350-y.
|
1192 |
TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.Life Sci. 2020 Jan 15;241:117171. doi: 10.1016/j.lfs.2019.117171. Epub 2019 Dec 13.
|
1193 |
ERRATUM.Oncol Res. 2017 Jan 2;25(1):155. doi: 10.3727/096504017X14811155525280.
|
1194 |
Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.Jpn J Cancer Res. 2002 Oct;93(10):1114-22. doi: 10.1111/j.1349-7006.2002.tb01213.x.
|
1195 |
Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.J Physiol Pharmacol. 2008 Sep;59 Suppl 4:53-65.
|
1196 |
Icb-1 gene polymorphism rs1467465 is associated with susceptibility to ovarian cancer.J Ovarian Res. 2014 Apr 23;7:42. doi: 10.1186/1757-2215-7-42. eCollection 2014.
|
1197 |
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.J Ovarian Res. 2019 Nov 17;12(1):112. doi: 10.1186/s13048-019-0590-5.
|
1198 |
Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):680-688. doi: 10.1158/1055-9965.EPI-17-1101. Epub 2018 Mar 12.
|
1199 |
TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.BMC Cancer. 2019 Mar 15;19(1):237. doi: 10.1186/s12885-019-5417-7.
|
1200 |
TMED2 promotes epithelial ovarian cancer growth.Oncotarget. 2017 Oct 6;8(55):94151-94165. doi: 10.18632/oncotarget.21593. eCollection 2017 Nov 7.
|
1201 |
Knockdown of TMEM14A expression by RNAi inhibits the proliferation and invasion of human ovarian cancer cells.Biosci Rep. 2016 Feb 19;36(1):e00298. doi: 10.1042/BSR20150258. Print 2016.
|
1202 |
Overexpression of TMEM158 contributes to ovarian carcinogenesis.J Exp Clin Cancer Res. 2015 Aug 4;34(1):75. doi: 10.1186/s13046-015-0193-y.
|
1203 |
Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells.Oncol Rep. 2015 Jun;33(6):3124-30. doi: 10.3892/or.2015.3902. Epub 2015 Apr 7.
|
1204 |
A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation.Gynecol Oncol. 2012 Jun;125(3):720-6. doi: 10.1016/j.ygyno.2012.03.026. Epub 2012 Mar 21.
|
1205 |
Thymosin 10 expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production.PLoS One. 2012;7(5):e35399. doi: 10.1371/journal.pone.0035399. Epub 2012 May 18.
|
1206 |
Tumor necrosis factor -induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy.Hum Pathol. 2018 Dec;82:239-248. doi: 10.1016/j.humpath.2018.02.031. Epub 2018 Aug 11.
|
1207 |
TRAIL-R3-related apoptosis: epigenetic and expression analyses in women with ovarian neoplasia.Gynecol Oncol. 2012 Aug;126(2):268-73. doi: 10.1016/j.ygyno.2012.04.038. Epub 2012 Apr 30.
|
1208 |
Overexpression of salusin- is associated with poor prognosis in ovarian cancer.Oncol Rep. 2017 Mar;37(3):1826-1832. doi: 10.3892/or.2017.5429. Epub 2017 Feb 7.
|
1209 |
TPM4 promotes cell migration by modulating F-actin formation in lung cancer.Onco Targets Ther. 2019 May 31;12:4055-4063. doi: 10.2147/OTT.S198542. eCollection 2019.
|
1210 |
Tripartite Motif 16 Inhibits the Migration and Invasion in Ovarian Cancer Cells.Oncol Res. 2017 Apr 14;25(4):551-558. doi: 10.3727/096504016X14758370595285. Epub 2016 Oct 12.
|
1211 |
TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.J Neurooncol. 2019 Nov;145(2):211-222. doi: 10.1007/s11060-019-03301-0. Epub 2019 Oct 11.
|
1212 |
TRIM50 acts as a novel Src suppressor and inhibits ovarian cancer progression.Biochim Biophys Acta Mol Cell Res. 2019 Sep;1866(9):1412-1420. doi: 10.1016/j.bbamcr.2019.06.002. Epub 2019 Jun 6.
|
1213 |
Poly r(C) Binding Protein 1 Regulates Posttranscriptional Expression of the Ubiquitin Ligase TRIM56 in Ovarian Cancer.IUBMB Life. 2019 Feb;71(2):177-182. doi: 10.1002/iub.1948. Epub 2018 Oct 3.
|
1214 |
Ovarian cancer proliferation and apoptosis are regulated by human transfer RNA methyltransferase 9-likevia LIN9.Oncol Lett. 2017 Oct;14(4):4461-4466. doi: 10.3892/ol.2017.6750. Epub 2017 Aug 14.
|
1215 |
Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity.Biochem Biophys Res Commun. 2007 Aug 24;360(2):363-9. doi: 10.1016/j.bbrc.2007.06.070. Epub 2007 Jun 19.
|
1216 |
TRRAP stimulates the tumorigenic potential of ovarian cancer stem cells.BMB Rep. 2018 Oct;51(10):514-519. doi: 10.5483/BMBRep.2018.51.10.042.
|
1217 |
Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity.Microbiol Immunol. 2004;48(4):339-45. doi: 10.1111/j.1348-0421.2004.tb03515.x.
|
1218 |
TSPAN12 Precedes Tumor Proliferation by Cell Cycle Control in Ovarian Cancer.Mol Cells. 2019 Jul 31;42(7):557-567. doi: 10.14348/molcells.2019.0015.
|
1219 |
Knockdown of miR-629 Inhibits Ovarian Cancer Malignant Behaviors by Targeting Testis-Specific Y-Like Protein 5.DNA Cell Biol. 2017 Dec;36(12):1108-1116. doi: 10.1089/dna.2017.3904. Epub 2017 Oct 3.
|
1220 |
ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.Int J Biochem Cell Biol. 2005 Mar;37(3):590-603. doi: 10.1016/j.biocel.2004.08.005.
|
1221 |
Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.J BUON. 2017 Sep-Oct;22(5):1314-1321.
|
1222 |
Sox9 and Hif-2 regulate TUBB3 gene expression and affect ovarian cancer aggressiveness.Gene. 2014 Jun 1;542(2):173-81. doi: 10.1016/j.gene.2014.03.037. Epub 2014 Mar 21.
|
1223 |
Ca(2+)/calmodulin-dependent protein kinase IV expression in epithelial ovarian cancer.Cancer Lett. 2002 Sep 26;183(2):185-93. doi: 10.1016/s0304-3835(02)00107-6.
|
1224 |
A polymerase-chain-reaction assay for the specific identification of transcripts encoded by individual carcinoembryonic antigen (CEA)-gene-family members.Int J Cancer. 1993 Sep 9;55(2):311-9. doi: 10.1002/ijc.2910550223.
|
1225 |
Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells.Oncogene. 2003 Jul 3;22(27):4243-56. doi: 10.1038/sj.onc.1206437.
|
1226 |
A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis.Biochem Biophys Res Commun. 2001 Feb 2;280(4):1148-54. doi: 10.1006/bbrc.2001.4250.
|
1227 |
Identification of the Critical Site of Calponin 1 for Suppression of Ovarian Cancer Properties.Anticancer Res. 2015 Nov;35(11):5993-9.
|
1228 |
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.Gynecol Oncol. 2020 Feb;156(2):488-497. doi: 10.1016/j.ygyno.2019.09.021. Epub 2019 Oct 17.
|
1229 |
Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1698-1703. doi: 10.1073/pnas.1803999116. Epub 2019 Jan 15.
|
1230 |
Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.Anticancer Res. 2001 Jul-Aug;21(4B):2983-7.
|
1231 |
Marked allelic imbalance on chromosome 5q31 does not explain alpha-catenin expression in epithelial ovarian cancer.Gynecol Oncol. 2004 Aug;94(2):416-21. doi: 10.1016/j.ygyno.2004.04.029.
|
1232 |
Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.Neoplasia. 2006 Apr;8(4):268-78. doi: 10.1593/neo.05502.
|
1233 |
The homeoprotein DLX4 stimulates NF-B activation and CD44-mediated tumor-mesothelial cell interactions in ovarian cancer.Am J Pathol. 2015 Aug;185(8):2298-308. doi: 10.1016/j.ajpath.2015.04.004. Epub 2015 Jun 9.
|
1234 |
Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.Carcinogenesis. 2004 May;25(5):693-701. doi: 10.1093/carcin/bgh066. Epub 2004 Jan 16.
|
1235 |
Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors.J Clin Oncol. 2005 Oct 10;23(29):7257-64. doi: 10.1200/JCO.2005.02.2541. Epub 2005 Aug 8.
|
1236 |
Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.Br J Cancer. 2004 Jun 1;90(11):2197-202. doi: 10.1038/sj.bjc.6601832.
|
1237 |
The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas.Int J Cancer. 2008 Oct 15;123(8):1761-9. doi: 10.1002/ijc.23708.
|
1238 |
RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.PLoS One. 2013 Aug 9;8(8):e72820. doi: 10.1371/journal.pone.0072820. eCollection 2013.
|
1239 |
Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.Mol Oncol. 2014 Oct;8(7):1326-38. doi: 10.1016/j.molonc.2014.04.009. Epub 2014 May 13.
|
1240 |
Aberrant expression of FGFRL1, a novel FGF receptor, in ovarian tumors.Int J Mol Med. 2005 Dec;16(6):1169-73.
|
1241 |
Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells.BMC Mol Biol. 2014 Oct 7;15:24. doi: 10.1186/1471-2199-15-24.
|
1242 |
Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.Oncol Rep. 2006 May;15(5):1265-71.
|
1243 |
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.Clin Cancer Res. 2004 Aug 1;10(15):5178-86. doi: 10.1158/1078-0432.CCR-03-0103.
|
1244 |
GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy.Clin Exp Metastasis. 2002;19(4):291-9. doi: 10.1023/a:1015545407700.
|
1245 |
The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers.Regul Pept. 2000 Jun 30;90(1-3):77-84. doi: 10.1016/s0167-0115(00)00114-2.
|
1246 |
Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis.Tumour Biol. 2013 Dec;34(6):4059-63. doi: 10.1007/s13277-013-0995-5. Epub 2013 Jul 25.
|
1247 |
Downregulation of HOXC6 in Serous Ovarian Cancer.Cancer Invest. 2015;33(7):303-11. doi: 10.3109/07357907.2015.1041641. Epub 2015 Jun 5.
|
1248 |
Genome-wide significant risk associations for mucinous ovarian carcinoma.Nat Genet. 2015 Aug;47(8):888-97. doi: 10.1038/ng.3336. Epub 2015 Jun 15.
|
1249 |
Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer.Oncol Rep. 2014 May;31(5):2139-46. doi: 10.3892/or.2014.3110. Epub 2014 Mar 24.
|
1250 |
Recombinant adenovirus-mediated overexpression of PTEN and KRT10 improves cisplatin resistance of ovarian cancer in vitro and in vivo.Genet Mol Res. 2015 Jun 18;14(2):6591-7. doi: 10.4238/2015.June.18.1.
|
1251 |
miR-762 can negatively regulate menin in ovarian cancer.Onco Targets Ther. 2017 Apr 12;10:2127-2137. doi: 10.2147/OTT.S127872. eCollection 2017.
|
1252 |
Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies.Gynecol Oncol. 2005 Jul;98(1):68-76. doi: 10.1016/j.ygyno.2005.04.002.
|
1253 |
Downregulation of NEK11 is associated with drug resistance in ovarian cancer.Int J Oncol. 2014 Sep;45(3):1266-74. doi: 10.3892/ijo.2014.2503. Epub 2014 Jun 18.
|
1254 |
OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.Carcinogenesis. 2014 Jul;35(7):1573-81. doi: 10.1093/carcin/bgu070. Epub 2014 Mar 25.
|
1255 |
Anti-apoptotic hPEBP4 silencing promotes TRAIL-induced apoptosis of human ovarian cancer cells by activating ERK and JNK pathways.Int J Mol Med. 2006 Sep;18(3):505-10.
|
1256 |
Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.Mol Cell Proteomics. 2014 Nov;13(11):3138-51. doi: 10.1074/mcp.M113.033217. Epub 2014 Aug 5.
|
1257 |
Nac1 interacts with the POZ-domain transcription factor, Miz1.Biosci Rep. 2014 Jun 5;34(3):e00110. doi: 10.1042/BSR20140049.
|
1258 |
Gonadotropin-releasing hormone retards doxorubicin-induced apoptosis and serine/threonine phosphatase inhibition in ovarian cancer cells.Oncol Rep. 2005 May;13(5):813-7.
|
1259 |
Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer.Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2216-23. doi: 10.1158/1078-0432.CCR-05-2433.
|
1260 |
Rab25 is responsible for phosphoinositide 3-kinase/AKTmediated cisplatin resistance in human epithelial ovarian cancer cells.Mol Med Rep. 2015 Mar;11(3):2173-8. doi: 10.3892/mmr.2014.2963. Epub 2014 Nov 17.
|
1261 |
RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis.Oncotarget. 2014 Aug 30;5(16):6734-45. doi: 10.18632/oncotarget.2244.
|
1262 |
Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.Oncogene. 2008 Mar 13;27(12):1805-11. doi: 10.1038/sj.onc.1210805. Epub 2007 Sep 24.
|
1263 |
Role of microsatellite instability in borderline ovarian tumors.Anticancer Res. 2003 Nov-Dec;23(6D):5139-41.
|
1264 |
Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.Clin Cancer Res. 2006 Jan 15;12(2):432-41. doi: 10.1158/1078-0432.CCR-05-0461.
|
1265 |
The role of S100A14 in epithelial ovarian tumors.Oncotarget. 2014 Jun 15;5(11):3482-96. doi: 10.18632/oncotarget.1947.
|
1266 |
Associations of genewide SNPs in SNAI1 and TWIST1 with breast cancer and ovarian cancer susceptibility among Chinese Han women.Oncol Rep. 2018 Dec;40(6):3573-3584. doi: 10.3892/or.2018.6725. Epub 2018 Sep 21.
|
1267 |
Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/-catenin signaling pathway.J Ovarian Res. 2014 Sep 5;7:87. doi: 10.1186/s13048-014-0087-1.
|
1268 |
Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients.Int J Cancer. 2006 Jan 15;118(2):412-21. doi: 10.1002/ijc.21332.
|
1269 |
Expression of betaglycan, an inhibin coreceptor, in normal human ovaries and ovarian sex cord-stromal tumors and its regulation in cultured human granulosa-luteal cells.J Clin Endocrinol Metab. 2003 Oct;88(10):5002-8. doi: 10.1210/jc.2003-030704.
|
|
|
|
|
|
|